Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 1 of 176 
CONFIDENTIAL    
Title Page  
Protocol Title:  A Phase 1 Study to Evaluate Safety, Tolerability, 
Pharmacokinetics and Pharmacodynamics of 
AMG 404,  a Programmed Death -1 (PD -1) 
Antibod y,  
, in Patients With 
Advanced Solid Tumors  
Short Protocol Title:  AMG 404 in Patients with Advanced Solid 
Tumors  
Protocol Number:  20180143  
Investigational Product:  AMG 404  
Trade Name:  Not applicable  
Sponsor  Name of Sponsor:  Amgen Inc.   
Address:  One Amgen Center Drive  
Thousand Oaks, CA 91320  
USA 
Telephone Number:  +1 (805) 447 -1000  
Key 
Sponsor 
Contact  Name:  , MD  
, Vet Dr  
Address:  One Amgen Center Drive  
Thousand Oaks, CA 91320  
USA 
Telephone Number:  
Email Address:  
EudraCT Number:  2018 -004268 -80 
Study ID: [REMOVED]  
Protocol Date:  Document Version  Date  
Original  
Amendment 1  
Amendment 2  
Amendment 3 23 October 2018  
02 January 2019  
15 July 2019  
31 January 2020  
Amendment 4  24 November 2020  
Amendment 5  16 July 2021  
Amendment 6 20 May 2022  
 
Version/Date:  Data Element Standards Version  
6.1 
 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 2 of 176 
CONFIDENTIAL    
Confidentiality Notice  
This document contains confidential information of Amgen Inc.  
This document must not be disclosed to anyone other than the site study staff and 
members of the institutional review board/independent ethics committee/institutional 
scientific review board or equivalent.  
The information in this document cannot be used for any purpose other than the 
evaluation or conduct of the clinical investigation without the prior written consent of 
Amgen Inc.  
If you have questions regarding how th is document may be used or shared, call the 
Amgen Medical Information number:  US sites, 1 - 800-77-AMGEN; Canadian sites, 
1-866-50-AMGEN;  [for all other countries, insert the local toll -free Medical Information 
number] ; Amgen’s general number in the US, 1 -805-447-1000.  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 3 of 176 
CONFIDENTIAL    
Investigator’ s Agreement:  
I have read the attached protocol entitled  A Phase 1 Study to Evaluate Safety, 
Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 404,  a Programmed 
Death -1 (PD -1) Antibod y, , in 
Patients With Advanced Solid Tumors , dated 20 May 2022 , and agree to abide by all 
provisions set forth therein.   
I agree to comply w ith the International Council for  Harmonisation (ICH) Tripartite 
Guideline on Good Clinical Practice (GCP), Declaration of Helsinki, and applicable 
national or regional regulations/guidelines.    
I agree to ensure that Financial Disclosure Statements will be completed by:  me 
(including, if applicable, my spouse and depende nt children)  and my sub -investigators 
(including, if applicable, their spouses and dependent children) at the start of the study 
and for up to 1 year after the study is completed, if there are changes that affect my 
financial disclosure status.  
I agree to ensure that the confidential information contained in this document will not be 
used for any purpose other than the evaluation or conduct of the clinical investigation 
without the prior written consent of Amgen Inc.  
 
_______________________________  
Signatu re 
 
_______________________________  ____________________________  
Name of Investigator  Date (DD Month YYYY)  
 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 4 of 176 
CONFIDENTIAL    
1. Table of Contents  
1. Table of Contents  ................................ ................................ ................................ ... 4 
2. Protocol Synopsis  ................................ ................................ ................................ . 11 
3. Study Schema and Schedule of Activities  ................................ .............................  20 
3.1 Study Schema  ................................ ................................ ...........................  20 
3.2 Schedule of Activities  ................................ ................................ ................  24 
4. Background and Rationale  ................................ ................................ ....................  39 
4.1 Disease and Target Background  ................................ ...............................  39 
4.1.1  PD-1/PD -L1 Inhibitors and Treatment of NSCLC  .......................  40 
4.2 Amgen Investigational Product Background:  AMG 404  ............................  41 
4.2.1  Nonclinical Pharmaco logy ................................ .........................  41 
4.2.2  Toxicology  ................................ ................................ .................  41 
4.2.3  Nonclinical Pharmacokinetics  ................................ ....................  42 
4.2.4  Rationale for Development AMG 404  ................................ ........  43 
4.5 Benefit/Risk Assessment  ................................ ................................ ...........  45 
4.5.1  Therapeutic Context  ................................ ................................ .. 46 
4.5.2  Benefits  ................................ ................................ .....................  46 
4.5.3  Risks  ................................ ................................ .........................  46 
5. Objectives, Endpoints and Hypotheses  ................................ ................................ . 50 
5.1 Objectives and Endpoints  ................................ ................................ ..........  50 
5.2 Hypotheses  ................................ ................................ ...............................  51 
6. Study Design  ................................ ................................ ................................ ........  51 
6.1 Overall Design  ................................ ................................ ..........................  51 
6.2 Number of Subjects  ................................ ................................ ...................  59 
6.2.1  Replacement of Subjects  ................................ ...........................  59 
6.2.2  Number of Sites  ................................ ................................ .........  59 
6.3 End of Study  ................................ ................................ .............................  60 
6.3.1  End of Study Definition  ................................ ..............................  60 
6.3.2  Study Duration for Subjects  ................................ .......................  60 
6.4 Dose Rationale  ................................ ................................ .........................  60 
6.4.1  First in Human Starting Dose Selection Rationale  .....................  60 
6.4.2  Recommended Phase 2 Dose Selection  ................................ ... 62 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 5 of 176 
CONFIDENTIAL    
6.5 Patient Input on Study Design  ................................ ................................ ... 66 
7. Study Population  ................................ ................................ ................................ .. 66 
7.1 Inclusion Criteria  ................................ ................................ .......................  66 
7.2 Exclusion Criteria  ................................ ................................ ......................  68 
7.3 Subject Enrollment  ................................ ................................ ....................  72 
7.4 Screen Failures  ................................ ................................ .........................  72 
8. Treatment Procedures  ................................ ................................ ..........................  73 
8.1 Investigational and Non -investigational Products  ................................ ...... 73 
8.1.1  Investigational Product:  AMG  404 ................................ ............  73 
8.1.2  Cohorts  1-9 Investig ational Product  ................................ ...........  75 
8.1.7  Medical Devices  ................................ ................................ ........  81 
8.1.9  Other Treatment Procedures  ................................ .....................  82 
8.1.10  Product Complaints  ................................ ................................ ... 82 
8.1.11  Excluded Treatments, Medical Devices, and/or 
Procedures During Study Period  ................................ ...............  83 
8.2 Method of Treatment Assignment  ................................ .............................  84 
8.3 Blinding  ................................ ................................ ................................ ..... 84 
8.4 Dose Modification  ................................ ................................ ......................  84 
8.4.1  Dose -cohort Study Escalation /De-escalation and 
Stopping Rules  ................................ ................................ ..........  84 
8.4.2  DLT Definition  ................................ ................................ ............  85 
8.4.3  Dosage Adjustments, Delays, Rules for Withholding or 
Restarting, Permanent Discontinuation  ................................ ..... 87 
8.4.3.1  Amgen Investigational Product:  AMG 404  ..............  87 
8.4.3.4  Immune -related Adverse Reactions  ........................  89 
8.4.3.5  Infusion -related Reactions  ................................ ....... 89 
8.4.3.6  Embryo -fetal Toxicity  ................................ ...............  89 
8.4.4  Hepatotoxicity Stopping and Rechallenge Rules  .......................  90 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 6 of 176 
CONFIDENTIAL    
8.4.5  Dose Modification Guidelines f or SARS -COV2 
Infection  ................................ ................................ ....................  90 
8.4.6  Dose Modification Due to Surgery During Study 
Treatment  ................................ ................................ ..................  91 
8.5 Preparation/Handling/Storage/Accountability  ................................ ............  91 
8.6 Treatment Compliance  ................................ ................................ ..............  91 
8.7 Treatment of Overdose  ................................ ................................ .............  91 
8.8 Prior and Concomitant Treatment  ................................ .............................  92 
8.8.1  Prior Treatment  ................................ ................................ .........  92 
8.8.2  Concomitant Treatment  ................................ .............................  92 
8.8.2.1  SARS -COV2 -Vaccination  ................................ ........  92 
9. Discontinuation Criteria  ................................ ................................ .........................  93 
9.1 Discontinuation of Study Treatment ................................ ...........................  93 
9.2 Discontinuation From the Study  ................................ ................................  94 
9.2.1  Reasons for Removal From Washout, Run -in or 
Invasive Procedures  ................................ ................................ .. 94 
9.2.2  Reasons for Removal From Study  ................................ .............  94 
9.3 Lost to Follow -up ................................ ................................ .......................  94 
10. Study Assessments and Procedures  ................................ ................................ .... 95 
10.1  General Study Periods  ................................ ................................ ..............  95 
10.1.1  Screening, Enrollment and/or Randomization  ............................  95 
10.1.2  Treatment Period  ................................ ................................ ....... 96 
10.1.3  Extended Treatment Period  ................................ .......................  96 
10.1.4  Safety Follow -up ................................ ................................ ........  96 
10.1.5  Long -term Follow -up ................................ ................................ .. 96 
10.1.6  End of Stud y for a Particular Study Subject  ...............................  96 
10.2  Description of General Study Assessments and Procedures  .....................  96 
10.2.1  General Assessments  ................................ ...............................  97 
10.2.1.1  Informed Consent  ................................ ....................  97 
10.2.1.2  Demographics  ................................ .........................  97 
10.2.1.3  Medical History  ................................ ........................  97 
10.2.1.4  Physical Examination  ................................ ..............  97 
10.2.1.5  Physical Measurements  ................................ ..........  97 
10.2.1.6  Performance Status ................................ .................  98 
10.2.2  Efficacy Assessments  ................................ ................................  98 
10.2.3  Safety Assessments  ................................ ................................ .. 99 
10.2.3.1  Adverse Events and Serious Adverse 
Events  ................................ ................................ ..... 99 
10.2.3.2  Vital Signs  ................................ .............................  103 
10.2.3.3  Electrocardiograms (ECGs)  ................................ ... 103 
10.2.4  Clinical Laboratory Assessments  ................................ .............  104 
10.2.4.1  Pregnancy Testing  ................................ ................  104 
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 7 of 176 
CONFIDENTIAL    
10.2.5  Pharmacokinetic Assessments  ................................ ................  105 
10.2.7  Antibody Testing Procedures  ................................ ...................  106 
11. Statistical Considerations  ................................ ................................ ....................  111 
11.1  Sample Size Determination  ................................ ................................ ..... 111 
11.2  Analysis Sets,  and Covariates  ................................ ..............  112 
11.2.1  Analysis Sets  ................................ ................................ ...........  112 
11.2.2  Covariates  ................................ ................................ ...............  112 
11.3  Adaptive Design  ................................ ................................ ......................  113 
11.4  Statistical Analyses  ................................ ................................ .................  113 
11.4.1  Planned Analyses  ................................ ................................ .... 114 
11.4.1.1  Interim Analysis and Early Stopping 
Guidelines  ................................ .............................  114 
11.4.1.2  Primary Analysis  ................................ ...................  118 
11.4.1.3  Final Analysis  ................................ ........................  118 
11.4.2  Methods of Analyses  ................................ ...............................  118 
11.4.2.1  General Considerations  ................................ .........  118 
11.4.2.2  Efficacy Analyses  ................................ ..................  118 
11.4.2.3  Safety Analyses  ................................ ....................  119 
11.4.2.4  Other Analyses  ................................ ......................  120 
12. References  ................................ ................................ ................................ .........  121 
13. Appendices  ................................ ................................ ................................ .........  124 
13.1  Appendix 1.  List of Abbreviations and Definitions of Terms  ....................  125 
13.2  Appendix 2.  Clinical Laborator y Tests  ................................ ....................  128 
13.3  Appendix 3.  Study Governance Considerations  ................................ ..... 129 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 8 of 176 
CONFIDENTIAL    
Committee(s)  ................................ ................................ ..........................  129 
Regulatory and Ethical Considerations  ................................ ....................  129 
Recruitment Procedures  ................................ ................................ ..........  130 
Informed Consent Process  ................................ ................................ ...... 130 
Data Protection/Subject Confidentiality  ................................ ...................  132 
Publication Policy  ................................ ................................ ....................  132 
Investig ator Signatory Obligations  ................................ ...........................  133 
Data Quality Assurance  ................................ ................................ ...........  134 
Source Documents  ................................ ................................ ..................  135 
Study and Site Closure ................................ ................................ ............  136 
Compensation  ................................ ................................ .........................  136 
13.4  Appendix 4.  Toxicity Management Guidelines  ................................ ........  137 
13.5  Appendix 5.  Safety Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up and Reporting  ................................ ..... 148 
Definition of Adverse Event  ................................ ................................ ..... 148 
Definition of Serious Adverse Event  ................................ ........................  149 
Reco rding Adverse Events and Serious Adverse Events  ........................  150 
Evaluating Adverse Events and Serious Adverse Events  ........................  150 
Reporting of Serious Adverse Event  ................................ ........................  152 
13.6  Appendix 6.  Contraceptive Guidance and Collection of 
Pregnancy and Lactation Information  ................................ ......................  158 
Definition of Females of Childbearing Potential  ................................ ....... 158 
Collection of Pregnancy Information  ................................ ........................  160 
Collection of Lactation Information  ................................ ..........................  161 
13.7  Appendix 7.  Sample Storage and Destruction  ................................ ........  164 
13.8  Appendix 8.  Hepatotoxicity Stopping Rules:  Suggested Actions 
and Follow -up Assessments and Study Treatment Rechallenge 
Guidelines  ................................ ................................ ...............................  166 
Criteria for Rechallenge of Amgen Investigational Product and 
Other Protocol -required Therapies After Potential 
Hepatotoxicity ................................ ................................ ..........  167 
Drug -induced Liver Injury Reporting and Additional 
Assessments  ................................ ................................ ...........  168 
13.9  Appendix 9.  ECOG Performance Status and NYHA 
Classification  ................................ ................................ ...........................  170 
13.10  Appendix 10.  Modified Response Evaluation Criteria in Solid 
Tumors Version 1.1 (Modified RECIST 1.1)  ................................ ............  171 
 
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 9 of 176 
CONFIDENTIAL    
List of Tables  
Table 2 -1.  Guideline for Dose Level Decisions  ................................ .............................  15 
Table 3 -1.  Schedule of Activities for Cohorts  1-9 ................................ ..........................  24 
Table 4 -1.  Key Safety Risks of AMG 404  ................................ ................................ ...... 47 
Table 4 -2.  Potential Safety C oncerns Based on Drug Class Effects, 
Biological Mechanism of Action, and Nonclinical Studies  ........................  48 
Table 6 -1.  Guideline for Dose Level Decisions for Cohort 2 (480 mg) and 
Cohort 4 (1050 mg)  ................................ ................................ ................  54 
Table 8 -1.  Cohorts 1 -9 Investigational Product:  AMG  404 ................................ ...........  75 
Table 8 -8. Dose Modification Guidelines for SARS -COV2 Infection  ...............................  91 
Table 11 -1.  Stopping Boundary Overall for Combined Monotherapy Data of 
Cohorts  3, 6, 7, 8, and 9 with Posterior Probability of 80% and 
Grade 4 or Higher Treatment -Related Adverse Event Limit of 
20% ................................ ................................ ................................ ...... 116 
Table  11-2.  Stopping Boundary for Enrollment within Cohorts 3, 6 - 
Individually with Posterior Probability of 80% and Subject 
Incide nce of Grade 4 or Higher Treatment -Related Adverse 
Event Limit of 20%  ................................ ................................ ................  117 
Table 11 -3.  Operating Characteristics  with Batch Size of 10 Subjects 
(Combining All Monotherapy Data of Expansion Cohorts 3, 6, 
7, 8 and 9)  ................................ ................................ ............................  117 
Table 11-4.  Operating Characteristics With Batch Size of 10 Subjects 
(Cohort -Specific Enrollment with Maximum Cohort Sample 
Size of n=40 Subjects)  ................................ ................................ ..........  117 
Table 13 -1.  Analyte Listing  ................................ ................................ .........................  128 
Table 13 -2.  Dose Modification and Toxicity Management Guidelines for 
Immune -Related Adverse Reactions Associated With 
AMG  404* ................................ ................................ .............................  137 
Table 13 -3.  Dose Modification Guidelines for Chemotherapy Hematological 
Toxicity  ................................ ................................ ................................ . 145 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 10 of 176 
CONFIDENTIAL    
Table 13 -4.  Dose Modification Guidelines for Chemotherapy 
Nonhematological Toxicity  ................................ ................................ .... 145 
Table 13 -5.  Management of Infusion -Related Reactions With AMG 404  ....................  146 
Table 13 -6.  Conditions for Withholding and/or Permanent Discontinuation of 
Amgen Investigational Product and Other Protocol -required 
Therapies Due to Potential Hepatotoxicity  ................................ ............  167 
List of Figures  
Figure 3 -1.  Study Schema  ................................ ................................ ............................  20 
Figure 3 -2.  Study Schema  ................................ ................................ ............................  21 
Figure 3 -3.  Study Schema  ................................ ................................ ............................  22 
Figure 3 -4.  Study Schema  ................................ ................................ ............................  23 
Figure 13 -1.  Sample Electronic Serious Adverse Event Contingency Report 
Form (Paper -Based Form)  ................................ ................................ .... 153 
Figure 13 -3.  Pregnancy and Lactation Notification Forms  ................................ ...........  162 
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 11 of 176 
CONFIDENTIAL    
2. Protocol Synopsis  
Protocol Title:   A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and 
Pharmacodynamics of AMG 404,  a Programmed Death -1 (PD -1) Antibod y,  
, in Patients With Advanced Solid 
Tumors  
Short Protocol Title:   AMG 404 in Patients with Advanced Solid Tumors  
Study Phase:   1 
Indication:   Advanced solid tumors  
Rationale  
The programmed cell death -1 (PD -1) receptor -ligand interaction is a major pathway that 
tumors use to suppress immune control. PD -1, part of the immunoglobulin (Ig) 
superfamily and related to CD28 and cytotoxic T -lymphocyte -associated protein -4 
(CTLA -4), has been shown to nega tively regulate antigen receptor signaling upon 
engagement of its ligands (PD -L1 and/or PD -L2).  
Enhancement of anti -tumor immunity through inhibition of PD -1 has been effective in 
treatment of many malignancie s when given as a single agent and when given as part of 
combination therapies . AMG  404, the investigational product under study, is a 
monoclonal antibody that binds to PD -1 and blocks its ability to interact with ligands 
PD-L1 and PD -L2.  
This first in human AMG  404 study is designed to assess  safety and tolerability of 
AMG  404 monotherapy ,  in patients with 
solid tumor malignancies.   
 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 12 of 176 
CONFIDENTIAL    
Objective(s)/Endpoint(s)  
 
Objectives  Endpoints  
Primary  
 To evaluate the safety and tolerability  
and determine the recommended 
phase 2 dose (RP2D)  of AMG  404 in 
patients with advanced solid tumors   Dose limiti ng toxicities (DLTs), 
treatment -emergent adverse events, 
treatment -related adverse events, and 
changes in vital signs, and clinical 
laboratory tests  
Secondary  
 To evaluate the pharmacokinetics 
(PK) of AMG  404 as a monotherapy 
 
  PK parameters of AMG  404 including, 
but not limited to, maximum observed 
serum concentration (C max), time to 
achieve C max (tmax), and area under 
the serum concentration -time curve 
(AUC)  
 To assess the immunogenicity of  
AMG  404 as a monotherapy  
  Subject incidence of anti -AMG  404 
antibodies  
 To evaluate the preliminary antitumor 
activity of AMG  404 as a 
monotherapy   Objective tumor response, duration of 
overall response, progression -free 
survival, disease control rate (DCR), 
and duration of stable disease 
measured by CT /MRI and assessed 
per modified RECIST 1.1  
 
Hypotheses  
AMG  404 is safe and well  tolerated in  patients with  advanced solid tumors .  
Overall Design  
This is a first -in-human (FIH), multicenter, non -randomized, open -label, phase 1 study to 
evaluate safe ty, tolerability, pharmacokinetics (PK) and pharmacodynamics of AMG  404 
as a monotherapy , in subjects with 
advanced solid tumors.  The study may be conducted in Australia,  United States , 
France, Poland,  Spain, Turkey,  United Kingdom, Belgium, South Korea, Taiwan, Japan, 
China , Singapore, Canada, Brazil , and Mexico .  Other countries or regions may 
participate.  .  Cohorts  1-9 will  evaluate the 
safety, tolerability, PK and pharmacodynamics of AMG  404 with the following  Q4W  
doses :  Cohort 1  – 240 mg , Cohort 2  – 480 mg,  Cohort 3 – Expansion at the dose of 
480 mg (subjects enrolled outside of China) , Cohort  4 – Exploratory Dose  of 1050 mg , 
Cohort 5 – China  and National Medical Products Administration (NMPA) certified sites in 
Taiwan and/or Hong Kong  Specific Expansion at the recommended phase 2 dose 
(RP2D)  with a safety lead -in  
Cohort  6 – Expansion at the RP2D  , Cohort 7  – Expansion at the RP2D  in specific 
indications as specified in Section  3.1, Cohort 8 – Expansion at the RP2D  in subjects 
with tumor s that are microsatellite instability -high (MSI -H) or mismatch repa ir deficient 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 13 of 176 
CONFIDENTIAL    
(dMMR), and Cohort  9 – Expansion at the RP2D in subject s with non -small cell lung 
cancer (NSCLC) that is PD -L1 positive, Tumor Proportion Score ( TPS)  50% 
(Cohort s 6-9 will enroll subjects outside of China) .  
In Cohorts  1-9, AMG  404 will be administered intravenously (IV) over ap proximately 
30 minutes, every 4  weeks in subjects with advanced solid tumors.   Cohort s 3 and 4 can 
be opened once Cohort 2 has been completed and determined to be tolerable .  Cohorts 
5-9 can be opened once  the first 6-9 subjects in Cohort 4 ha ve completed the DLT 
evaluation period and data ha ve been reviewed to determine the RP2D.  The DLT 
evaluatio n period will be 28 days.   The Dose Level Review Meeting (DLRM) may 
recommend escalation to the next planned dose, escalation to an intermediate dose (a 
dose lower than the next planned dose), continuation or delay in dosing, repetiti on or 
expansion of a cohort, de -escalation to a lower dose, or termination of the study . 
Administration of AMG  404 (in  all cohorts ) may continue until evidence of disease 
progression, intolerance to study medication, withdrawal of consent, or in the absence of 
the above up to 12 months if subject achieves a complete response, and up to 
24 months if partial response or stable disease.   Subjects with complete response  may 
be permitted to continue treatm ent beyond 12  months , up to a maximum of 24  months 
of total therapy, upon disc ussion with  the medical monitor.  Subjects with complete 
response, partial response, stable disease or continued clinical benefit at 
24 months of treatment, may continue treatment for up to an additional 24  months 
(up to 48  months of treatment in total) , upon discussion with  the medical monitor .  
If a subject completes or discontinues treatment for reasons other than progression, 
tumor evaluations should continue according to the Schedule of Activities ( Table 3 -1) 
until progression or start of a new treatment regimen.  
Cohort s 1, 2 and Cohort 4 
The doses of 240 mg, 480 mg and 1050 mg will be examined for safety, tolerability, PK, 
and pharma codynamics of AMG  404 in subjects with advanced solid tumors.  Rules for 
dose determination , and dose expansion are derived using a modified Toxicity 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 14 of 176 
CONFIDENTIAL    
Probability Interval (mTPI) model (Ji et al. 2010) with a target toxicity probability interval 
(TPI) of 0.20 to 0.33 with a TPI   0.33 defined as excessive toxicity.   
 Subjects will not be dosed at a level above the dose level indicated by the mTPI 
model.  In particular, subjects will not be dosed at the current dose level or higher 
when the mTPI model indic ates stopping enrollment at the current dose level and 
patients will not be dosed at an escalated dose level when the mTPI indicates 
staying at the current dose level.  
 After reviewing a broad range of safety information including vital signs, 
laboratory va lues and detailed adverse events profiles, the team may choose to 
dose subjects below the dose level indicated by the mTPI model.  For example, 
the team may choose to stop enrollment at the current dose level even if the 
mTPI model indicates staying at the  current dose level.  
The Dose Level Review Team (DLRT) will review data, monitor safety, and make 
recommendations  on dose modifications  based on all subject s that have been enrolled.   
A Dose L evel Review Meeting will be conducted after Cohorts 1 , 2 and 4 and may 
convene ad hoc to review safety data if deemed necessary.  
Three  dose  levels are planned to be  tested : 
 Cohort 1:  240 mg every 4 weeks (N  2-4) 
 Cohort s 2 and 3:  480 mg  every 4 weeks ( Cohort 2:  N  6-9; Cohort 3: N   20) 
 Cohort 4:  1050 mg  every 4 weeks (N   20) 
Dose es calation will begin with a run -in dose level of 240 mg (Cohort 1) .  If no DLT s are  
observed  in Cohort 1 , dose  escalation will continue to the next planned dose level in 
Cohort 2.  If DLTs are observed in Cohort 1 , subsequent dosing  will be determined by 
Amgen after consulting with the Dose Level Review Team (DLRT)  and constrained by 
the mTPI model .  
The table below show s rules for dose  determination  and dose expansion per the mTPI 
model.  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 15 of 176 
CONFIDENTIAL    
Table 2-1.  Guideline for Dose Level Decisions  
No. of Subjects  Number of DLT observed at current dose  
ESCALATEa STAY AT CURRENT 
DOSE  STOP ENROLLMENT 
AT CURRENT DOSE  
3 N/A ≤ 1 ≥ 2 
4 N/A ≤ 1 ≥ 2 
5 N/A ≤ 2 ≥ 3 
6 0 1 – 2 ≥ 3 
7 ≤ 1 2 – 3 ≥ 4 
8 ≤ 1 2 – 3 ≥ 4 
9 ≤ 1 Maximum sample size 
reached  Maximum sample size 
reached   
a For Cohort 4 (1050 mg), if the rules for dose escalation are met, enrollment may be stopped as there is 
sufficient evidence that 1050 mg dose is safe and tolerable; and this is the highest planned dose level 
being investigated on study.  
Cohort 3 
Upon  completion of  Cohort  2 of the study and depending on data obtained, dose 
expansion  may proceed with the  planned  dose of 480 mg in Cohort 3 (N  20) outside of 
China .  
Cohort s 5-9  
Upon completion of the first 6-9 subjects in Cohort 4 of the study and depending on data 
obtained, dose expansion may proceed with the RP2D in Cohort  5 with a safety lead -in 
(from China  or NMPA  certified sites in Taiwan and/or Hon g Kong  only) and Cohort s 6-9 
(from all countries participating on the study, excluding China) .  The RP2D will be 
determined following review of available data o btained in Cohorts 1  through 4  including 
safety, tolerabili ty, PK and PD data.   . 
Cohort 5 was a China /Taiwan/Hong Kong -specific expansion cohort with a safety 
lead-in at one dose below the RP2D followed by evaluation at RP2D, as appropriate.    
Up to 12 subjects would  be enrolled  in China, and/or in Taiwan, and /or Hong Kong ( if 
Taiwan or Hong Kong , only NMPA certified sites will participate) .   
Intrasubject dose escalation  for Cohorts  1-9 
Intra-Subject  dose escalations are allowed on this study for subjects enrolled, where 
applicable.  Subjects enrolled to Cohort 1 w ho complete the DLT period may proceed to 
480 mg once Cohort 2 has been deemed safe by the DLRT; subjects receiving 480 mg 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 16 of 176 
CONFIDENTIAL    
(in Cohorts 1 -3) who complete the DLT period may proceed to the RP2D once 
determined if a dose higher than 480 mg is selected as the RP2D.  Subjects enrolled to 
the safety lead -in dose in Cohort 5, may escalate to the RP2D dose level once the RP2D 
is determined safe following the China /Taiwan/Hong Kong  specific DLRT 
recommendation.  . 
All intra -subject dose es calations may occur after consultation with the sponsor if:  
 No DLT has been reported for this subject during or after completion of the DLT 
period  
Subjects who do not proceed to the higher dose may receive additional cycles at the 
original dose.  

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 17 of 176 
CONFIDENTIAL    
Number of Subjects  
Cohort 1 : Up to 4 evaluable subjects may be enrolled to this cohort.  
Cohort 2:  Up to 9 evaluable subjects may be enrolled to this cohort.  
Cohort 3:  An additional  20 evaluable subjects will be enrolled in the dose exp ansion part 
of the study  outside of China . 
Cohort 4:  Up to 20 evaluable subjects may be enrolled to this cohort.  
Cohort 5 :  Approximately 12  evaluable subjects will be enrolled from China , or from 
National Medical Products Administration (NMPA) certified sites in Taiwan and/or Hong 
Kong    
Cohort 6 :  Approximately 20 evaluable subjects will be enrolled in the dose expansion at 
the RP2D outside of China.   
Cohort 7 :  Up to 40 evaluable subjects   
Cohort 8 :  Up to 40 evaluable subjects  
Cohort 9 :  Up to 40 evaluable subjects  
Summary of Subject Eligibility Criteria  
Adult subjects (  18 years old) with histologically or cytologically proven metastatic or 
locally advanced solid tumors  who are checkpoint inhibitor naïve.   Subjects  enrolled to 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 18 of 176 
CONFIDENTIAL    
Cohort 9 may not have received prior  systemic  treatment for  their metastatic or recurrent 
disease (prior neoadjuvant, adjuvant, and/or chemotherapy given concurrently with 
definitive radiation is allowed) .  
Once consented to the study, subjects will provide a medical history and undergo 
screening safety tests to confirm all eligibility requirements of the study have been met.  
For a full list of eligibility crite ria, , please 
refer to Section 7.1 and Section 7.2. 
Treatments  
In Cohorts  1-9, AMG  404 will be administe red intravenously (IV) over ap proximately 
30 minutes, ever y 4 weeks in subjects with advanced solid tumors.  
Three dose  levels are planned to be tested :  
 Cohort 1:  240 mg every 4 weeks (N   2-4) 
 Cohort s 2 and 3 :  480 mg every 4 weeks ( Cohort 2:   N  6-9; Cohort 3: N   20) 
 Cohort  4:  1050 mg  every 4 weeks (N   20)  
Upon  completing Cohort  2 of the study and depending on data obtained, the dose 
expansion may proceed with the  planned  dose of 480 mg in Cohort 3 (N  20) outside of 
China . 
After the first 6-9 subjects have completed the DLT evaluation per iod in Cohort 4 of the 
study and depending on data obtained, the dose expansion may p roceed with the RP2D 
in Cohort s 5-9,     
Procedures  
After written informed consent has been obtained, all screening tests and procedures will 
be performed within 28 days of administration of the first dose (cycle 1, day 1) of 
AMG  404, unless otherwise noted.  Subjects will be seen in clinic where critical clinical 
safety and study evaluations will be performed including physical examination, vital 
signs, clinical laboratory tests, electrocardiograms (ECGs), PK, and  sample  
collections.  
For a full list of study procedures, including the timing of each procedure, please refer to 
General Assessments ( Section  10.2) and the Schedule of Activiti es (for Cohorts  1-9, 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 19 of 176 
CONFIDENTIAL    
refer to Table 3 -1  
 
Statistical Considerations  
The primary analysis will occur when target enrollment is complete and each subject 
either completes 6 months on study or withdraws from the study.  
The DLRT will review data, monitor safety, and make recommendations  on dose 
modifications  based on all subj ects that have been enrolled .  Rules for dose  
determination and  dose expansion are derived using a modified Toxicity Probability 
Interval (mTPI) model.  
Descriptive statistics will be provided for selected demographics, safety, PK, efficacy  
 by cohort , or time as appropriate.  Descriptive statistics on continuous 
data will include means, medians, standard deviations and ranges, while  categorical 
data will be summarized using frequency counts and percentages.  
The PK Analysis Set will contain all subjects who have received at least 1  dose of the 
investigational product and have at least 1 PK sample collected.  These subjects will be 
evaluated for PK analysis unless the number of data points required for analysis is not 
enough, or signif icant protocol deviations have affected the data, or if key dosing or 
sampling information is missing . 
The proportion of subjects with an objective tumor response (partial and complete 
response) and disease control rate (DCR) (partial or complete control) with 
corresponding exact 80% CI will be calculated and tabulated.  Similarly, the proportion of 
subjects and 80% CI will be tabulated for 1 -year duration of overall response, 1 -year 
PFS, 1 -year duration of stable disease  and 1 -year OS .  Kaplan -Meier curve s will be 
presented for duration of overall response, PFS, OS, and duration of stable disease with 
estimates for rate and 80% CI at selected weeks if data allows.  
For a full description o f statistical analysis methods, please refer to Section  11. 
Sponsor Name:  Amgen Inc.   

Product:  AMG 404   
Protocol  Number:  20180143  
Date:  20 May 2022  Page 20 of 176 
CONFIDENTIAL    
3. Study Schema and Schedule of Activities  
3.1 Study Schema  
Figure 3-1.  Study Schema  
Cohort 1
(Dose Escalation)
Cohort 2
(Dose Escalation)
Cohort 3
(Dose Expansion)Cohort 4
(Safety Exploratory Dose)Cohort 5
(China/Taiwan/Hong Kong
RP2D* Expansion)
Cohort 6
(RP2D Expansion)
Cohort 8
(Tumor Specific Efficacy)
Cohort 9
(Tumor Specific Efficacy)Cohort 7
(Tumor Specific Efficacy)
RP2D = Recommended Phase 2 Dose; Q3W = every 3 weeks; and Q6W = every 6 weeks
* With safety lead -in
Refer to the schematics for each cohort below and Section 6.1 for further details
 
Page  1 of 4 

Product:  AMG 404   
Protocol  Number:  20180143  
Date:  20 May 2022  Page 21 of 176 
CONFIDENTIAL    
Figure 3-2.  Study Schema  
Amgen Proprietary -Confidential
End of TreatmentAMG 404 240 mg IV
every 4 weeksScreening
Safety Follow up
Long Term Follow 
upCohort 1: 240 mg Dose Escalation (N=2 -4) Cohort 2: 480 mg Dose Escalation (N=6 -9)End of TreatmentAMG 404 480 mg IV
every 4 weeksScreening
Safety Follow up
Long Term Follow 
up
Cohort 3: 480 mg Dose Expansion (N=20)
End of TreatmentAMG 404 480 mg IV
every 4 weeksScreening
Safety Follow up
Long Term Follow 
upCohort 4: 1050 mg Safety Exploratory Dose (N=20)
End of TreatmentAMG 404 1050 mg IV
every 4 weeksScreening
Safety Follow up
Long Term Follow 
upEnd of TreatmentAMG 404 RP2D* IV
every 4 weeksScreening
Safety Follow up
Long Term Follow 
upCohort 5: RP2D* China/Taiwan/Hong Kong Specific Expansion (N=12) Cohort 6: RP2D Expansion (N=20)
End of TreatmentAMG 404 RP2D IV
every 4 weeksScreening
Safety Follow up
Long Term Follow 
up
RP2D = Recommended Phase 2 Dose ; and IV = intravenous
*With safety lead -in
 
Page  2 of 4 
Product:  AMG 404   
Protocol  Number:  20180143  
Date:  20 May 2022  Page 22 of 176 
CONFIDENTIAL    
Figure 3-3.  Study Schema  
Amgen Proprietary - ConfidentialCohort 7 (N 40)
 Melanoma
 Small Cell Lung Cancer
 NSCLC, PD-L1 positive
 Head and Neck Squamous Cell Cancer, PD-L1 positive
 Urothelial, PD-L1 positive
 Gastric or GEJ adenocarcinoma, PD-L1 positive
 Esophageal, squamous, PD-L1 positive
 Cervical, PD-L1 positive
 Hepatocellular Carcinoma
 Merkel Cell Carcinoma
 Squamous Cell Carcinoma of the skin
 Renal Cell Carcinoma, clear cell
 Subtypes of sarcoma
o Undifferentiated pleiomorphic / malignant 
fibrous histiocytoma
o Poorly differentiated and/or dedifferentiated 
liposarcoma
o Alveolar Soft Tissue Sarcoma
o Angiosarcoma
 Thymic carcinoma
 Nasopharyngeal carcinoma ( )
 Mesothelioma
RP2D = Recommended Phase 2 Dose; PD-L1 = programmed death-ligand 1; 
GEJ = esophagogastric junction adenocarcinoma ; ; IV = intravenous; 
TPS = tumor proportion score; NSCLC = non-small cell lung cancer ; 
MSI-high = microsatellite instability; and dMMR = mismatch repair deficient
End of TreatmentAMG 404 RP2D IV
every 4 weeksScreening
Safety Follow up
Long Term Follow 
upCohort 7: RP2D Tumor Specific Efficacy (N=40) Cohort 8: RP2D Tumor Specific Efficacy (N=40)
End of TreatmentAMG 404 RP2D IV
every 4 weeksScreening
Safety Follow up
Long Term Follow 
up
Cohort 9: RP2D Tumor Specific Efficacy (N=40)
End of TreatmentAMG 404 RP2D IV
every 4 weeksScreening
Safety Follow up
Long Term Follow 
upCohort 8  (N = 40)
 MSI- high or dMMR subjects
-20 metastatic colorectal cancer
Cohort 9  (N = 40)
 Non-small cell lung cancer, PD- L1 positive, 
TPS 50
 
Page 3 of 4 

Product:  AMG 404   
Protocol  Number:  20180143  
Date:  20 May 2022  Page 23 of 176 
CONFIDENTIAL    
 
Page  4 of 4 

Product:  AMG 404   
Protocol  Number:  20180143  
Date:  20 May 2022  Page 24 of 176 
CONFIDENTIAL    
3.2 Schedule of Activities  
Table 3-1.  Schedule of Activities  for Cohorts  1-9 
CYCLES  Screening  
(up to 
28 days 
before 
Day 1) Treatment Period  Follow -up 
1* 2* 3* and 
beyond  Extended 
Treatment     
DAYS  1* 2 4 8 
(1d) 15 
(1d) 1* 2 4 8 
(1d) 15 
(1d) 1* 1* EOT12 Safety  
F/U10, 12 LTFU10 
Hours  
(relative to end of infusion)   Pre 
dose  0 
EOI 2 4 24 72 168 336 Pre 
dose  0 
EOI 2 4 24 72 168 336 Pre 
dose  0 
EOI Pre 
dose  0 
EOI    
GENERAL AND SAFETY A SSESSMENTS  
Informed consent  X                   X     
Inclusion and exclusion criteria  X                        
Demographics  X                        
Physical examination , ECOG 
PS, wt, (Ht at screening only)   X X      X X X        X  X  X X  
Medical history  X                        
ECG triplicate measurement1 X X1 X1  X1      X1        X1  X1    
Vital signs  X X X X X   X X X X X X     X X X X X X  
Adverse events review     
Serious Adverse Events17 X  
Concomitant medication review  X  
LABORATORY ASSESSMEN TS 
Pregnancy test (females of 
childbearing potential only)2 X X        X        X  X  X X  
Coagulation  X                        
Hematology  X X      X X X        X  X  X X  
Chemistry3 X X      X X X        X  X  X X  
HIV, Hepatitis B and C 
screening  X                        
Urinalysis  X X        X        X  X  X X  
ACTH, ANA, ANCA4 X X4                X4  X4  X4 X4  
Page 1 of 2  
Footnotes defined on next page of this table  
Product:  AMG 404   
Protocol  Number:  20180143  
Date:  20 May 2022  Page 25 of 176 
CONFIDENTIAL    
Table 3 -1.  Schedule of Activities  for Cohorts  1-9 
CYCLES  Screening  
(up to 
28 days 
before 
Day 1) Treatment Period  Follow -up 
1* 2* 3* and 
beyond  Extended 
Treatment     
DAYS  1* 2 4 8 
(1d) 15 
(1d) 1* 2 4 8 15 1* 1* EOT12 Safety  
F/U10, 12 LTFU10 
Hours (relative to end of 
infusion)   Pre 
dose  0 
EOI 2 4 24 72 168 336 Pre 
dose  0 
EOI 2 4 24 72 168 336 Pre 
dose  0 
EOI Pre 
dose  0 
EOI    
RADIOLOGICAL ASSESSM ENTS  
Tumor Evaluation/staging  
(CT, MRI, as appropriate)5 X                 X5  X5  X   
Brain MRI  or CT with contrast5 X                 X5  X5     
PHARMACOKINETIC ASSESSMENTS6 
Cohorts 1 –6 (all subjects), 
Cohorts 7 –9 (at least 
10 subjects of each cohort)   X X X X X X X X X X X X X X X X X X   X X  
Cohorts 7 –9 (remaining 
subjects)   X X       X X       X X   X X  
RESEARCH LABS, ALL S ITES  
ADA/ Immunogenicity   X       X X       X X9    X X  
Whole Blood for Cytometry13 X X   X X  X X X        X8       
LTFU  
Phone Call                         X 
Page 2 of 2  
Footnotes defined on next page of this table  

Product:  AMG 404   
Protocol  Number:  20180143  
Date:  20 May 2022  Page 26 of 176 
CONFIDENTIAL    
* A Cycle is defined as 28 ( 3) days; Day 1 assessment s must be done within 48  hours of AMG 404 infusion; screening assessments if done within 48 hours do not have to be repeated on 
day 1 of treatment; AMG 404 will be infused on Day 1 after all safety assessments have been complet ed. 
CT  computed tomography;  ECG  electrocardiogram; ECOG PS  Eastern Cooperative Oncology Group Performance Status; EOT  end of 
treatment ; HIV  human immunodeficiency virus; LTFU  long-term follow -up; MRI  magnetic resonance imaging; PK  pharmacokinetic; SFU   safety follow -up. 
1 A set of triplicate ECGs must be performed at screening; all ECGs will be triplicates with each tracing approximately 30 seco nds apart and run consecutivel y.  ECGs will only be collected 
for subjects enrolled to Cohorts 1 , 2 and 4 at the following time points :  Screening, C1D1 predose and end of infusion, C1 D1 ( 4 hours post dose), C2D1 end of infusion, C3D1 end of 
infusion, C4D1 end of infusion, and C5D1 end of infusion.  Beginning with Cycle 6  and beyond  for subjects enrolled to Cohorts 1 , 2 and 4 will have  ECGs performed  if clinically indicated.  
Subjects enrolled to Cohort 3 and Cohorts 5 -9 will have an ECG performed at screening and then as clinic ally indicated.  
2 Pregnancy testing is required for all female subjects of childbearing potential.  Serum pr egnancy test at screening and 48  hours prior  first dose  of AMG 404.  Beginning  with cycle 2 and 
beyond, a urine or serum pregnancy test is required within 48 hours prior to AMG 404 infusion.  
3 Chemistry to include:  Albumin, A lkaline  Phosphatase, ALT, AST, BUN/Total urea, Bicarbonate or CO2,  Calcium,  Calcium Corrected,  Chloride, Creatin ine, Glucose,  Potassium, Sodium, 
Total Bilirubin, Total protein, TSH, Free T4  
4 ACTH to be done  at screening, prior to C1D1, and then  every 8 weeks  (prior to cycles 1, 3, etc) . ANA and ANCA  (cytoplasmic and perinuclear)  to be done at screening and then if clinically 
indicated.  
5 tumor  evaluation scans every 8  ( 1) weeks, same modality should be used throughout study. MRI  or CT of brain required for all 
subjects during screening and  required on study only if subject has history of CNS disease; otherwise as clinically indicated.  If a subject discontinues treatment for reasons other than 
progression, tumor assessments should continue in follow up e very 8 (1) weeks until progression or start of a new treatment regimen.   Subjects with extended treatment  will undergo 
tumor evaluation scans every 12 (  2) weeks , and  MRI or CT of brain as clinically indicated.  
6 PK blood samples should be collected at the exact nominal time point as noted above (see hour postdose column).  If unable to collect a blood sample at the specified nominal time point, 
collect it as close as possible to the nominal time point and record t he actual collection time.  PK samples not collected at exact nominal time point will not be considered protocol 
deviations.  
9 Beginning with cycle 3, ADA/Immunogenicity sample collected every cycle, predo se (ie,  cycle 3, cycle 4, cycle 5, etc).  
10 Safety follow -up visit is to take place 30  ( 3) days  and 140 days  (7 days ) after last dose.  Long -term follow -up phone call at 6 months ( 1 week) after last dose to collect information on 
survival, start of new therapies, and disease status.  
12 The EOT and SFU may be combined if the visit occurs 30 (  3) days after the last dose of AMG  404.  In addition, for subjects that continue treatment of AMG  404 in the extended 
treatment period only, assessments for ADA/immunog enicity and PK will not be collected at EOT and SFU visits.   
13 Whole blood cytometry collections are required for Cohorts 1 -6 only for receptor occupancy immunophenotyping.  Last sample is collected cycle 3 predose (not required cycle 4 and 
beyond).  
14 Whole blood immunophenotyping collections are required for Cohorts 7 -9 only for analysis of lymphocyte activation and exhaustion.  Last sample is collected cycle 3  predose (not 
required cycle 4 and beyond).  
During the long-term follow -up phase serious adverse events suspected t o be related to investigational products that the investigator becomes aware of  
will be reported to Amgen.  After end of study , serious adverse events suspected to be related to investigational products will be reported to Amgen.   Please refer to 
Section  10.2.3.1.1.3  for additional details . 
  

Product:  AMG 404   
Protocol  Number:  20180143  
Date:  20 May 2022  Page 27 of 176 
CONFIDENTIAL    

Product:  AMG 404   
Protocol  Number:  20180143  
Date:  20 May 2022  Page 28 of 176 
CONFIDENTIAL    

Product:  AMG 404   
Protocol  Number:  20180143  
Date:  20 May 2022  Page 29 of 176 
CONFIDENTIAL    

Product:  AMG 404   
Protocol  Number:  20180143  
Date:  20 May 2022  Page 30 of 176 
CONFIDENTIAL    

Product:  AMG 404   
Protocol  Number:  20180143  
Date:  20 May 2022  Page 31 of 176 
CONFIDENTIAL    

Product:  AMG 404   
Protocol  Number:  20180143  
Date:  20 May 2022  Page 32 of 176 
CONFIDENTIAL    
 
 
 

Product:  AMG 404   
Protocol  Number:  20180143  
Date:  20 May 2022  Page 33 of 176 
CONFIDENTIAL    

Product:  AMG 404   
Protocol  Number:  20180143  
Date:  20 May 2022  Page 34 of 176 
CONFIDENTIAL    

Product:  AMG 404   
Protocol  Number:  20180143  
Date:  20 May 2022  Page 35 of 176 
CONFIDENTIAL    

Product:  AMG 404   
Protocol  Number:  20180143  
Date:  20 May 2022  Page 36 of 176 
CONFIDENTIAL    

Product:  AMG 404   
Protocol  Number:  20180143  
Date:  20 May 2022  Page 37 of 176 
CONFIDENTIAL    

Product:  AMG 404   
Protocol  Number:  20180143  
Date:  20 May 2022  Page 38 of 176 
CONFIDENTIAL    
 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 39 of 176 
CONFIDENTIAL    
4. Background and Rationale  
4.1 Disease and Target Background  
Anti-tumor surveillance  by the immune system  is a well -known mechanism to prevent 
growth and spread of malignancies.  This natural defense mechanism is, however, 
susceptible to fatigue.  T cells can lose their efficacy through increased expression of  the 
programmed cell death -1 (PD-1) proteins and their ligands, PD -L1. (Riley et al,  2009).  
The programmed cell death -1 (PD -1) receptor -ligand interaction is a major pathway 
hijacked by tumors to suppress immune control (Pedoeem et al, 2014).  The normal 
function of PD -1, expressed on the cell surface of activated T cells under healthy 
conditions, is to down -modulate unwanted or excessive immune responses, including 
autoimmune reactions.  PD -1 (encoded by the gene Pdcd1) is an immunoglobulin (Ig) 
superfamily member related to CD28 and cytotoxic  T-lymphocyte -associated protein 4 
(CTLA -4), which has been shown to negatively regul ate antigen receptor signaling upon 
engagement of its ligands (PD -L1 and/or PD -L2). 
Enhancement of anti -tumor immunity through inhibition of PD-1/PD -L1 has been 
effective in treatment of many malignancies ( Pembrolizum ab US Prescribing 
Information, Nivolumab US Prescribing Information  and Cemiplimab US Prescribing 
Information ).  For example, use of PD-1/PD -L1 monoclonal antibodies have resulted in 
objective tumor response  and/or improved survival in lung cancer, melanoma, uro thelial 
carcinoma, head and neck squamous cell carcinoma, and cutaneous squamous cell 
carcinoma  (Gong et al, 2018) . 
While objective responses have been achieved in many patients, some do not benefit 
from anti -PD-1 monotherapy.  Optimal therapy will likely require combining anti -PD-1 
monoclonal antibody treatment with conventional therapies and novel targeted or 
immunotherapy approaches.   
The use  of combination s of chemotherapy , targeted therapy, and other checkpoint 
inhibitors and immune modulating agents a long with PD -L1 inhibitors is being 
investigated in multiple disease states and has  been  shown to improve efficacy over 
some of the former stand ard therapies (for example, in non -small cell lung cancer  in 
combination with chemotherapy or in combination wit h chemotherapy and 
antiangiogenic th erapy [ Socinski et al , 2018 ], and in melanoma in combination with 
CTLA -4 inh ibitors [ Wolchok et al , 2017 ]). 
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 40 of 176 
CONFIDENTIAL    
4.1.1  PD-1/PD -L1 Inhibitors and Treatment of NSCLC  
Programmed  cell death -1 checkpoint blockade has transfor med the treatment of 
NSCLC.  Programmed  cell death -1, and then PD -L1 inhibitors were first approved for 
NSCLC in the second line or later setting based on studies showing significant 
anti-tumor activity and improved overall survival in both squamous and no n-squamous 
NSCLC when compared to docetaxel alone.  Nivolumab, pembrolizumab, and 
atezolizumab are approved by the United States Food and Drug Administration ( US 
FDA) for treatment of second line  or later advanced or metastatic  NSCLC  (Doroshow et 
al, 2019) .   
In the front -line setting, clinical trials with PD -1/ PD-L1 inhibitors have demonstrated 
improved overall survival when given as monotherapy in PD -L1 expressing tumors  and 
in combination with chemotherapy .  Pembrolizumab is US FDA approved for first li ne 
monotherapy in advanced NSCLC expressing PD -L1 with tumor proportion score 
(TPS)  1% (Keytruda USPI) .  Cemiplimab is approved for the first -line treatment of 
NSCLC with high PD -L1 TPS  50% (Libtayo USPI).  Atezolizumab is also approved for 
first-line treatment of tumors with high PD -L1 expression (Tecentriq  USPI).  The addition 
of PD -1/PD -L1 inhibitors to first line chemotherapy demonstrated improvement in overall 
survival in metastatic NSCLC regardless of PD -L1 expression. (Chiang et al, 2020).  The 
Keynote -189 study compared pembrolizumab, platinum -based drug,  and pemetrexed to 
placebo, carboplatin, and pemetrexed in subjects with non -squamous NSCLC and 
reported a 12  month overall survival of 69.2% versus 49.4% 
(HR  0.49;  95% CI: 0.38 to 0.64;  P  0.001), and led to the FDA approval of 
pembrolizumab, platinum -based drug , and pemetrexed for first line treatment of 
metastatic nonsquamous NS CLC regardless of PD -L1 expression (Gandhi  et al,  2018) . 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 41 of 176 
CONFIDENTIAL    
4.2 Amgen Investigational Product Background:  AMG 404  
4.2.1  Nonclinical Pharmacology  
AMG  404 is a fully human antibody that binds human and cynomolgus monkey PD -1 
with high affinity and blocks the ability of these receptors to interact with human ligands, 
PD-L1 and PD -L2.  The ligand blocking activity of AMG  404 was evaluate d in three 
different assays using three different readouts and both cell -expressed, as well as 
recombinant, soluble ligands.  In each assay, AMG  404 demonstrated the expected 
dose -dependent activity, indicating it is a potent inhibitor of human and cynomol gus 
monkey PD -1 binding .   
AMG  404 blocks the interaction between cynomolgus monkey PD -1 and human PD -L1 
with a similar IC 50 as human PD -1 and human PD -L1, suggesting that cynomolgus 
monkey is an appropriate species for nonclinical safety evaluation.    
AMG  404 is an IgG1 antibody; however, the Fc region has been modified to eliminate 
undesired interactions with Fc gamma receptors.  The absence of Fc -binding to Fc  
gamma receptors was demonstrated in a functional assay where the ability of AMG  404 
to induce A DCC activity was compared to a positive control anti -CD38 antibody and 
negative control antibodies.  In this assay, AMG  404 activity  was comparable to the 
negative control antibodies  and was much less than the positive control .  These results 
demonstrate t hat the Fc region of AMG  404 does not interact with Fc gamma receptors.  
4.2.2  Toxicology  
The potential for AMG 404  to cause acute release of cytokines from human peripheral 
blood leukocytes (PBL ) in the presence of human endothelial cells (HUVEC s) was 
evalua ted in vitro.  H uman PBL were  cultured in autologous Platelet Poor Plasma (PPP) 
in the presence of HUVECs with AMG 404 (0.0112 – 35 µg/mL)  for 24  hours, and 
supernatants from the cultures were  subsequently assess ed for the presence of 
cytokines ( IFNγ, IL-1β, IL -2, IL-4, IL-6, IL-8, IL-10, IL -12 p70, and TNFα).  Under the 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 42 of 176 
CONFIDENTIAL    
conditions tested in this assay, AMG 404 did not induce cytokine release above 
background levels.  
AMG 404 was evaluated in a 28 -day GLP toxicology study in cynomolgus monkeys.  
Doses of  0, 10 or 100 mg/kg were administered by slow IV bolus, and doses of 0 or 
100 mg/kg were administered SC (3 animals/sex/group).  Animals were dosed once 
weekly (4 total doses).  There were no AMG 404 -related clinical signs or effects on body 
weight, food c onsumption, respiratory rate, body temperature, organ weights, or 
urinalysis parameters and no AMG 404 -related ocular, electrocardiographic, neurologic, 
or macroscopic findings.  AMG 404 -related clinical pathology changes were limited to 
mild decreases in lymphocytes for females at all dose levels on Day 2 that were 
generally similar to control and/or baseline values on Day 9 and throughout the 
remainder of the study, and  mildly increased C -reactiv e protein in some animals.  
AMG  404-related microscopic find ings included an increased incidence and/or severity 
of mononuclear cell infiltration in the brain (minimal to mild) and/or spinal cord (minimal) 
of animals given  10 mg/kg IV or 100 mg/kg SC and at the administration site (minimal 
to mild) of males given  100 mg/kg SC.  The increased incidence and/or severity of 
mononuclear cell infiltration in the brain and/or spinal cord observed in this study may 
represent an exacerbation of this background finding in cynomolgus monkeys, while the 
mononuclear cell infil tration at the administration site was considered an expected 
reaction to the administration of an exogenous protein.  In conclusion, administration of 
AMG 404 by  once weekly IV bolus or SC injection was well tolerated in cynomolgus 
monkeys at levels of 10  mg/kg IV and 100 mg/KG IV and SC.  
4.2.3  Nonclinical Pharmacokinetics  
The PK of AMG 404 was characterized after single intravenous (IV) bolus injection at 0.5 
and 5 mg/kg and single subcutaneous (SC) injection at 5 mg/kg to male cynomolgus 
monkeys.  Serum concen trations of AMG 404 declined in a biphasic manner for the first 
168 hours post dose followed by a more rapid decrease , most  likely because of the 
formation of  anti-AMG 404 antibodies  (ADA)  which were  observed in all animals at 
336 hours post dose.   
The to xicokinetics (TK) of AMG 404 were characterized in a Good Laboratory Practice 
(GLP) study after weekly IV administration of 10 or 100 mg/kg or SC administration of 
100 mg/k g for four consecutive weeks.  Following  repeat dose administration , AMG  404 
exposur e increased approximately dose -proportionally from 10 to 100 mg/kg as 
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 43 of 176 
CONFIDENTIAL    
measured by C max and AUC over 6 days.  AMG  404 exposures were similar between 
male and female animals.   
4.2.4  Rationale for Development AMG 404  
Blockade of the PD -1/PD -L1 T-cell checkpoint pathway is an effective and generally well 
tolerated approach to stimulating  immune response to tumor cells.  While objective 
responses have been achieved in many patients, some do not benefit from PD -1 
monotherapy. Optimal therapy will likely require comb ining anti -PD-1 monoclonal 
antibody treatment with conventional therapies and novel targeted or immunotherapy 
approaches.   Amgen is developing a large oncology portfolio and to maximize this 
portfolio for patient benefit , Amgen is developing AMG  404.  Acce ss to AMG  404 allows  
Amgen to develop a deeper understanding of target engagement and pharmacodynamic 
profile in combination with our portfolio and  facilitates more rapid do sing and dose 
frequency adaptations while studying across multiple malignancies (so lid tumors  and 
hematologic malignancies) .   
This study will evaluate AMG  404 as a monotherapy  
 to determine safety and tolerability.   

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 44 of 176 
CONFIDENTIAL    

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 45 of 176 
CONFIDENTIAL    
4.5 Benefit/Risk Assessment  
AMG  404  
This is a first -in-human study with AMG  404.  Based on nonclinical toxicity studies of 
AMG  404, clinical experience with AMG  404, and clinical experience with other 
anti-PD(L)  -1 therapies, the overall benefit/risk profile favors clinical development of 
AMG  404 for patients with advanced solid tumors.   
Clinical signs and symptoms, along with other safety laboratory parameters, will be 
monitored during the study and at the appropriate time points to ensure subjects’ safety.   
The following benefit /risk assessment supports the conduct of this clinical tria l.  Refer  to 
the AMG  404 Investigator’s Brochure for further information . 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 46 of 176 
CONFIDENTIAL    
4.5.1  Therapeutic Context  
AMG  404 
AMG  404 will be investigated in subjects with advanced solid tumors  as monotherapy 
 
4.5.2  Benefits  
AMG  404 
As AMG  404 is  in early development and clinical experienc e is limited, key benefits are 
being investigated and will be described when the data become available.  
4.5.3  Risks  
AMG  404 
AMG  404 is being evaluated as an ongoing monotherapy in the current study.   
Based on the available clinical  data with AMG  404, hypothyroidism , colitis, 
pneumonitis, and myasthenia gravis are identified risks  of AMG  404 (see 
Table  4-1). 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 47 of 176 
CONFIDENTIAL    
Table 4-1.  Key Safety Risks of AMG 404  
Safety Risk  Description  
Hypothyroidism  Administration of AMG  404 has been associated with 
hypothyroidism or blood thyroid stimulating hormone increased.  
Signs and symptoms that may be associated with 
hypothyroidism include fatigue, increased sensitivity to cold, 
constipation, dry skin, weight gain, hoarseness, muscle 
weakness, myalgia, arthralgia, menstrual disturbance, alopecia, 
bradycardia, hypercholesterolemia, depression, impaired 
memory, and enlarged thyroid gland (goiter).  
Hypothyroidism or blood thyroid stimulating hormone increased 
reported events did not lead to AMG  404 discontinuation or 
AMG  404 treatment interruption.  Subjects should be monitored 
for laboratory values of thyroid stimulating hormone and Free T4, 
and signs and symptoms of hypothyroidism during AMG  404 
treatment.  Subj ects should continue to be monitored after 
discontinuation of AMG  404 due to the risk of late onset 
hypothyroidism.  Requirements for monitoring and management 
of hypothyroidism are provided in the clinical study protocol.  
Colitis  Administration of AMG  404 has been associated with colitis.  
Signs and symptoms that may be associated with colitis include 
diarrhea, abdominal pain, abdominal cramping, and blood or 
mucus in the stool.  
Colitis events have led to AMG  404 discontinuation.  Subjects 
should be mon itored for signs and symptoms of colitis during 
AMG  404 treatment.  Subjects should continue to be monitored 
after discontinuation of AMG  404 due to the risk of late onset 
colitis.  Requirements for monitoring and management of colitis 
are provided in the clinical study protocol(s).  
Pneumonitis  Administration of AMG  404 has been associated with 
pneumonitis.  Signs and symptoms that may be associated with 
pneumonitis include cough, shortness of breath, chest pain and 
fatigue.  Pneumonitis events have led to  discontinuation of 
AMG  404.  Subjects should be monitored for signs and symptoms 
of pneumonitis during AMG  404 treatment.  Subjects should 
continue to be monitored after discontinuation of AMG  404 due to 
the risk of late onset pneumonitis.  Requirements for monitoring 
and management are provided in the clinical study protocol(s).  
Myasthenia Gravis  Administration of AMG  404 has been associated with the serious 
myasthenia gravis in one subject in a combination study of 
AMG  404 and AMG  160 for prostate can cer. 
Signs and symptoms that may be associated with myasthenia 
gravis include diplopia, ptosis, muscle weakness and fatigability, 
difficulty with speech, swallowing, and/or breathing.  Myasthenia 
gravis event led to permanent discontinuation of the study d rugs.  
Subjects should be monitored for signs and symptoms of 
myasthenia gravis during AMG  404 treatment.  
 
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 48 of 176 
CONFIDENTIAL    
Additional key safety information, which are based on the mechanism of action, 
the nonclinical safety pharmacology and toxicology studies for AMG  404, 
available data from the ongoing clinical study, and class effects of approved 
PD-1/PD -L1 checkpoint inhibitors, but for which a causal association with 
AMG  404 has not been established, are summarized below  (see Table 4-2). 
Table 4-2.  Potential Safety Concerns Based on Drug Class Effects, Biological 
Mechanism of Action, and Nonclinical Studies  
Safety Risk  Description  
Immune -related toxicities  Immune -related adverse effects associated with PD -1 blocking 
agents include pneumonitis, colitis, hepatitis, endocrinopathies, 
nephritis and renal dysfunction, skin reactions, encephalitis, and 
other immune -related adverse reactions  (including the 
identified risks of hypothyroidism, colitis, pneumonitis, and 
myasthenia gravis).   
Infusion -related reactions  Severe and life -threatening infusion -related reactions have 
been observed with other anti -PD-1 therapies and may occur 
with the administration of AMG  404.  Signs and symptoms may 
include pyrexia, chills, rigors, flushing, urticaria, hypotension, 
dyspnea, wheezing, headache, back pain, and abdominal pain.  
Embryofetal toxicity  Based on its mechanism  of action, AMG  404 may cause fetal 
harm if administered during pregnancy.  Animal studies 
published in the literatures have demonstrated that 
inhibition of the PD -1/PD -L1 pathway can lead to increased 
risk of immune -mediated rejection of the developing fe tus 
resulting in fetal death.  However, the risk to a fetus 
following conception by an AMG  404 exposed male, or the 
risk to a fetus from an AMG  404 exposed male sexual partner 
of a pregnant woman, is uncharacterized.  
PD-1  programmed cell death 1; PD -L1  programmed death ligand 1  
Clinical signs and symptoms of immune -related toxicities and infusion -related reactions, 
along with safety laboratory parameters, will be monitored during the study to ensure 
subjects’ safety.  To mitigate embryofetal toxicity r isk, study subject contraception will be 
required, and pregnancy status will be monitored.  Refer to Section 8.4.3  for specific 
recommendations regarding the mitigation and management of immune -related 
toxicities , infusion -related reactions , and embryofetal toxicity . 
For additional key safety information, refer to the AMG  404 Investigator’s 
Brochure.
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 49 of 176 
CONFIDENTIAL    

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 50 of 176 
CONFIDENTIAL    
Refer to the AMG  404 Investigator’s Brochure ,
 for further description of key 
safety information . 
5. Objectives, Endpoints and Hypotheses  
5.1 Objectives and Endpoints  
 
Objectives  Endpoints  
Primary  
 To evaluate the safety and tolerability  
and determine the recommended 
phase 2 dose (RP2D)  of AMG  404 in 
patients with advanced solid tumors   Dose limiti ng toxicities (DLTs), 
treatment -emergent adverse events, 
treatment -related adverse events, and 
changes in vital signs, and clinical 
laboratory tests  
Secondary  
 To evaluate the pharmacokinetics 
(PK) of AMG  404 as a monotherapy 
 
  PK parameters of AMG  404 including, 
but not limited to, maximum observed 
serum concentration (C max), time to 
achieve C max (tmax), and area under 
the serum concentration -time curve 
(AUC)  
 To assess the immunogenicity of  
AMG  404 as a monotherapy  
  Subject incidence of anti -AMG  404 
antibodies  
 To evaluate the preliminary antitumor 
activity of AMG  404 as a 
monotherapy   Objective tumor response, duration of 
overall response, progression -free 
survival, disease control rate (DCR), 
and duration of stable disease 
measured by CT /MRI and assessed 
per modified RECIST 1.1  
 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 51 of 176 
CONFIDENTIAL    
 
Exploratory  
 
5.2 Hypotheses  
AMG  404, as a monotherapy  is safe and 
well tolerated in patients with advanced solid tumors . 
6. Study Design  
6.1 Overall Design  
This is a first -in-human (FIH), multicenter, non -randomized, open -label, phase 1 study to 
evaluate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of 
AMG 404 in subjects with advanced solid tumors.  The study may be conducted in 
Australia, United States , France, Poland, United Kingdom, Belgium,  Spain, Turkey,  
South Korea, Taiwan, Japan,  Singapore,  China , Canada , Brazil and Mexico . Other 
countries or regions may participate.  The study will co nsist of up to 9 cohorts to 
evaluate the safety, tolerability, PK and PD of AMG  404 administered every  4 weeks 
(Q4W) with the following doses:  Cohort 1 – 240 mg, Cohort 2  – 480 mg,  
Cohort  3 – Expansion at the dose of 480 mg  (subjects enrolled outside of China) , 
Cohort  4 – Exploratory Dose of 1050 mg , Cohort 5  – China /Taiwan/Hong Kong  Specific 
Expansion at the recommended phase 2 dose (RP2D)  with a safety lead -in (  
), Cohort  6 – Expansion at the RP2D , 
Cohort  7 – Expansion  at the RP2D in specific indi cations as specified in Section  2.1, 
Cohort  8 – Expansion at the RP2D in subjects with tumors that are microsatellite 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 52 of 176 
CONFIDENTIAL    
instability -high (MSI -H) or mismatch repair deficient (dMMR), and Cohort  9 – Expansion 
at the RP2D in subject s with non -small cell lung cancer (NSCLC) that is PD -L1 positive, 
TPS  50% (Cohort s 6-9 will enroll subjects outside of China) .   
In Cohorts  1-9, AMG 404 will be administered intravenously (IV) over approximately total 
30 minutes, every 4  weeks in subjects with advanced  solid tumors.  Cohort s 3 and 4 can 
be opened once Cohort 2 has been completed and determined to be tolerable.  Cohorts 
5-9 can be opened once  the first 6-9 subjects in Cohort 4 ha ve completed the DLT 
evaluation period and data ha ve been reviewed to determine the RP2D.   The DLT 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 53 of 176 
CONFIDENTIAL    
evaluation period will be 28 days.  The Dose Level Review Meeting (DLRM) may 
recommend escalation to the next planned dose, escalation to an intermediate dose (a 
dose lower than the next planned dose), continuation or delay in dosing, repetiti on or 
expansion of a cohort, de -escalation to a lo wer dose, or termination of the study.  
Administration of AMG  404 may continue until evidence of disease progression, 
intolerance to study medication, withdrawal of consent, or in the absence of the above 
up to 12  months if subject achieves a complete respo nse, and up to 24  months if partial 
response or stable disease.  For subjects with complete response , treatment beyond 
12 months may be permitted upon discussion with the medical monitor .  After 
discussion with the medical monitor, subjects with complete response, partial 
response, stable disease or continued clinical benefit at 24  months of treatment, 
may continue treatment for up to an additional 24  months (up to 48  months of 
treatment in total) .  If a subject compl etes or discontinues treatment for reas ons other 
than progression, tumor evaluations should continue according to the Schedule of 
Activities ( for Cohorts  1-9, refer to Table 3 -1,  
 
 until progression or start of a new treatment reg imen.  
Cohort 1 , 2 and Cohort 4 
The doses of 240 mg, 480 mg and 1050 mg will be examined for safety, tolerability, PK, 
and PD of AMG  404 in subjects with advanced solid tumors.  Rules for dose 
determination, and dose expansion are derived using a modified T oxicity Probability 
Interval (mTPI) model (Ji et al. 2010) with a target toxicity probability interval (TPI) of 
0.20 to 0.33 with a TPI   0.33 defined as excessive toxicity.   
 Subjects will not be dosed at a level above the dose level indicated by the mTPI  
model.  In particular, subjects will not be dosed at the current dose level or higher 
when the mTPI model indicates stopping enrollment at the current dose level and 
patients will not be dosed at an escalated dose level when the mTPI indicates 
staying at the current dose level.  
 After reviewing a broad range of safety information including vital signs, 
laboratory values and detailed adverse events profiles, the team may choose to 
dose subjects below the dose level indicated by the mTPI model.  For example, 
the team may choose to stop enrollment at the current dose level even if the 
mTPI model indicates staying at the current dose level.  
The Dose Level Review Team (DLRT) will review data, monitor safety, and make 
recommendations  on dose modifications based on all subjects that have been enrolled.   
A Dose L evel Review Meeting will be conducted after Cohorts 1 , 2 and 4 and may 
convene ad hoc to review safety data if deemed necessary.   

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 54 of 176 
CONFIDENTIAL    
Three dose  levels are planned to be tested:  
 Cohort 1:  240 mg every 4 weeks (N   2-4) 
 Cohort s 2 and 3 :  480 mg every 4 weeks ( Cohort 2:  N  6-9; Cohort 3: N   20) 
 Cohort 4:  1050 mg every 4 weeks (N   20) 
Dose escalation will begin with a run -in dose level of 240 mg (Cohort 1).  If no DLTs are 
observed in Cohort 1, dose escalation will continue to the next planned dose level in 
Cohort 2.  If DLTs are observed in Cohort 1 subsequent will be determined by Amgen 
after consulting with the Dose Level Review Team (DLRT) and constrained by the mTPI 
model.  
The table below shows rules for dose determination and dose expansion per the mTPI 
model.  
Table 6-1.  Guideline for Dose Level Decisions for Cohort 2 (480 mg) and Cohort 4 
(1050 mg ) 
No. of Subjects  Number of DLT observed at current dose  
ESCALATEa STAY AT CURRENT 
DOSE  STOP ENROLLMENT 
AT CURRENT DOSE  
3 N/A ≤ 1 ≥ 2 
4 N/A ≤ 1 ≥ 2 
5 N/A ≤ 2 ≥ 3 
6 0 1 – 2 ≥ 3 
7 ≤ 1 2 – 3 ≥ 4 
8 ≤ 1 2 – 3 ≥ 4 
9 ≤ 1 Maximum sample size 
reached  Maximum sample size 
reached   
a For Cohort 4 (1050 mg), if the rules for dose escalation are met, enrollment may be stopped as there is 
sufficient evidence that 1050 mg dose is safe and tolerable; and this is the highest planned dose level 
being investigated on study.  
Cohort 3 
Upon  completion of  Cohort 2 of the study and depending on data obtained, dose 
expan sion may proceed with the  planned  dose of 480 mg in Cohort 3 (N  20) outside of 
China . 
Cohort s 5-9 
Upon completion of the first 6 -9 subjects in Cohort 4 of the study and depending on data 
obtained, dose expansion may proceed with the RP2D in Cohort  5 with a safety lead -in 
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 55 of 176 
CONFIDENTIAL    
(from China , and from National Medical Products Administration ( NMPA ) certified sites in 
Taiwan and Hong Kong ) and Cohorts 6 -9 (from all countries participating on the study, 
excluding China).   The RP2D  will be determined following review of available data 
obtained in Cohorts 1 through 4 including safety, tolerability, PK and PD data.    
   
Cohort 5 was a China /Taiwan/Hong Kong -specific expansion cohort with a safety lead -in 
at one dose below the RP2D followed by evaluation at RP2D, as appropriate.   Up to 
12 subjects would  be enrolled  in China  and NMPA certified sites  in Taiwan, and /or Hong 
Kong.   
The o verall study design is described by a study schema in Figure 3-1.  The endpoints 
are defined in Section 5.1. 
Intra -subject dose escalation  for Cohorts  1-9 
Intra-subject dose escalations are allowed on this study for subjects enrolled, where 
applicable.  Subjects enrolled to Cohort 1 who complete the DLT period may proceed to 
480 mg once Cohort 2 has been deemed safe by the DLRT; subjects receiving 480  mg 
(in Cohorts 1 -3) who complete the DLT period may proceed to the RP2D once 
determined if a dose higher than 480 mg is selected as the RP2D.  Subjects enrolled to 
the safety lead -in dose in Co hort 5, may escalate to the RP2D dose level once the RP2D 
is determined safe following the China /Taiwan/Hong Kong  specific DLR T 
recommendation.   . 
All intra -subject dose escalations may occur after consultation with the sponsor if:  
 No DLT has been reported for this subject during or after completion of the DLT 
period  

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 56 of 176 
CONFIDENTIAL    
Subjects who do not proceed to the higher dose may receive additional cycles at the 
original dose.  

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 57 of 176 
CONFIDENTIAL    

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 58 of 176 
CONFIDENTIAL    

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 59 of 176 
CONFIDENTIAL    
6.2 Number of Subjects  
Up to 275 evaluable subjects  with advanced solid tumors  will be enrolled in the study . 
Subjects in this clinical investigation shall be referred to as “subjects .”  For the sample 
size justification, see Section 11.1. 
6.2.1  Replacement of Subjects  
Subjects that are not DLT -evaluab le may be replaced.  A DLT -evaluable subject is 
defined as:  
 Subject who has received at least 90% of the planned dose of investigational 
product (s) and is followed for at least 1 cycle , or  
 Subject who has experienced a DLT ; 
In addition, for subjects enrolled to Cohor ts 7- subjects must complete an on -study 
radiographic assessme nt. 
6.2.2  Number of Sites  
Approximatel y 35 investigative sites in Australia, United States, France, Poland, Turkey, 
Spain, United Kingdom, Belgium, South Korea, Taiwan, Japan,  China,  Singapore, 
Canada , Brazil, Mexico , and ot her countries or regions may participate i n the study.  

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 60 of 176 
CONFIDENTIAL    
Sites th at do not enroll subjects within 3 months (provided slots are available)  of site 
initiation may be closed . 
6.3 End of Study  
6.3.1  End of Study Definition  
Primary Completion:   The primary completion date is defined as the date when the last 
subject is assessed or receives an intervention for the final collection of data for the 
primary  endpoint(s), for the purposes of conducting the primary analysis, whether the 
study concluded as planned in the protocol or was terminated early.  
End of Study:   The end of study date is defined as the date when the last subject 
across all sites is assesse d or receives an intervention for evaluation in the study (ie, last 
subject last visit), following any additional parts in the study (eg, long -term follow -up), as 
applicable.  
6.3.2  Study Duration for Subjects  
It is anticipated that an individual subject will  participate in the study for up to 
approximately 2.5 years .  This includes, the  screening period lasting up to 28 days , a 
treatment period up to 2 years,  and a follow up period of 6 months  after end of 
treatment .  Subjects with continued clinical benefit may have their study duration  
extended for up to 2 additional years  of treatment  (refer to Section  10.1.3 ). 
The actual du ration for individual subjects will vary depending upon tolerability of study 
treatment(s) , evide nce of clinical progression, and willingness to participate in the study.  
6.4 Dose Rationale  
6.4.1  First in Human Starting Dose Selection Rationale  
The PK of AMG  404 was based on allometric scaling of clearance and volume 
parameters obtained from studies in cynomolgus monkeys.  The AMG  404 human PK 
parameter estimates were comparable to those derived from human population PK 
models for pembrolizumab and nivolumab (Aha madi, 2017; Bajaj, 2017).  The predicted 
terminal elimination half -life (t 1/2,z) is estimated to be consistent with other therapeutic 
anti-PD1 mAbs.  The planned doses of AMG  404 in this study are 240, 480 and 1050 mg 
administered as short -term IV infusions  (approximately 0.5 hours) every four weeks 
(Q4W) in patients with advanced malignancies.  Dose escalation decisions will be 
guided primarily by observed safety and tolerability of AMG  404, 
Dose selection was informed  by the clinical experience with other therapeutic anti -PD1 
mAbs .  Pembrolizumab and nivolumab have been shown to be generally well-tolerated  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 61 of 176 
CONFIDENTIAL    
at and above exposures of their approved  doses in patients , which are 200 mg Q3W and 
240 mg Q2W, respectively , where  flat exposure -response relationships  for safety were  
observed (Chatterjee, 2016; Feng, 2017; Wang, 2017; CDER Clin Pharm Biopharm 
Review for nivolumab; CDER Clin Pharm Biopharm Review for pembrolizumab ).  
AMG  404 is a human IgG1 anti-PD1 mAb analogue  that targets the human PD -1.  The 
fractio n crystallizable ( Fc) region of AMG 404 has been engineered to eliminate 
undesired interactions with Fc gamma receptors and complement.  In studies with Hut78 
T cells and human peripheral blood mononuclear cells , AMG  404 did not have residual 
antibody -depe ndent cellular cytotoxicity (ADCC) activity.  Taken together, the projected 
AMG  404 efficacious dose is expected to be well-tolerated .  Implementing precautionary 
measures for AMG  404 as a new molecular entity, a 2 -fold safety factor was added to 
the projected efficacious dose estimate for the starting dose.   
To determine the starting dose, efficacious exposure  targets for AMG  404 were first 
computed by scaling clinically efficacious exposures (as assessed by the time -averaged 
concentration over a dos ing interval at steady state [C avg,ss]) for approv ed dosing 
regimens of anti -PD-1 mAbs , pembrolizumab (200 mg Q3W) and nivolumab (240 mg 
Q2W) (Freshwater, 2017; Zhao, 2017) by the corrections for molecular weight ratios and 
the ratios of in vitro pharmacol ogical activity for inhibition of human PD -1 binding to 
PD-L1.  In combination with human PK predictions, the efficacious doses of AMG  404 
that achieve the predicted C avg,ss exposures were determined to be between 350 and 
720 mg Q4W IV using the results of  the 2 studies with a mean  estimate  of 535 mg 
Q4W  IV.  
The starting dose of 240 mg Q4W IV was selected  using the efficacious dose estimate of 
480 mg based on both approximately the mean  efficacious dose estimate (535 mg Q4W 
IV) and evaluation of in vitro pharmacological activities of  AMG  404 and nivolumab , 
which is also approved for dosing at 480 mg Q4W IV (Prescribing information for 
Opdivo®) and addition of the 2 -fold safety factor .  By starting  one dose level below the 
predicted efficacious dose, exposu re of subjects to doses that are not expected to be 
efficacious is limited.  Receptor occupancy (RO) data were  not utilized  for FIH dose 
selection given that  saturated  receptor occupancy of other therapeutic anti -PD1 mAbs  
was observed at subtherapeutic dos es in patients.  
The starting dose is also supported by  the 28-day GLP  nonclinical toxicology study  in 
cynomolgus monkeys.  AMG 404 has been well -tolerated at doses up to 100 mg/kg  QW.  
At the predicted human exposures of proposed starting dose, exposure mu ltiples for 
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 62 of 176 
CONFIDENTIAL    
AUC and C max are calculated to be 24- and 23-fold, respectively  when compared to the 
AUC and C max at the highest non -severely toxic dose ( HNSTD ) of 100 mg/kg QW in 
monkey s. 
The highest planned dose is 1050 mg Q4W  IV.  At this dose, exposure multiples for both 
AUC and C max are calculated to be 5-fold when compared to the AUC and C max at the 
HNSTD in monkey s. 
A fixed dose regimen was selected for the FIH study given that,  for mAb -based 
therapies, body weight may or may  not be a  determinant of PK variability  (Wang, 2009; 
Bai, 2012).   Use of fixed dosing for AMG 404 is further supported by the flat 
exposure -response relationships for efficacy and safety of other therapeutic anti-PD1 
mAbs, indicating that fixed dosing of AMG 404 is not expected  to have a clinically 
meaningful effect on safety and efficacy.  In addition, fixed dosing has logistical 
advantages including ease of administration, reduced risk of dosing errors, minimal 
preparation by hospital staff, and reduced patient waiting time.  
6.4.2  Recommended Phase 2 Dose Selection  
Predicted efficacious exposure targets for AMG  404 monotherapy in subjects were 
computed by scaling clinically efficacious exposures, as assessed by time -averaged 
concentration over a dosing interva l at steady state (C avg,ss), for approved dosing 
regimens of anti -PD-1 mAbs  as described above in Section  6.4.1 .  Using preliminary 
human PK para meter estimates from population PK modeling of observed data from the 
study, the efficacious monotherapy dose of AMG  404 that achieves the computed 
exposure target is predicted to be within range of 480  mg IV Q4W, which is the 
cohort -2 dose.  
Safety, tolera bility, PK, and PD of AMG  404 at dose levels of 240, 480, and 1050  mg are 
being investigated in subjects with advanced solid tumors.  As of 0 8-October -2019 data 
cut-off date, AMG 404 was safe and well tolerated across the 240 - and 1050 -mg dose 
range with no dose -related increases in frequency or severity of adverse events in 
subjects and no DLTs.  Preliminary PK results were consistent with those for other 
therapeutic anti -PD-1 mAbs . Maximum observed drug concentrations (C max) of AMG  404 
occurred at or nea r the end of infusion with a median t max of 0.5 to 2.5 hours, as 
expected with 0.5 -hour IV infusion administration.  An approximately dose -proportional 
increase was observed over the dose range of 240 to 1050 mg IV Q4W  with ~5 -fold 
increases in exposure fo r both Cmax and AUC for a 4.4-fold increase in AMG  404 
dose.   Peripheral RO data were not expected to provide meaningful information to 
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 63 of 176 
CONFIDENTIAL    
assess efficacy of AMG  404, given that saturating peripheral RO has been observed 
clinically at exposures lower than the rapeutic doses of other anti -PD-1 mAbs.   However, 
preliminary PD results at the 240 -mg and 1050-mg dose levels were consistent with the 
expected saturation of RO for these doses given the potent inhibition of PD -1/PD -L1 
interactions in vitro with low nanom olar IC 50 values and preliminary observed AMG  404 
exposures in human subjects.   As of the data cutoff date , 6/36 (16.7%) subjects with 
postbaseline results are positive for binding ADAs. Of the 6 binding ADA -positive 
subjects, 5 were in the 480 mg cohort a nd 1 was in the 1050 mg cohort.  Of the 
5 binding ADA -positive subjects in the 480 mg cohort, 1 subject had pre -existing binding 
ADAs and the rest were treatment -emergent.  3/5 of the binding ADA -positive subjects in 
the 480 mg cohort had an ADA response that was transient.  The 1 binding ADA -positive 
subject in the 1050 mg cohort had treatment -emergent ADA that was sustained at SFU.   
All of the binding ADAs observed in this study as of the data cu toff date were of low 
magnitude, with no impact on exposure and have no association with clinical sequelae.  
Taking into consideration cumulative preliminary safety data PK, PD, and ADA data, the 
AMG  404 recommended phase 2 dose for monotherapy  is 480  mg IV  Q4W in subjects 
with advanced solid tumors.   The efficacious monotherapy dose of AMG 404 is predicted 
to be within range of this dose.    

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 64 of 176 
CONFIDENTIAL    

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 65 of 176 
CONFIDENTIAL    

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 66 of 176 
CONFIDENTIAL    
6.5 Patient Input on Study Design  
No patient input was obtained for the design of this study.  
7. Study Population  
Eligibility criteria will be evaluated during screening.  Subjects must meet eligibility 
criteria on Cycle 1, Day 1 of treatment.   
Before any study -specific activities/procedures, the appropriate written informed consent 
must be obtained (see Section 13.3).  
7.1 Inclusion Criteria  
Subjects are eligible to participate  in the study only if all of the following criteria apply:  
101 Subject has provided informed consent prior to initiation of any study specific 
activities/procedures.  
102 Age  18 years  old at the time of signing informed consent  
103 Life expectancy of  3 months, in the opinion of the investigator  
104 Subject must have histologically or cytologically confirmed metastatic or locally 
advanced solid tumors  not amenable to curative trea tment with surgery or 
radiation . Additionally, for : 
 Cohort 7:  subject must have a tumor as specified in the Study Schema 
(Section 3.1)  
 Cohor t 8, :  subject must be MSI -H or MMR -deficient  

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 67 of 176 
CONFIDENTIAL    
 Cohort 9:  subject must have NSCLC, PD -L1 positive, TPS  50%; not have 
EGFR or ALK or ROS1 genomic tumor aberrations and may n ot have 
received prior systemic treatment for the advanced disease (prior 
neoadjuvant , adjuvant , or concurrent chemoradiation  is allowed).  
105 At least 1 measurable lesion as defined by modified RECIST 1.1  which has not 
undergo ne biopsy within 3 months of the screening scan.  This lesion cannot be 
biopsied at any time during the study.  Note:   If there is only one lesion available 
for biopsy and radiographic assessment, it may be permitted to be biopsied after 
discussion with spo nsor.  
106 Subjects with treated brain metastases are eligible provided they meet the 
following criteria : 
 Definitive therapy was completed at least 2 weeks prior to enrollment.  
 No evidence of radiographic CNS progression or CNS disease following  
definitive therapy and by the time of study screening.  Patients manifesting  
progression in lesions previously treated with stereotactic radiosurgery may  
still be eligible if pseudoprogression can be demonstrated by appropriate  
means and after discussion w ith the medical monitor.  
 Any CNS disease is asymptomatic, any neurologic symptoms due to CNS  
disease have returned to baseline or are deemed irreversible, the patient is  
off steroids for at least 7 days (physiologic doses of steroids are permitted),  
and th e patient is off or on stable doses of anti -epileptic drugs for malignant  
CNS disease.  
107 Eastern Cooperative Oncology Group (ECOG) Performance Status of  2. 
108 Hematologic function , as follows without  growth factor support within 2 weeks 
prior to study day 1 :   
 Absolute neutrophil count (ANC)  1.0 x 109/L 
 Platelet count  75 x 109/L  
 Hemoglobin  9 g/dL  (90 g/L)  
109 Adequate renal laboratory assessments, as follows:  
Estimated glomerular filtration rate based on MDRD (Modification of Diet  in Renal 
Disease) calculation  60 ml/min/1.73 m2 for Cohorts 1, 2, 4, 5 , and .  
Estimated glomerular filtration rate based on MDRD (Modification of Diet in Renal 
Disease) calculation  45 ml/min/1.73 m2 for Cohorts 3 , 6, 7, 8, 9, .  
110 Hepatic function, as follows:  
 Total bilirubin  1.5 x ULN or  3 x ULN for subjects with liver metastasis  

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 68 of 176 
CONFIDENTIAL    
 AST  3 x ULN or  5 x ULN for subjects with liver metastasis  
 ALT  3 x ULN or  5 x ULN for subjects with liver metastasis  
 Alkaline phosphatase  2.5 x ULN or  5 x ULN for subjects with liver  
metastasis  (Note :  elevated alkaline phosphatase  is acceptable if it  is due to 
non-hepatic associated  pathology  [eg, bone disease ]).  
111 Cohort 5 only:  Subject is a resident in China , Taiwan, or Hong Kong . 
7.2 Exclusion Criteria  
Subjects are excluded from the study if any  of the following criteria apply : 
Disease Related  

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 69 of 176 
CONFIDENTIAL    
201 Primary brain tumor, u ntreated or symptomatic brain metastases and 
leptomeningeal disease  (exception: benign asymptomatic tumors are permitted) .  
Other Medical Conditions  
202 History of other malignancy within the past  2 years, with the following  
exception[s]:  
 Malignancy treated with curative intent and with no known activ e disease 
present for  2 years before enrollment and felt to be at low risk for 
recurrence by the treating physician.  
 Adequately treated non -melanoma skin cancer or lentigo maligna without 
evidence of disease.  
 Adequately treated cervical carcinoma in situ without evidence of disease.  
 Adequately treated breast ductal carcinoma in situ without evidence of 
disease.  
 Prostatic intraepithelial neopl asia without evidence of prostate cancer.  
 Adequately treated urothelial papillary noninvasive carcinoma or carcinoma in  
situ. 
 Other m alignanc ies which do not require systemic therapy, may be 
considered upon discussion with the medical monitor.  
203 History of solid organ transplantation.  
204 Major surgery within 28 days of study day 1 .  
Prior/Concomitant Therapy  
205 Prior treatment with anti -programmed death 1 (PD -1), anti -PD-L1, CTLA -4 or 
other checkpoint inhibitor drugs  ( ).  
206 Anti-tumor therapy (radiotherapy, chemotherapy, antibody therapy, molecular 
targeted therapy, or investigational agent) within 21 days prior to study day  1. 
Note:  Palliative radiotherapy is permitted.  
207 Live vaccine therapy  within 4 weeks prior to study drug administration . 
208 Current treatment or within 14 days of day 1 with immunosuppressive 
corticosteroid defined as  10 mg prednisone daily or equivalent. Corticosteroids 
with no or minimal systemic effect (such as topical or inhalation) are permitted.  
Note:  Corticosteroids  10 mg prednisone used for management of contrast 
allergy for study scans is allowed  
Prior/Concurrent Clinical Study Experience  
209 Currently receiving treatment in another investigational device or drug study, or 
less than 21 days prior to study day 1  since ending treatment on another 
investigational device or drug study(ies).   
Diagnostic As sessments  
210 Evidence of i nterstitial lung disease or active, non -infectious pneumonitis.  

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 70 of 176 
CONFIDENTIAL    
211 History of any immune -related colitis. Infectious colitis is allowed if evidence of 
adequate treatment and clinical recovery exists and at least 3 months interval 
observ ed since diagnosis of colitis.  
212 History of allergic reactions or acute hypersensitivity reaction to antibody 
therapies . 
213 Positive /Non -negative  test for Human Immunodeficiency Virus (HIV) . 
214 Has known active Hepatitis B (eg, hepatitis B antigen [H BsAg] reactive) or 
Hepatitis C (eg, HCV RNA [qualitative] is detected).  
215 Subject currently has an a ctive infection requiring systemic therapy  
216 Active or history of any autoimmune disease or immunodeficiencies.  Subjects 
with Type I diabetes, vitiligo, psoriasis, hypo - or hyper -thyroid disease not 
requiring immunosuppressive treatment are permitted.  
217 Myocardial infarction within 6 months of study day 1, symptomatic congestive 
heart failure (New York Heart Association  class II), unstable angina, or cardiac 
arrhyth mia requiring  antiarrhythmi c medication  
218 Unresolved toxicities from prior anti -tumor therapy, defined as not having 
resolved to Common Terminology Criteria for Adverse Events (CTCAE) version 
5.0 grade 1, or are stable and well controlled with minimal, local , or non -invasive 
intervention AND  there is agreement to allow by both the investigator and the 
Amgen Medical Monitor .  
Other Exclusions  
219 Males and females of reproductive potential who are unwilling to practice highly 
effective methods of birth control whi le on study through 6 months (females) and 
8 months (males)  after receiving the last dose of AMG 404,  
 
See 
Sectio n 13.6 for additional details regarding contraception requirements).  
220 Females with a positive pregnancy test . 
221 Females who are lactating/breast feeding or planning to breastfeed while on 
study through 6 months  after receiving the last dose of study drug.  
222 Females planning to become pregnant while on study through 6 months  after 
receiving the last dose of the stud y drug.  
223 Males unwilling to  abstain from donating sperm during treatment and for an 
additional 8 months  after the last dose of AMG 404,  
224 Subject has known sensitivity to any of the products or components  to be 
administered during dosing.  
225 Subject likely to not be ava ilable to complete all protocol -required study visits or 
procedures, and/or to comply with  all required study procedures to the best of the 
subject and investigator’s knowledge.  
226 History or evidence of any other clinically significant disorder , condition or 
disease (with the exception of those outlined above) that, in the opinion of the 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 71 of 176 
CONFIDENTIAL    
investig ator or Amgen physician, if consulted, would pose a risk to subject safety 
or interfere with the study evaluation, procedures or completion.  
227 Subjects with known sensitivity to any of the products to be administered during 
the study.  

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 72 of 176 
CONFIDENTIAL    
7.3 Subject Enrollment  
All screening tests and procedures should be performed within 28 days pri or to study 
day 1, unless otherwise indicated.  All blood and urine samples collected for screening 
assessments will be submitted and analyzed by the local laboratory.  Time permitting, 
screening laboratory assessments used to determine subject eligibility  may be repeated 
if necessary.  
Subjects who do not meet eligibility criteria within the 28 day screening period will not be 
eligible for enrollment.  Sub jects may be re -screened up to 3  additi onal times at the 
discretion of the investigator.  The subject must be re -consented if a re -screening 
attempt occurs outside of the 28 day screening period.  Subjects who are deemed 
ineligible will be documented as screen failures.  
An Amgen representative will notify the site in writing when a cohort is open to screen  
and enroll subjects.  Subjects may be eligible to enroll once all screening tests and 
procedures are completed and results indicate that all eligibility criteria are met.  A site 
representative will complete and send the enrollment eligibility worksheet t o Amgen  
accompanied with medical history, treatment history for the disease being investigated 
and list of current medications .  The eligibility worksheet and accompanying information 
should be completed and emailed to the Amgen representative at least 3  days prior to 
the planned day of first dose.  The Amgen representative will acknowledge receipt of the 
paperwork and send confirmation of the cohort and dose level assignment for the 
subject.  
A subject is considered enrolled when  the investigator decides th at the subject has met 
all eligibility criteria (date eligibility worksheet been signed by investigator). The 
investigator is to document this decision  and date, in the subject’s medical record and 
in/on the enrollment case report form (CRF).  
7.4 Screen Fail ures  
Screen failures are defined as subjects who consent to participate in the clinical study 
but are not subsequently enrolled in the study.  A minimal set of screen failure 
information will be collected that includes demography, screen failure details,  eligib ility 
criteria, and any serious adverse events.  
Individuals who do not meet the criteria for participation in this study (screen failure) may 
be rescreened.   Refer to Section 10.1.1 . 
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 73 of 176 
CONFIDENTIAL    
8. Treatment Procedures  
All investigational and non -investigational products  must be prepared and administered 
by a qualified healthcare profes sional. Subjects should be assessed clinically for 
adverse events/ toxicity prior to each dose using the CTCAE version 5 .0. Complete 
blood count with differential and chemistry panels including liver enzyme laboratory tests 
(ALT and AST) and total bilirubin should be obtained according to the Schedule of 
Activities (section  3.2) and the results should be check ed within 2  days prior to each  
dose of  treatment.  
The treatment cycle interval may be increased due to toxicity. If a subject requires 
corticosteroid dosing of >  10 mg prednisone daily (or equivalent) as supportive care, 
AMG 404 dosing must be held until the corticosteroid dose has decre ased to 
< 10 mg prednisone daily (or equivalent) .   
 
  
8.1 Investigational and Non -investigational Products  
8.1.1  Investigational Product:  AMG  404 
AMG 404 will be manufact ured and packaged by Amgen Inc. and  distributed using 
Amgen clinical study drug distribution procedures.  
The investigational product will be dispensed at the research facility by a qualified staff 
member.  
At the beginn ing of a treatment cycle a physician or nurse trained in emergency medical 
care must be available when the infusion of investigational product is started for 
immediate intervention in case of complications.  
AMG 404 will be delivered using infusion pumps ap proved for use by the appropriate 
regulatory authority for the country in which the subject is undergoing treatment.  
AMG 404 solution for infusion will be prepared in bags for IV infusion and delivered 
through infusion lines.    
The drug will be administe red as an IV infusion at a constant flow rate over 30 minutes . 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 74 of 176 
CONFIDENTIAL    
For Cohorts  1-9, each cycle of AMG 404 will be 28 days in length.  Subjects will receive 
240 mg, 480 mg or 1050  mg of AMG 404 depending on the cohort the subject is enrolled 
into.  All subseque nt doses will be administered every 28  days (±  3 days).   
. 
All safety assessments must be performed within 2 days prior to start of cycle.  
Assessments should be performed as indicated in the Schedule of Activities 
(see section  3.2).  AMG  404 may be withheld or discontinued as necessary for safety 
reasons.   
 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 75 of 176 
CONFIDENTIAL    
8.1.2  Cohorts  1-9 Investigational Product  
 
Table 8-1.  Cohorts 1 -9 Investigational Product :  AMG  404 
 
 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 76 of 176 
CONFIDENTIAL    

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 77 of 176 
CONFIDENTIAL    

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 78 of 176 
CONFIDENTIAL    

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 79 of 176 
CONFIDENTIAL    
 
 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 80 of 176 
CONFIDENTIAL    

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 81 of 176 
CONFIDENTIAL    
8.1.7  Medical Devices  
There ar e no investigational medical devices being used in this study.   
Investigational product must be administered using infusion pumps approved for use by 
the appropriate regulatory authorities for the country in which the subject is undergoing 
treatment in the outpatient setting.  Investigational product solution for infusion will be 
prepared in bags for IV infusion and delivered through infusion lines that are both 
compatible with the investigational product.  Other non -investigational medical devices 
may be u sed in the conduct of this study as part of standard care.  Non-investigational 
medical devices (eg, syringes, sterile needles), that are commercially available are not 
usually provided or reimbursed by Amgen (except, for example, if required by local 
regulation).  The investigator will be responsible for obtaining supplies of these devices.  
  
  

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 82 of 176 
CONFIDENTIAL    
8.1.9  Other Treatment Procedures  
There are no other treatment procedures in this study.  
8.1.10  Product Complaints  
A product complaint is any written, electronic or oral communication that alleges 
deficiencies related to the identity, quality, durability, reliabil ity, safety, effectiveness, or 
performance of a drug, combination product, or device  after it is released for distribution 
to market or clinic by either (1) Amgen or (2) distributors or partners for whom Amgen 
manufactures the material.   This includes all components distributed with the drug, such 
as packaging drug containers, delivery systems, labeling, and inserts.  
This includes  any investigational /non-investigational  product (s) provisioned and/or  
repackaged/modified by Amgen . AMG 404   are the investigational product s 
in this study.  

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 83 of 176 
CONFIDENTIAL    
Any product complaint(s) associated with an investigational product(s) or 
non-investigational product(s), supplied by Amgen are to be reported.  
Amgen Rave EDC system is being used to report produc t complaints.  
Regardless of the reporting method, all product complaints must be reported to Amgen 
within 24 hours of discovery.  
8.1.11  Excluded Treatments, Medical Devices, and/or Procedures 
During Study Period  
Any anti -tumor therapy other th an the investigational product  and protocol -specified 
therapies , including cytotoxic and/or  cytostatic drugs, hormonal therapy,  systemic 
corticosteroids  (except for subjects who were receiving ≤ 10 mg prednisone or 
equivalent at the time of enrollment are permitted  to remain on it ), immunotherapy or any 
biological response modifiers,  any other investigational agent,  and other 
immunosuppressive therapies are excluded.   
Primary prophylactic use of hematopoietic growth factors such as granulocyte -colony 
stimu lating factor (G -CSF) is not allowed during the DLT -evaluation period.  
Administration of systemic corticosteroids  (AMG 404 must be discontinued if ≥ 10 mg 
per day prednisone or equivalent is continue d for more than 12 weeks) , 
immunomodulators, and hormona l replacement therapy for the management of toxicities 
(eg, immune -related adverse events)  is allowed. Corticos teroids with no or minimal 
systemic effect ( eg, topical, inhalation) are allowed  (  
 
). 
Any live vaccine therapies for the prevention of infectious disease  are excluded.  
Radiotherapy is not permitted except for palliation of symptoms and should be discussed  
with the s ponsor’s Medical Monitor first. Investigators should ensure that the need for  
radiation does not indicate progressive disease and that for subjects with measurable  
disease, radiation is not to the sole site of measurable disease.  
The following procedures should also not be undertaken within the timeframes specified  
prior to enrollment and during the study:  
 Participation in an investigational study (drug or device) within 21 days of study 
day 1 
 Major surgery within 28 days of study day 1  
 Enrollment into ano ther investigational drug or device study  

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 84 of 176 
CONFIDENTIAL    
8.2 Method of Treatment Assignment  
Subjects who meet the eligibility criteria will be assigned to treatment with AMG 404.   
The treatment assignment date is to be documented in the subject’s medical record and 
on th e enrollment CRF. 
8.3 Blinding  
This is an open -label study ; blinding procedures are not applicable.   
8.4 Dose Modification  
8.4.1  Dose -cohort Study Escalation/De -escalation and Stopping Rules  
Planned DLRMs will be held to review data, monitor safety, and recommend dose 
changes or other necessary actions, on a per cohort basis.  Considering each cohort 
independently, a DLRM will occur after the required DLT -evaluable subjects have 
completed the DLT window:  
 All in Cohorts 1 and 2  
 The first 6 -9 subjects of Co hort 4  
  
 Ad hoc if deemed necessary by the Medical Monitor   
The review team will be composed of the investigators, Amgen Medical  Monitor, Amgen 
Global Safety Officer or designated safety scientist, Amgen Early  Clinical Development 
Manager, and Biostatistics representative. Additional members  may be added as 
needed (eg,  Clinical Pharmacologist).   The Medical Monitor must be in attendance and 
cannot be represented by a voting designee or delegate. Voting des ignees can be 
identified as appropriate by the GSO or site investigators.  
The China /Taiwan/Hong Kong  specific DLRT will be composed of the investigators in 
China /Taiwan/Hong Kong  or designee, Amgen Medical Monitor, Amgen Global Safety 
Officer or designated  safety scientist, Amgen Early Clinical Development Manager, and 
Biostatistics representative. Additional members may be added as needed (e g, Clinical 
Pharmacologist).  
A quorum, defined as the majority  (defined as greater than or equal to 50%)  of actively  
screening and enrolling investigators or their qualified designee (ie,  sub-investigator), 
Amgen Medical Monitor, and the Amgen Global Safety Officer or delegate  must be in 
attendance for DLRM to proceed.  The DLRM will be rescheduled if a quorum is not 
reached.  

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 85 of 176 
CONFIDENTIAL    
Voting members of t he DLRM will include the Amgen Medical M onitor, the Amgen 
Global  Safety Officer or designated safety scientist, and all actively screening and 
enrolling  investigators or their qualified sub -investigator designee.   For cohorts with  
dosing decisions, th e team may recommend  escalation to the next planned dose, 
escalation to an intermediate dose (a dose lower  than the next planned dose), 
continuation or delay in dosing, repetition or expansion of a  cohort, de -escalation to a 
lower dose, or termi nation of the study.   Intra-subject dose e scalation is  allowed , where 
applicable.  When the subject completes the DLT period the subject may proceed to 480 
mg for the following treatment cycle once Cohort 2 has been deemed safe by the DLRT ; 
subjects receiving 480 mg (Cohorts  1-3) who complete the DLT period may proceed to 
the RP2D once determined if a dose higher than 480 mg is selected as the RP2D.   
Subjects enrolled at the safety lead -in dose in Cohort 5 may escalate to the RP2D once 
deemed safe by the China /Taiwan/Hong Kong  specific DLRT.  All intra -subject dose 
escalations may occur after consultation with the sponsor as described in Section  6.1.  
The Amgen M edical  Monitor and Global Safety Officer or designee and the majority  
(defined as great er than or equal to 50%)  of actively screening and  enrolling 
investigators participating in the DLRM must cast a positive vote indicating an  
acceptable safety profile was observed for AMG 404 to allow the dose level modification  
and/or cohort continuation/expansion to proceed. All a vailable study data including  
demographics, medical history, concomitant medications, AEs, electrocardiograms  
(ECGs), vital signs, laboratory results, and emerging PK or pharmacodynamics data will  
be reviewed. Data to be reviewed may be unqueried.    
The do sing schedule is described by a schema in the protocol synopsis.  
8.4.2  DLT Definition  
The DLT window (ie, DLT -evaluable period) will be the first 28 days  of AMG 404  
treatment (starting cycle 1, day 1)  for Cohorts  1-9.   
 
 
  The DLT 
window ma y also be extended to assess events starting within the window in case the 
DLT definition is time dependent.  
The subject will be DLT evaluable if the subject has completed the DLT window as 
described above , or experienced a DLT any time during the DLT window, or has 
received at least 90% of the planned dose of investigational product(s) and is followed 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 86 of 176 
CONFIDENTIAL    
for at least 1  cycle . A subject will not be DLT evaluable if he/she drops out before 
completion of the DLT -evaluable period for reasons other than a DLT. Al l available 
safety da ta for subjects who are not DLT -evaluable will still be evaluated and considered 
in DLR T recommendations  (see also Section 13.3). 
See Section 6.2.1  for description of replacement of subjects.  
An adverse event will be considered related to study treatment (possibly, probably, or  
definitely related to the study treatment)  if there is a suspected “reasonable causal  
relationship” to the study treatment (ICH E2A), and not only a lack of an alternative  
explanation for the toxicity. All toxicities will be graded using the CTCAE version 5.0 .  
The occurrence of any of the followi ng toxicities during  the DLT evaluation period will be 
considered a DLT, unless the toxicity is clearly and incontrovertibly due to disease 
progression or other extraneous causes:  
 Any treatment related grade 5 toxicity  
 Grade 4 neutropenia or thrombocytope nia > 7 days in duration  
 Febrile neutropenia  
 Grade 4 anemia  
 Grade 3 or 4 non -hematologic toxicity , with the following exceptions : 
 DLT Exemption:  Grade 3 endocrinopathies  if manageable with replacement 
therapy  
 DLT Exemption:  Grade 3 nausea/vomiting or dia rrhea < 72 hours in the 
absence of maximal medical therapy  
 DLT Exemption:  Grade 3 fatigue < 1 week  
 DLT Exemption:  Asymptomatic ≥ grade 3 electrolyte abnormalities that last  
< 72 hours, is not clinically complicated, and resolved spontaneously or 
responds  to conventional medical interventions  
 DLT Exemption:   ≥ Grade 3 amylase or lipase that is not associated with 
symptoms or clinical manifestations of pancreatitis  
 DLT Exemption:  Other select lab abnormalities that do not appear to be 
clinically relevant o r harmful to the patient and/or can be corrected with 
repla cement or modifications (eg,  grade 3 lymphopenia, grade 3 
hypoalbuminemia)  
 Recurrent grade 2 pneumonitis  
 Delay in cycle 2 treatment for > 14 days  due to an adverse event in the dose 
escalation portion of the study due to study drug -related toxicity  
 Any other toxicity requiring permanent discontinuation of AMG 404  or
per Table 13 -2 and section  8.4.3.2  

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 87 of 176 
CONFIDENTIAL    
Cumulative adverse events profile will be taken into consideration when making  
decisions on dose escalation or de -escalation.  
Any subject meeting the criteria for Hy’s Law case (ie, severe drug -induced liver injury)  
will be consid ered a DLT.  A Hy’s Law case is defined as:  AST or ALT values of ≥ 3 x 
ULN AND with serum total bilirubin level (TBL) of > 2 x ULN without signs of cholestasis 
and with no other clear alternative reason to explain the observed liver -related laboratory 
abnormalities (see Table 13 -2 on hepatotoxicity management and Section 13.8 for 
further explanation of Hy’s law case and Management of Hepatic Function).  
If a subject experiences a DLT during the DLT evaluation period, study treatment should  
be discontinued for that subject.   Additionally, any treatment related toxicity mee ting the  
DLT definition after day 28 should result in discontinuation of th erapy , unless Table  13-2 
recommends otherwise .  In subjects with  PR, CR or evidence of clinical benefit (as 
determined by the investigator), an option to  continue at the same or at a reduced dose 
level can be considered once the toxicity  returns to the subject’s baseline value or 
CTCAE grade ≤ 1 if deemed appropriate by the  inves tigator and sponsor.  
8.4.3  Dosage Adjustments, Delays, Rules for Withholding or 
Restarting, Permanent Discontinuation  
The causality of each adverse event will be assessed individually for each 
protocol -mandated therapy.  
 
 
 
 
8.4.3.1  Amgen Investigational Product:  AMG 404  
Each subject will stay on the dose level assigned  unless treatment needs to be stopped. 
The reason for dose  withholds  and dose  delays is to be recorded on each subject’s 
CRF.   AMG  404 may be temporarily with held or discontinued as necessary, but a partial 
dose reduction is not permitted.  

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 88 of 176 
CONFIDENTIAL    

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 89 of 176 
CONFIDENTIAL    
8.4.3.4  Immune -related  Adverse Reactions  
Adverse events following the administration of AMG  404 may represent an immunologic 
etiology. Based on clinical experience with other anti -PD-L1 therapies, these 
immune -related  toxicities may occur shortly after the first dose to several months after 
the last dose of treatment  and may affect more than one  body system simultaneously.   
Early recognition and management are critical to reduce complications.  
Most immune -related adverse events require adequate evaluation to confirm etiology or 
exclude other causes.   Additional procedures or tests, such as bronc hoscopy, 
endoscopy, or skin biopsy, may be included as part of the evaluation.  
Based on the type and severity of the immune -related adverse event, withholding or 
permanent discontinuation of AMG 404 , may be required, in addition to 
treatment with corticosteroids and/or other therapies.  Dose  modification and toxicity 
management guidelines for immune -related adverse reactions are provided in 
Table  13-2.  
8.4.3.5  Infusion -related Reactions  
Infusion -related reactions may occur with the administration of AMG 404.  Monitor 
patients for signs and symptoms of infusion -related reactions, including pyrexia, chills, 
rigors, flushing, urticaria, hypotension, dyspnea, wheezing, headache, back pain, and 
abdominal pain.  If an infusion -related reaction is suspected, perform a  physical 
examination, monitor vital signs, monitor pulse oximetry, and perform and ECG if the 
patient is experiencing chest pain or sustained tachycardia.  
For mild or moderate infusion -related reactions, interrupt or slow the rate of infusion.   For 
sever e or life -threatening infusion -related reactions, permanently discontinue AMG 404 , 
  Treatment guidelines for infusion reactions associated  with the 
administration of AMG  404 are provided in Table  13-4.   
8.4.3.6  Embryo -fetal Toxicity  
Based on its mechanism of action, AMG 404 may cause fetal harm if administered 
during pregnancy. Animal studies have demonstrated that inhibition of the PD -1/PD -L1 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 90 of 176 
CONFIDENTIAL    
pathw ay can lead to increased risk of immune -mediated rejection of the developing fetus 
resulting in fetal death.  
Male and female subjects of childbearing potential must receive pregnancy prevention 
counseling and be advised of the risk to the fetus if they become pregnant or father a 
child during treatment and for 6 months (female subjects) or 8  months  (male subjects)  
after the last dose of AMG 404.  Refer to Sec tion 13.6 for contraceptive requirements 
during the s tudy.  
Pregnan cy testing will be conducted prior to administration of each dose of AMG 404 , 
for female subjects of childbearing potential (see  section  3.2). 
8.4.4  Hepatotoxicity Stopping and Rechallenge Rules  
Refer to  Section  13.8 for details regarding drug -induced liver injury guidelines, as 
specified in the Guidance for Industry Drug -Induced Liver Injury:  Premarketing Clinical 
Evaluation, July 2009 .  
8.4.5  Dose Modificati on Guidelines for SARS -COV2 Infection  
Guidance for dose modifications due to subjects with confirmed SARS -COV2 infection is 
provided below in  Table 8 -8.  

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 91 of 176 
CONFIDENTIAL    
Table 8-8. Dose Modification Guidelines for SARS -COV2 Infection  
 Symptom 
Severity  Protocol Therapy 
Modification  Treatment  Discontinuation  
SARS -COV2 
Infection  Asymptomatic  Withhold treatment 
for at least 10 days 
from positive 
RT-PCR test  Treatment 
per local 
standard of 
care For treatment 
delay longer than 
6 weeks, discuss 
with medical 
monitor  Mild/Moderate  Withhold treatment 
until resolution of 
clinically relevant 
symptoms and a 
minimum of 10 days 
after symptom onset  
Severe  Withhold treatment 
until resolution of 
clinically relevant 
symptoms and a 
minimum of 20 days 
after symptom onset  
RT-PCR = reverse transcription polymerase chain reaction; SARS COV2 = severe acute respiratory 
syndrome coronavirus 2  
8.4.6  Dose Modification Due to Surgery During Study Treatment  
Should significant surgery occur during study treatment, in general it is anticipated that 
study treatment  should not be resumed before a  28 day post -operative period .  
Exceptions to the minimum 28 day post -operative period should be approved by the 
medical monitor.  
8.5 Preparation/Handling/Storage/Accountability  
Guidance and information on preparation, handling, storage, accountability, destruction, 
or return of the investigational product during the study are provided in the  
Investigational Product Instruction Manual . 
8.6 Treatment Compliance  
Compliance to treatment and the corresponding assessments should be followed 
according to the Schedule of Activitie s (Section  3.2) and the Treatment Procedures 
(Section  8). 
8.7 Treatment of Overdose  
AMG  404 Overdose  

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 92 of 176 
CONFIDENTIAL    
There is no treatment for overdose of this product.  In the event of an overdose, the 
investigator should contact the Amgen Medical Monitor immediately.  
8.8 Prior and Concomitant Treatment  
8.8.1  Prior Treatment  
Prior therapies that were being taken  for the disease under study will be collected  from 
time of initial diagnosis to time of consent . 
8.8.2  Concomitant Treatment  
Throughout the study, investigators may prescribe any  concomitant medications or 
treatments deemed necessary to provide adequate supportive care except for those 
listed in Section  8.1.11 .  
Concomitant therapies are to be collected from informed consent  through  safety follow 
up.  Concomitant therapies collected from safety follow up through end of study are to be 
collected if administered to treat a reportable AE or SAE.  
Collected therapy name, indication, dose, unit, frequency, route, start date, and stop 
date to be record ed in the eCRF.  
8.8.2.1  SARS -COV2 -Vaccination  
Every effort should be made to fully vaccinate subjects prior to 14 days from first dose of 
investigational product.  The use of vaccines except live and live attenuated vaccines will 
be allowed during therapy per regional and institutional standard of care. However, 
SARS -COV2 vaccinations should be avoided during screening (within a minimum of 
14 days from first dose of IP) and should be also avoided in the first treatment cycle for 
better assessment of safety parameters.  Throughout the trial, SARS -COV2 vaccination 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 93 of 176 
CONFIDENTIAL    
should be avoided within 3 days after the administration of IP.   Record SARS -COV2 
vaccination as a concomitant medication and collect therapy name, indication, dose, 
unit, frequency, route, and date of administra tion. 
9. Discontinuation Criteria  
Subjects have the right to withdraw from investigational product and/or other 
protocol -required therapies, protocol procedures, or the study as a whole at any time 
and for any reason without prejudice to their future medi cal care by the physician at the 
institution.  
The investigator and/or sponsor can decide to withdraw a subject(s) from investigational 
product, device, and/or other protocol -required therapies, protocol procedures, or the 
study as a whole at any time prior  to study completion  for the reasons listed in 
Sections  9.1,  and 9.2.2 . 
9.1 Discontinuation of Study Treatment  
Subjects (or a legally acceptable representative) can decline to continue receiving 
investigationa l product and/or other protocol -required therapies or procedures at any 
time during the study but continue participation in the study.  If this occurs, the 
investigator is to discuss with the subject the appropriate processes for discontinuation 
from investigational product or other protocol -required therapies and must discuss with 
the subject the possibilities for continuation of the Schedule of Activities ( Section  3.2) 
including different options of follow -up (eg, in person, by phone/mail, through 
family/friends, in correspondence/communication with other treating physicians, from the 
review of medical records) and collection of data, including endpoints , adverse eve nts, 
and must document this decision in the subject’s medical records .  Subjects who have 
discontinued investigationa l product and/or other protocol -required therapies or 
procedures should not be automatically removed from the study.  Whenever safe and 
feasible, it is imperative that subjects remain on -study to ensure safety surveillance 
and/or collection of outcome data.  
Reasons for removal from protocol -required investigational product(s) or procedural 
assessments include any of the following:  
 Decision  by Sponsor  
 Lost to follow -up 
 Death  
 Ineligibility determined  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 94 of 176 
CONFIDENTIAL    
 Protocol deviation  
 Non-compliance  
 Adverse event  
 Subject request  
 Disease prog ression  
 Pregnancy  
9.2 Discontinuation From the Study  
Withdrawal of consent for a study means that the subject does no t wish to receive 
further protocol -required therapies or procedures, and the subject does not wish to or is 
unable to continue further study participation.  Subject data up to withdrawal of consent 
will be included in the analysis of the study, and where p ermitted, publicly  available data 
can be included after withdrawal of consent.  The investigator is to discuss with the 
subject appropriate procedures for withdrawal from the study, and  must document the 
subject’s decision to withdraw in the subject’s medi cal records .   
If a subject withdraws from the study, he/she may request destruction of any samples 
taken and not tested, and the investigator mus t notify Amgen accordingly (see  
Section  13.7 for further details).  Refer to the Schedule of Activities  (Section  3.2) for data 
to be collected at the time of study discontinuation and follow -up and for any furt her 
evaluations that need to be completed . 
9.2.1  Reasons for Removal From  Washout, Run -in or Invasive 
Procedures  
This section is not applicable.  
9.2.2  Reasons for Removal From Study  
Reasons for removal of a subject from the study are:  
 Decision by sponsor  
 Withdrawal of consent from study  
 Death  
 Lost to follow -up 
9.3 Lost to Follow -up 
A subject will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by the study site.  
The following actions must be taken if a subject fails to return to the clinic for a required 
study visit:  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 95 of 176 
CONFIDENTIAL    
 The site must attempt to contact the subject and reschedule the missed visit as 
soon as possible and counsel the subject on the importance of maintaining the 
assig ned visit schedule and ascertain whether or not the subject wishes to and/or 
is able to continue in the study.  
 In cases in which the subject is deemed lost to follow -up, the investigator or 
designee must make every effort to regain contact with the subject  (where 
possible, 3 telephone calls and, if necessary, a certified letter to the subject’s last 
known mailing address or local equivalent methods).  These contact attempts are 
to be documented in the subject’s medical record.  
 If the subject continues to be  unreachable, he/she will be considered to have 
withdrawn from the study with a primary reason of lost to follow -up.  
 For subjects who are lost to follow -up, the investigator can search publicly  
available records [where permitted]  to ascertain survival sta tus.  This ensures 
that the data set(s) produced as an outcome of the study is/are as 
comprehensive as possible.  
10. Study Assessments and Procedures  
Study procedures and their time points are summarized in the Schedule of Activities 
(see Section  3.2).  
As protocol wa ivers or exemptions are not allowed if an enrolled subject is subsequently 
determined to be ineligible for the study, this must be discussed with the sponsor 
immediately upon occurrence or awareness to determine if the subject is to continue or 
discontinue  study treatment.  
Adherence to the study design requirements, including those specified in the Schedule 
of Activities, is essential and required for study conduct.  
10.1 General Study Periods  
10.1.1  Screening, Enrollment and/or Randomization  
A signed and dated IRB /IEC-approved informed consent must be obtained before any 
study -specific procedures are performed.  Procedures that are part of routine care are 
not considered study -specific procedures and may be used at screening to determine 
eligibility.   All subjects w ill be screened for eligibility before enrollment.  Only eligible 
subjects will be enrolled into the study.  The screening window is up to 28 days prior to 
day 1 . 
If a subject has not met all eligibility criteria at the end of the screening period, the 
subject will be registered as a screen fail.  Screen fail subjects may be eligible for 
re-screening  up to  3 additional times.  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 96 of 176 
CONFIDENTIAL    
10.1.2  Treatment Period  
Visits will occur per the Schedule of Activities ( Section  3.2).  The date of the firs t dose of 
study drug administration  is defined as day 1.  All subsequent doses and study visits will 
be scheduled based on the day 1 date.   
10.1.3  Extended Treatment Period  
Visits will occur per the Schedule of Activities (Section  3.2).  Subjects with 
complete response, partial response, stable disease or continued clinical benefit 
at 24  months of treatment, may continue treatment for up to an additional 
24 months (up to 48  months of treatment in total) after discussion with the 
medical monitor.  A separate informed consent for extended treatment must be 
signed.  
10.1.4  Safety Follow -up 
Upon permanent discontinuation from the study treatment for any reason, two safety 
follow -up visits are required.  A safety follow -up visit will be performed approximately 30 
(+ 3) days after the last administration  of study drug , and also 1 40 days ( ±7 days)  after 
the last administration  of AMG  404.  Adverse events should continue to be reported 
through 140 days ( ± 7 days) after the last administration of AMG  404. 
10.1.5  Long -term Follow -up 
Subjects will be contacted 6 months ( ± 1 week) after the  last dose of study drug.  The 
purpose of the calls is to collect information on  survival,  start of new therapies and 
disease status .  
10.1.6  End of Study  for a Particular Study Subject  
The end of study for a particular study subject will be the day of the last scheduled long 
term follow up call.  
10.2 Description of General Study Assessments and Procedures  
The sections below provide a description of the individual study procedures for required 
time points.  

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 97 of 176 
CONFIDENTIAL    
10.2.1  General Assessments   
10.2.1.1  Informed Consent  
All subjects or their legally authorized representative must sign and personally dat e the 
IRB/IEC approved in formed consent before any study -specific procedures are 
performed . 
10.2.1.2  Demographics  
Demographic data coll ection including sex, age, race, and ethnicity will be collected in 
order to study their possible association with  subject safety and treatment effectiveness.   
Additionally, demographic data may be used to study the impact of the protocol -required 
therapy on  PK. 
10.2.1.3  Medical History  
The Investigator or designee will collect a comple te medical and surgical history that 
started prior to screening and through screening until start of treatment.   Medical history 
will include information on the subject's concurrent medical conditions.   Record all 
findings on the medical history CRF.  In addition to the medical history above, the 
condition under study history must date back to the original diagnosis .  The current 
toxicity grade will be collected for each condition that has not resolved.  
10.2.1.4  Physical Examination   
Physical examina tion will be performed as per standard of care  by the investigator or 
designee at screening and at the time points specified  in the Schedule of Activities  
(Section  3.2).  The physical examination will include general appearance, including 
examination of the skin, spleen, respiratory, cardiovascular, musculoskeletal, and 
neurological systems.  
The individual performing the physical examination will characterize their findings as  
either normal or abnormal. Abnormal physical examination findings found during 
screening should be reported on the Medical History eCRF.  Abnormal physical 
examination findings found after the subject has received investigational product will be 
reported on the Event eCRF.   
10.2.1.5  Physical Measurements  
Height should be measured without shoes at screening only.  Weight should be 
measured without shoes  at the time points specified in the S chedule of Activities  
(Section  3.2). 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 98 of 176 
CONFIDENTIAL    
10.2.1.6  Performance Status   
Subjects will be graded according to the Eastern Cooperative Oncology Group (ECOG)  
Performance Status.  The ECOG criteria for this protocol are further defined in  
Appendix 8 . 
10.2.2  Efficacy Assessments  
Tumor evaluations (by CT or MRI as appropriate) and tumor markers, if app licable, are 
to be collected at time points specified in the Schedule of Activities ( Section  3.2). 
Imaging may also be performed more frequently if clinically necessitated at the 
discretion of the managing physician.  Radiographic res ponse (Complete Response, 
Partial Response) requires confirmation by a repeat, consecutive scan at least 4 weeks 
after the first documentation of response and may be delayed until the next scheduled 
scan to avoid unnecessary procedures.  Radiographic progr ession (Progressive 
Disease) requires confirmation by a repeat, consecutive assessment 4 -6 weeks after the 
first detection of radiological progression.  Upon discussion with the Sponsor, in the 
absence of clinical deterioration and with the subject’s conse nt (subject must sign 
addendum consent) , subjects may continue to receive AMG 404 treatment after 
confirmation of radiographic progressive disease as long as they continue to derive 
clinical benefit, until clinical disease progression, or intolerance of st udy treatment, or 
clinically significant deterioration  of health status requiring discontinuation, or the subject 
withdrawal of consent, whichever occurs first   
 
).  In some circumstances it may be difficult to distinguish residual disease from 
scar or normal tissue.  When the evaluation of CR depends on this determination, the 
residual lesion may be further investigated by addition al scans to be discussed with 
Sponsor, or possibly fine needle aspirate/biopsy, to confirm the CR status.  Subjects 
who continue on AMG 404 treatment , and/or other cancer therapies  following 
confirmation of radiographic progressive disease will have radiol ogical imaging 
assessment every 8  (± 1) week s thereafter  following the confirmation of radiological 
progression for Cohorts  1-9,  
 
.  
If a subject discontinues treatment for reasons other than progression, tumor evaluations 
should continue according to the Schedule of Activities ( Section  3.2) until  progression or 
start of a new treatment regimen.  

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 99 of 176 
CONFIDENTIAL    
10.2.3  Safety Assessments  
Planned time points for all safety assessments are listed in the Schedule of Activities  
(see Section  3.2). 
10.2.3.1  Adverse Events  and Serious Adverse Events  
The method of recording, evaluating, and assessing causality of adverse events, 
and serious adverse events, and the procedures for completing and transmitting  
serious adverse event reports are provided in Section  13.5. 
10.2.3.1.1  Time Peri od and Frequency for Collecting  and Reporting Safety 
Event Information  
10.2.3.1.1.1  Adve rse Events  
The adverse event grading scale to be used for this study will be the Common 
Terminology Criteria for Adverse Events (CTCAE) version 5.0  and is described in 
Section 13.5 
The investigator is res ponsible for ensuring that all adverse events observed by the 
investigator or reported by the subject that occur after the first dose of investigational 
product through the  end of the safety follow -up period of 140  days  [± 7 days ] after last 
dose of IP are  reported using the Event CRF.  
10.2.3.1.1.2  Serious Adverse Events  
For Cohorts  1- the investigator is responsible for ensuring that all serious adverse 
events observed by the investigator or repor ted by the subject that occur after signing of 
the informed consent through the  end of the safety follow -up period of 140  days 
( 7 days ) after last dose of IP  are reported  using the Event CRF.    
. 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 100 of 176 
CONFIDENTIAL    
All serious adverse events will be collected, recorded and reported to the sponsor or 
designee within 24  hours  of the investigator’s awareness of the event , as indicated in 
Section  13.5.  The investigator will submit any updated serious adverse event data to the 
sponsor within 24  hours of it being available.  
Since the criteria  the CTCAE grading scale differs from the regulatory criteria for 
serious adverse events , if adverse events correspond to grade  4 CTCAE toxicity 
grading scale criteria (eg, laboratory abnormality reported as grade 4 without 
manifestation of life threatening status), it will be left to the investigator’s judgment to  
also r eport these abnormalities as serious adverse events.   For any adverse event 
that applies to this situation, comprehensive documentation of the event severity 
must be recorded in the subject medical records.  
10.2.3.1.1.3  Serious Adverse Events After the Protocol -require d Reporting 
Period  
If the investigator becomes aware of serious adverse events  suspected to be 
related to investigational products after the protocol -required reporting period (as 
defined in  Section  10.2.3.1.1.2 ) is complete, then these serious adverse events will 
be reported to Amgen within 24 hours following the investigator’s awareness of 
the event on the Events CRF . 
After End of Study, there is no  requirement to actively monitor study subjects 
after the study  has ended with regards to study subjects treated by the 
investigator.  However, if the investigator becomes aware of serious adverse events 
suspected to be related to investigational product, then these serious adverse 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 101 of 176 
CONFIDENTIAL    
events  will be r eported to Amgen within 24  hours following the investigator’s awareness 
of the event.  
Serious adverse events reported outside of the protocol -required reporting period  will be 
captured within the safety database a s clinical trial cases and handled accordingly based 
on relationship to investigational product.  
If further safety related data is needed to fulfill any regulatory reporting requirements for 
a reportable event, then additional information may need to be collected from the 
subject’s records after the subject ends the study.  
10.2.3.1.2  Method of Detecting Adverse Events and Serious Adverse Events  
Care will be taken not to introduce bias when detecting adverse events and/or serious 
adverse events.  Open -ended and non -leading verbal questioning of the subject is the 
preferred method to inquire about adverse event  occurrence.  
10.2.3.1.3  Follow -up of Adverse Events and Serious Adverse Events  
After the initial adverse event/serious adverse event report, the investigator is required to  
proactively follow each subject at subsequent visits/contacts.  All adverse events and 
serious adverse events will be followed until resolution, stabilization, until the event is 
otherwise explained, or the subject is lost to follow -up (as defined in Sect ion 9.3).  
Further information on follow -up procedures is given in Section  13.5. 
All new information for previously reported serious adverse events m ust be sent to 
Amgen within 24 hours following awareness  of the new information.  If specifically 
requested, the investigator may need to provide additional follow -up information, such as 
discharge summaries, medical records, or extracts from the medical r ecords.  
Information provided about the serious adverse event must be consistent with that 
recorded on the Event CRF.  
10.2.3.1.4  Regulatory Reporting Requirements for Serious Adverse Events  
If subject is permanently withdrawn from protocol -required therapies because of a 
serious adverse event, this information must be submitted to Amgen.  
Prompt notification by the investigator to the sponsor of serious adverse events is 
essential so that legal obligations and ethical responsibilities towards the safety of 
subjects and  the safety of a study treatment under clinical investigation are met.  
The sponsor has a legal responsibility to notify both the local regulatory authority and 
other regulatory agencies about the safety of a study treatment under clinical 
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 102 of 176 
CONFIDENTIAL    
investigation.  The sponsor will comply with country -specific regulatory requirements 
relating to safety reporting to the regulatory authority, IRB s/IECs, and investigators.  
Individual  safety reports must be prepared for suspected unexpected serious adverse 
reactions according to local regulatory requirements and sponsor policy and forwarded 
to investigators as necessary.  
An investigator who receives an individual safety report describi ng a serious adverse 
event or other specific safety information (eg, summary or listing of serious adverse 
events) from the sponsor will file it along with the Investigator’s Brochure and will notify 
the IRB/IEC, if appropriate according to local requireme nts. 
10.2.3.1.5  Safety Monitoring Plan  
Subject safety will be routinely monitored as defined in the Amgen’s safety surveillance 
and signal management processes.  
10.2.3.1.6  Pregnancy and Lactation  
Details of all pregnancies and/or lactation in female subjects and female partners  of 
male study subjects will be collected after the start of study treatment, and until 6 months 
for female study subjects and 8  months for female partners of male study subjects after 
the last dose  of AMG  404.   
If a pregnancy is r eported, the investigator is to inform Amgen within 24 hours of learning 
of the pregnancy and/or lactation and is to follow the procedures outlined in 
Section  13.6.  Amgen Global Patient Safety will follow -up with the investigator regarding 
additional information that may be requested.  
Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered serious adverse events.  
Further details regarding pregnancy and lactation are provided in Section 13.6. 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 103 of 176 
CONFIDENTIAL    
10.2.3.2  Vital Signs  
The following measurements must be performed:  systolic/diastolic blood pressure (BP),  
respiratory rate, heart rate and temperature.   Subject must  be in rested and calm state  
for at least 5 minutes before BP assessments are conducted.  The position selected for  
a subject should be the same that is used throughout the study and documented on the  
vital sign eCRF. Record all measurements on the vital signs eCRF.  
The temperature location selected for a subject should be the same that is used  
throughout the study and documented on the vital signs/temperature eCRF.  Vital signs  
will be recorded by the investigator or designee  at screening and time  points specified in 
the Schedule of Activities  (see Section  3.2). 
Abnormal measurements may be repeated at the discretion of the investigator and must  
be reported on the corresponding eCRF page.   When vital signs and blood sample  
collection occur at the same time, vital signs should be performed before blood samples  
are drawn.  
10.2.3.3  Electrocardiograms (ECGs)  
Subject must be in a supine position in a rested and  calm state for at least 5 minutes  
before ECG assessment is conducted. If the subject is unable to be in the supine  
position, the subject should be in the most recumbent position as possible.  
ECGs sh ould be performed in accordance with the Schedule of A ctivities (see  
Section  3.2), in trip licate, in a standardized method, prior to blood draws or other 
invasive  procedures. Each ECG must include the following measurements:  QRS, QT, 
QTc, RR,  and PR intervals.  
All ECGs will be triplicates with each tracing approximately 30 seconds apart and run 
consecutively.  
For subjects enrolled to Cohorts 1 , 2 and 4, triplicate ECGs must be performed at   
 Screening  
 Cycle 1 :  day 1 predose, end of infusion, and 4 hours postdose  
 Cycle 2 :  day 1 end of infusion  
 Cycle 3 :  day 1 end of infusion  
 Cycle 4 :  day 1  end of infusion  
 Cycle 5 :  day 1  end of infusion  
 Beginning with Cycle 6, ECGs will be done if clinically indicated  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 104 of 176 
CONFIDENTIAL    
For subjects enrolled to Cohort 3, and Cohorts  6-9 triplicate ECGs must be performed at 
screening and then as clinically indicated.  
The PI or designated sub -investigator will review all ECGs. ECGs will be transferred 
electronically to a central Amgen vendor. Once r eviewed and signed by PI or 
sub-investigator, the original ECG tracing will be retained with the subject's source 
documents. At the request of the sponsor, a copy of the original ECG will be made 
available to Amgen. Standard ECG machines will be provided by Amgen for all 
study -related ECG requirements.  
10.2.4  Clinical Laboratory Assessments  
Refer to  Section  13.2 for the list of clinical laboratory tests to be performed and to the 
Schedule of Activitie s (Section  3.2) for the timing and frequency. All tests (except for PK 
) are to be  performed at a local laboratory and test results are to be 
recorded in the eCRF. Additional safety laboratory assessments may be performed if 
clinically indicated at the discretion of the investigator.  
The investigator is responsible for reviewing labora tory test results and recording any 
clinically relevant changes occurring during the study in the Event CRF.  The investigator 
must determine whether an abnormal value in an individual study subject represents a 
clinically significant change from the subje ct’s baseline values.  In general, abnormal 
laboratory findings without clinical significance (based on the investigator's judgment) 
are not to be recorded as adverse events.  However, laboratory value changes that 
require treatment or adjustment in curren t therapy are considered adverse events.  
Where applicable, clinical sequelae (not the laboratory abnormality) are to be recorded 
as the adverse event.  
All protocol -required laboratory assessments, as defined in Section  13.2, must be 
conducted  in accordance with the laboratory manual and the Schedule of Activities  
(Section  3.2).  
10.2.4.1  Pregnancy Testing  
A serum  pregnancy test must be performed at screening and within 48 hours of cycle 1 
dose of  AMG 404; beginning with cycle 2, a urine or serum pregnancy test must be 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 105 of 176 
CONFIDENTIAL    
performed  within 48 hours  prior to the AMG 404 dose  for females of childbearing 
potential  (see Schedule of Activities Section  3.2). 
Additional on -treatment pregnancy testing may be performed at the investigator’s 
discretion or as required per local laws and regulations.    
Note:  Females who have undergone a bilateral t ubal ligation/occlusion should have 
pregnancy testing per protocol requirements.  (If a female subject, or the partner of a 
male subject, becomes pregnant it must be reported on the Pregnancy Notification 
Form , see  Figure 13 -3).  Refer to Section  13.6 for contraceptive requirements.   
10.2.5  Pharmacokinetic Assessments  
All subjects enrolled  will have pharmacokinetic samples assessed.  
Blood  samples  will be collected for measurement of serum  concentrations of AMG 404  
as specified in the Schedule of Activities  (Section  3.2),  
  Instructions for the 
collection and handling of biological samples will be prov ided by the sponsor.  The actual 
date and time (24 -hour clock time) of each sample will be recorded.  

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 106 of 176 
CONFIDENTIAL    
10.2.7  Antibody Testing Procedures  
Blood sampl e(s) for antibody testing are to be collected according to the time  points 
specified in the Schedule of Activities  (Section  3.2) for the measurement of anti -AMG 
404 antibodies .
Samples testing positive for binding antibodies  to AMG  404  may be further 
characterized.  Additional blood samples may be obtained to rule out anti-AMG 404  
antibodies during the study.  
Subjects who test positive for anti-AMG 404  antibodies at the final 
scheduled antibody time point  and have clinical sequelae that are considered potentially 
related to an anti-AMG 404 antibody response will be asked to return for 
additional follow -up testing.  Sample collection and testing will occur approximately every 
3 months from the safety follow up visit until:  (1) anti -AMG  404 
antibodies are no longe r detectable; or (2) the subject has been followed for a period of 
at least 1 year ( ± 4 weeks) post administration of AMG  404  All follow -up 
results, both positive and negative, will be communicated to the sites.  More frequent 
testing (eg, every month) or testing for a longer period of time may be requested in the 
event of safety -related concerns.   Refer to the Schedule of Activities ( Section  3.2), as 
applicable, for specific time points, and the laboratory manual for detailed collection and 
handling instructions.  

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 107 of 176 
CONFIDENTIAL    

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 108 of 176 
CONFIDENTIAL    

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 109 of 176 
CONFIDENTIAL    

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 110 of 176 
CONFIDENTIAL    

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 111 of 176 
CONFIDENTIAL    
11. Statistical Considerations  
11.1 Sample Size Determination  
Up to 275  evaluable  subjects will be enrolled in this study.   Approximately , 2 to 4 
DLT-evaluable subjects will be enrolled in Cohort 1.   Approximately , 6 to 9  
DLT-evaluable subjects will be enrolled  each  in Cohort 2.  Approximately , 20 subjects 
will be enrolled  each  in Cohort s 3, 4, and 6 all outside of China.   Approximately , 
12 subjects will be enrolled to Cohort 5 in China /Taiwan/Hong Kong .  Approximately , 
40 subjects , respectively,  will be enrolled to Cohort 7, Cohort 8, and Cohort 9 .  
 
  
. 
With 2 subjects in Cohort 1 , there is a 36 – 55% probability of observing at least 1 DLT. 
With 4 subjects in Cohort 1 , there is a 59 - 80% probability of observing at least 1 DLT if 
the true DLT rate is 20 – 33%.  
Similarly, w ith 6 sub jects per cohort, there is a 74  - 91% probability of observing at least 
1 DLT.  With 9 subje cts per cohort, there is a n 87 - 97% probability of observing at lea st 
1 DLT if the true DLT rate is 2 0-33%.   
In Cohort s 3, 4, 6,  a subject number of 20 will provide an 88% probability of 
observing at least one adverse event with 10% incident rate. An exact 80% binomial 
confidence interval (CI) will be provided  for overall response rate. With the 20 subjects 
and 25% overall response rate, the expected 80% CI would be 13% to 42%.  
In Cohort 5, a subject number of 12 will provide a 72% probability of observing at least 
one adverse event with 10% incident rate.  An exact 80% binomial confidence interval 
(CI) will be provided for overall response rate.  With the 12 subjects and 25% overall 
response rate, the expected 80% CI would be 10% to 48%.  

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 112 of 176 
CONFIDENTIAL    
In Cohort 7, Cohort  8, and Cohort 9, the sample size is N~40 subjects.  A subject 
number of N~40 subjects will provide an 87% probability of observing at least one 
adverse event with 5% incident rate.  An exact 80% binomial confidence interval (CI)  will 
be provided for ov erall response rate.  With the 40 subjects and 25% over all response 
rate, the expected 80% CI would be 16% to 36%.  
11.2 Analysis Sets,  and Covariates  
11.2.1  Analysis Sets  
The analysis of all endpoints, unless noted otherwise, will be conducted on the Safety 
Analysis Set defined as all s ubjects that are enrolled and receive at least one dose of 
AMG 404.  
The PK Analysis Set will contain all subjects who have received at least 1  dose of 
AMG  404 and have at least 1 PK sample collected.  These subjects may be evaluated 
for PK analysis unless the number of data points required for analysis is not enough, or 
significant protocol deviations have affected the data, or if key dosing or sampling 
information is missing .   
11.2.2  Covariates  
The relationship of covariates to efficacy endpoints may be expl ored if appropriate.  

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 113 of 176 
CONFIDENTIAL    
11.3 Adaptive Design  
Dose level decisions are based on a modified toxicity probability interval design (mTPI). 
The mTPI was developed by Ji et al. (2010).  The mTPI models the probability of toxicity 
for each dose level using a Bayesian model where each dose level has the same prior 
on the probabi lity of toxicity, a Beta (1,1).  When subjects are treated at the current dose 
level, the posterior probability of toxicity is updated using the observed data from this 
level.  Dose level recommendation are made based on this posterior probability of 
toxicity, using three toxicity probability intervals (TPI).  
 Under -dosing TPI:   DLT rate from 0 to < 20%  
 Target TPI:   DLT rate from 20% to 33%    
 Over -dosing:   DLT rate > 33%  
For the current dose level and after adjusting for the width of the under -dosing TPI, if the 
DLT rate is most likely in the under -dosing TPI then the recommendation is to dose 
escalate.  If the DLT rate is most likely in the target TPI then the recommendation is to 
stay at the current level.  If the DLT rate is most likely in the over -dosin g TPI then the 
recommendation is to stop the enrollment .  If DLTs are observed, the maximum tolerated 
dose (MTD) is the dose level with a DLT toxicity rate closest to 26.7% (Ji et al. 2010).  
During enrollme nt and treatment at the RP2D using data from cohorts 3 and 6 and 
additionally using data from cohorts 7 -9, objective response rate will be monitored with 
futility stopping rules described in Section  11.4.1.1 . These futility stopping rules are 
selected using practical considerations.  
During enrollment and treatment at the RP2D using data from cohorts 3 and 6 and 
cohorts 7 -9, subject  incidence  of grade 4 treatment related adverse events will be 
monitored with safety stopping rules described in Section  11.4.1.1 .  The safety stoppin g 
rules use a Bayesian approach proposed by Thall,  Simon, and Estey (1995)  to terminate 
a cohort  if the posterior probability that the subject incidence of grade 4 or higher 
treatment -related adverse event s is greater than 20% is > 80%.  The st opping 
bound aries assume a prior distribution of Beta  (0.40, 1.60) . 
11.4 Statistical Analyses  
The statistical analysis plan will be developed and finalized before database lock.  Below 
is a summary of the timing and methods for the planned statistical analyses.   To 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 114 of 176 
CONFIDENTIAL    
preserve study integrity , the final analysis will be conducted and reported following the 
end of study, as defined in Section  6.3.1 . 
11.4.1  Planned Analyses  
11.4.1.1  Interim Analysis and Early Stopping Guidelines  
Safety data will be reviewed on an ongoing basis.  In the dose level review meetings, 
Amgen, in consultation with the site investigators, will review all available cumulative 
data by cohort prior to making dose determination decisions.  Adverse events and DL Ts 
observed in all subjects will be evaluated continually and fully integrated into all dose 
level review meetings and considered in all enrollment and dosing decisions.   
Additional details regarding the dose review meeting are providing in 
Sections  8.4.1  and 13.3. 
There is a planned treatment of N ~40 subjects at the RP2D with enrollment to cohorts 3 
and 6. Additionally, ther e is a planned treatment of N~ 40 subjects at the RP2D with 
enrollment to Cohort 7, N~ 40 subjects enrolled to Cohort 8 and N~40 subjects enrolled 
to Cohort 9. For each of these cohorts (Cohort 3/6, Cohort  7, Cohort 8, Cohort 9) , futility 
will be assessed af ter treating 15 and 25 subjects for at least 3 months.  If the observed 
rate of responses is consistent with a  lower than 15% response rate , enrollment  and 
treatment at the RP2D  may be terminated due to futility.  For purposes of assessing 
futility, a response is defined as an objective response per RECIST 1.1.  The guidelines 
for early termination due to futility are as follows:  
Number of Treated Subjects  Futility Termination Guideline  
15 1 or fewer responders  
25 4 or fewer responders  
40 Enrollment to dose expansion cohort complete  
If the true response rate is 15% then these termination guidelines result in a 69.4% 
probability of terminating dose expansion early with an expected sample size of 26.4 
subjects. If the true response rate is 3 0% then there is a 90% probability of continuing 
enrollment to N~40 total subjects.  
During this enrollment and treatment at the RP2D  combining data from cohorts 3, 6, 7, 8 
and 9 (up to 1 60 total subjects enrolled)   
, Amgen will conduct evaluations of the ongoing subject incidence grade 4 
or higher treatment -related adverse event rate to assess if the threshold for possible 
early termination  of a cohort  has been reached.  If the threshold is met  in the combined 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 115 of 176 
CONFIDENTIAL    
monotherapy data of expansion cohorts  3, 6, 7, 8, and 9 enrollment to all ongoing 
cohorts in the study, , will be halted pending review of safety data 
by the DLRT.  If the threshold is met in a specific coh ort, then enrollment to the specific 
cohort will be halted pending review of safety data by the DLRT.  After receiving the 
DLRT recommendation, Amgen will choose to take one of the following actions.  
When overall safety threshold exceeded in combined monotherapy dat a of expansion 
cohorts  3, 6, 7, 8, and 9: 
1) Terminate the trial  
2) Amend the protocol to potentially improve t he benefit/risk for subjects (eg,  increase 
safety monitoring, modify dose/schedule, mandate premedication)  
3) Continue  monotherapy  dose expansion cohorts  and other cohorts, as appropriate, 
without any changes  
When cohort -specific safety threshold exceeded:  
1) Terminate enrollment to the cohort  
2) Amend the protocol to potentially improve the benefit/risk for subjects in the cohort of 
concern (eg, increase safety monitoring, modify dose/schedule, mandate 
premedication)  
3) Continue enrollment to the specific cohort (as appropriate) without any changes  
The methods for deriving the stopping boundaries overall for the combined monotherapy 
data of expansion cohorts 3, 6, 7, 8 and 9, or for within a cohort are described in 
Section  11.3 with the stopping boundaries overall for the combined monotherapy data of 
expansion cohorts 3, 6, 7, 8 and 9 presented in Table 11 -1 and stopping boundaries for 
within a cohort presented in  Table  11-2.  Operating characteristics with  pre-specified 
batch size of 10 new subjects per batch are presented in Table 11 -3. 
 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 116 of 176 
CONFIDENTIAL    
(Overall the combined monotherapy data of expansion cohorts 3, 6, 7, 8 and 9 ) and in 
Table 11 -4 (cohort with planned sample size of 40 subjects) .  The operating 
characteristics in  Table 11-3 and Table 11-4 provide the probability of stopping the trial 
early for given hypothetical true rate of grade 4 or higher treatment -related adverse 
events, whereas the stopping criteria in Table 11 -1 and Table  11-2 are based on 
situations where the empirical evidence would result in a posterior probability of ≥ 80% 
that the true grade 4 or higher treatment -related adverse event rate is ≥ 20%.  
Table 11-1.  Stopping Boundary  Overall  for Combined Monotherapy Data of 
Cohorts  3, 6, 7, 8, and 9 with Poster ior Probability of 80% and Grade 4 or Higher 
Treatmen t-Related Adverse Event Limit of 20%  
Number of subjects  Stop study if observing this many  subjects with  grade 4 or higher 
treatment -related adverse events  
10 ≥ 4 
20 ≥ 6 
30 ≥ 9 
40 ≥ 11 
50 ≥ 13 
60 ≥ 15 
70 ≥ 18 
80 ≥ 20 
90 ≥ 22 
100 ≥ 24 
110 ≥ 26 
120 ≥ 28 
130 ≥ 31 
140 ≥ 33 
150 ≥ 35 
160 Combined Monotherapy Data for Cohorts 3, 6, 7, 8 and 9 
Complete  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 117 of 176 
CONFIDENTIAL    
Table  11-2.  Stopping Boundary for Enrollment within Cohorts 3, 6 - Individually 
with Posterior Probability of 80% and Subject Incidence of Grade 4 or Higher 
Treatment -Related Adverse Event Limit of 20%  
Number of subjects 
treated  Stop cohort enrollment if observing th is many subjects with grade 
4 or higher treatment -related adverse events  
5 ≥ 3 
10 ≥ 4 
20 ≥ 6 
30 ≥ 9 
40 Cohort Enrollment Complete*  
* Enrollment for cohorts 7, 8, and 9 completes after n  = 40 subjects enroll ed.  Enrollment for cohorts 3,  6,  
completes after n  = 20 subjects enrolled.  .  Early stopping 
rules (eg , at 5 or 10 treated subjects) are the same regardless of planned maximum sample size in a cohort.  
Table 11-3.  Operating Characteri stics with Batch Size  of 10 Subjects (Combining 
All Monotherapy Data of Expansion Cohorts 3, 6, 7, 8 and 9)  
True grade 4 or higher 
treatment -related adverse 
event rate  Probability of early stopping of 
dose expansion  Average sample size  of 
overall combined 
monotherapy data  
0.10 2.1 % 156.9  
0.15 12.7 % 143.1  
0.20 46.4 % 105.8  
0.25 86.4 % 58.7 
0.30 98.9 % 31.5 
Table 11-4.  Operating Characteri stics With Batch Size  of 10 Subjects (Cohort -
Specific Enrollment with Maximum Cohort Sample Size of n=40 Subjects)  
True grade 4 or higher 
treatment -related adverse 
event rate  Probability of early stopping of 
cohort enrollment  Average cohort sample 
size 
0.10 2.0 % 39.5 
0.15 9.7 % 37.6 
0.20 25.8 % 33.9 
0.25 47.8 % 28.8 
0.30 69.2 % 23.4 
 
 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 118 of 176 
CONFIDENTIAL    
11.4.1.2  Primary Analysis  
The primary analysis will occur when target enrollment is complete, a nd each subject 
had the opportunity to complete 6  months o n study or withdraws from study .  
11.4.1.3  Final Analysis  
A final analysis is planned after all cohorts and dose -expansion subjects have ended the 
study.  Primary and final analysis may be combined in case all subjects have ended 
study close to the time point of the primary analysis.   
11.4.2  Methods of Analyses  
11.4.2.1  General Considerations  
Descriptive statistics will be provided for selected demographics, safety, PK, 
pharmacodynamics  by cohort , or time as appropriate.  Descriptive 
statistics on continuous data will include means, medians, standard deviations and 
ranges, while categorical data will be summarized using frequency counts and 
percentages.  Grap hical summaries of the data may also be presented.  All descriptiv e 
statistics and graphical summaries may be presented separately for Cohort 5 ,  
 versus all the other cohorts.  Similarly, all the 
efficacy analyses in Section 11.4.2.2  and all the safety analyses in Section  11.4.2.3  may 
be conducted separately for Cohort 5 ,  
versus all the other cohorts.   
. 
Efficacy endpoints will be summarized separately for Cohort 7, Cohort 8 , Cohort 9 , 
.  
Confidence intervals (CI) for proportions will be estimated using an exact method 
proposed by Clopper -Person (Clopper & P earson, 1934). Kaplan -Meier methods will be 
used to estimate the median and percentiles for time to event endpoints with CI 
calculated using the Brookmeyer and Crowley method (Brookmeyer & Crowley, 1982). 
Kaplan -Meier methods will be used to estimate landm arks for time to event endpoints 
(eg, 1 -year OS) with the Greenwood formula (Kalbfleisch & Prentice, 1980) used to 
estimate the standard error used in CI calculation.  
11.4.2.2  Efficacy Analyses  
 
Endpoint  Statistical Analysis Methods  
Primary  Not applicable  
Secondary  For all subjects treated at the RP2D and separately by cohort, the following 
analyses will be done. The proportion of subjects with an objective tumor 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 119 of 176 
CONFIDENTIAL    
response (partial and complete response) and disease control rate (DCR) 
(partial or complete co ntrol) with corresponding exact 80  CI will be 
calculated and tabulated. Similarly, the proportion of subjects and 80  CI will 
be tabulated for 1 -year duration of overall response, 1 -year PFS, 1 -year 
duration of stable disease  and 1 -year OS . Kaplan -Meier c urve will be 
presented for duration of overall response, PFS, OS and duration of stable 
disease with estimates for rate and 80  CI at selected weeks if data allows.  
Exploratory  Not applicable  
 
11.4.2.3  Safety Analyses  
11.4.2.3.1  Analyses of Primary Safety Endpoint(s)  
 
Endpoint  Statistical Analysis Methods  
Primary  Unless otherwise specified, statistical analyses on safety endpoints will be 
done using subjects from the safety analysis set, which includes subjects that 
are enrolled and received AMG 404. The statistical an alysis methods are 
described in sections 11.4.2.3.2  through 11.4. 2.3.6 . 
11.4.2.3.2  Adverse Events  
Subject incidence of all treatment -emergent adverse events will be tabulated by system 
organ class and preferred term.  Tables of fatal adverse events, serious adverse events, 
adverse events leading to withdrawal from investigat ional product,  and other significant 
treatment emergent adverse events will also be provided.   Subject incidence of  
device -related events, if applicable, will be tabulated by system organ class and 
preferred term.  
11.4.2.3.3  Laboratory Test Results  
Clinical chemistry, hematology, and urinalysis data will be summarized .  Depending on 
the size and scope of changes in laboratory data, summaries of laboratory data over 
time and/or changes from baselin e over time may be provided.  Tables of maximum 
shifts from baseline for selected laboratory values may also be provided . 
11.4.2.3.4  Vital Signs  
Depending on the size and scope of changes, summaries of vital signs data over time 
and/or changes from baseline over time may be provided . 
11.4.2.3.5  Physical Measurements  
The analyses of physical measurements may include summary statistics over time by 
treatment cohort.  
11.4.2.3.6  Electrocardiogram  
Summaries over time and/or changes from baseline over time will be provided for all 
ECG parameters. Subjects' maximum change from baseline in (QTcF, QTcB) will be 
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 120 of 176 
CONFIDENTIAL    
categorized and the number and percentage of subjects in each group will be 
summarized. Subjects' maximum post baseline values will also be categorized and the 
number and percent age of subjects in each group will be summarized . 
11.4.2.3.7  Antibody Formation  
The inciden ce and percentage of subjects who develop anti -AMG 404 antibodies ,  
, will be tabulated  overall, and 
by cohort .  
11.4.2.3.8  Exposure to Investigational Product  
Details of AMG 404  adminis tration will be  summarized .  
11.4.2.3.9  Exposure to Other Protocol -required Therapy  
Not applicable . 
11.4.2.3.10  Exposure to Concomitant Medication  
All medication will be coded using the WHO drug d ictionary.   All concomitant 
medications will be summarized .  
11.4.2.4  Other Analyses  
The PK parameters of AMG 4 04 including, but not limited to, Cmax, tmax, and AUC  for 
serum AMG 4 04 will be est imated using non -compartmental methods for subjects where 
intense PK sampling was collected (ie, subjects in Cohorts  1-6 , at least 
10 subjects in Cohorts 7 -9). 
.  The 
parameter estimates will be summarized by dose level using means, geometric means, 
standard deviations, coefficients of variation, medians, minimums, and maximums.  
Individual concentration -time profiles will be summarized by dose level.  Serum 
concentrations for AMG 404 at each time point along with PK parameter 
values may be listed for each subj ect.  Summary statistics will be computed for each 
sampling time and parameter as appropriate .  The relationship between AMG 404 
exposure and efficacy/safety may be conducted.  
 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 121 of 176 
CONFIDENTIAL    
12. References  
AMG 404 Investigator’s Brochure. Thousand Oaks, CA. Amgen Inc.  
Anne C Chiang and Roy S. Herbst. Frontline immunotherapy for NSCLC - the tale of the 
tail. Nat Rev Clin Oncol 2020 ; 17:73 -74. 3)   
Ahamadi M, Freshwater T, Prohn M et al. Model -based characterization of the  
pharmacokinetics of pembrolizumab: A humanized anti-PD-1 monoclonal antibody in  
advanced solid tumors. CPT Pharmacometrics Syst Pharmacol . 2017; 6(1): 49 -57. 
Avastin (bevacizumab) injection, for intravenous use .  United States Prescribing 
Information.  South San Francisco, CA :  Genentech, Inc .  January  2021.  
Azzoli CG, Kris MG, Pfister DG. Cisplatin versus carboplatin for patients with metastatic 
non-small -cell lung cancer --an old rivalry renewed. J Natl Cancer Inst.  2007;99(11):828.   
Bai S, Jorga K, Xin Y et al. A guide to rational dosing of monoclonal  antibodies. Clin 
Pharmacokinet . 2012; 51(2): 119 -35. 
Bajaj G, Wang X, Agrawal S, Gupta M, Roy A, Feng Y. Model -based population  
pharmacokinetic analysis of nivolumab in patients with solid tumors. CPT 
Pharmacometrics Syst Pharmacol . 2017; 6(1): 58 -66. 
Bogaerts J, Ford R, Sargent D, Schwartz LH, Rubinstein L, Lacombe D, Eisenhauer E,  
Verweij J, Therasse P, RECIST Working Party. Individual patient data analysis to assess  
modifications to the RECIST. European Journal of Cancer. 2009 Jan; 45(2):248 -60. 
Brah mer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I,  
Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Chakrabarty JH, Leighl NB, Mammen  
JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner  
CA, Santomas so BD, Seigel C, Spira A, Suarez -Almazor ME, Wang Y, Weber JS,  
Wolchok JD, Thompson JA, in collaboration with the National Comprehensive Cancer  
Network. Management of Immune -Related Adverse Events in Patients Treated with  
Immune Checkpoint Inhibitor Therap y: American Society of Clinical Oncology Clinical  
Practice Guideline. Journal of Clinical Oncology, 36:1714 -1768.  2018 American  
Society of Clinical Oncology and National Comprehensive Cancer Network   
Center for Drug Evaluation and Research, Clinical Phar macology and Biopharmaceutics  
Review, Keytruda (pembrolizumab), Application Number 125514Orig1s000, Submission  
date: February 27, 2014.  
Center for Drug Evaluation and Research, Clinical Pharmacology and Biopharmaceutics  
Review, Opdivo (nivolumab), Applicat ion Number 125554Orig1s000, Submission date:  
July 30, 2014.  
Chatterjee M, Turner DC, Felip E et al. Systematic evaluation of pembrolizumab dosing  
in patients with advanced non -small -cell lung cancer. Ann Oncol . 2016; 27(7): 1291 -8. 
Doroshow D, Sanmamed M, Hastings K, et al. Immunotherapy in Non -Small Cell Lung 
Cancer: Facts and Hopes. Clin Cancer Res  2019; 25:4592 -4602.  
Feng Y, Wang X, Bajaj G et al. Nivolumab exposure -response analyses of efficacy and  
safety in previously treated sq uamous or nonsquamous non -small cell lung cancer. Clin 
Cancer Res . 2017; 23(18): 5394 -5405.  
Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable 
hepatocellular carcinoma. N Engl J Med . 2020; 382:1894 -1905.  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 122 of 176 
CONFIDENTIAL    
Freshwater T, Kondic A, A hamadi M et al. Evaluation of dosing strategy for  
pembrolizumab for oncology indications. J Immunother Cancer . 2017, 5: 43.  
Gandhi L, Rodríguez -Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in 
metastatic non -small -cell lung cancer. N Engl J Me d. 2018 May 31; 378: 2078 -2092.  
Gong J, Chehrazi -Raffle A, Reddi S, Salgia R. Development of PD -1 and PD -L1 
inhibitors as a form of cancer immunotherapy: a comprehensive review of registration  
trials and future considerations. J Immunother Cancer . 2018;6(1 ):8. 
Huinen ZR, Huijbers E, Va Beijnum J, et al. Anti -Angiogenic agents - overcoming tumour 
endothelial cell anergy and improving immunotherapy outcomes. Nat Rev Clin Oncol  
(2021) https://doi.org/10.1038/s41571 -021-00496 -y  
International Committee of Medic al Journal Editors, Uniform Requirements for  
Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical  
Publication. 2013. http://www.icmje.org/  
Ji Y, Liu P, Li Yisheng, Bekele BN. A modified toxicity probability interval method for  
dose -finding trials. Clinical Trials 2010; 7:653 -663. 
KEYTRU DA (pembrolizumab) injection, for intravenous use [prescribing information].  
Whitehouse Station, NJ: Merck & Co, Inc.; 2018.  
Lee MS, Ryoo BY, Hsu CH, et al. Atezolizumab with or without bevacizumab in 
unresectable hepatocellular carcinoma (GO30140): an open -label, multicentre, phase 1b 
study. Lancet Oncol . 2020; 21:808 -820. 
LIBTAYO (cemiplimab -rwlc) injection, for intravenous use [prescribing information].  
Tarrytown, NJ: Regeneron Pharmaceuticals, Inc.; 2018.  
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP.  
Toxicity and response criteria of the Eastern Cooperative Oncology Group. American  
Journal of Cl inical Oncology. 1982 Dec; 5(6): 649 -55. 
OPDIVO (nivolumab) injection, for intravenous use [prescribing information]. Princeton,  
NJ: Bristol -Myers Squibb Co.; 2018.  
Osama Rahma and F. Stephen Hodi. The intersection between Tumor Angiogenesis 
and Immune Su ppression. Clin Cancer Res  2019; 25:5449 -57. 
Pedoeem A, Azoulay -Alfaguter I, Strazza M, Silverman GJ, Mor A. Programmed death -1 
pathway in cancer and autoimmunity. Clin Immunol. 2014 JUL; 153(1):145 -52. 
Reardon DA, Groot JFD, Colman H, et al. Safety of pembrolizumab in combination with 
bevacizumab in recurrent glioblastoma (rGBM). J. Clin. Oncol . 2016; 34: 2010.  
Riley JL. PD -1 Signaling in primary T cells. Immunological Reviews 2009; 229: 114 -25.  
Rini BI , Powles T, Atkins MB, et al. Atezolizumab plus bevacizumab versus sunitinib in 
patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a 
multicentre, open -label, phase 3, randomised controlled trial.  Lancet . 2019;393: 2404 -
2415.  
Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus 
gemcitabine with cisplatin plus pemetrexed in chemotherapy -naive patients with 
advanced -stage non -small -cell lung cancer. J Clin Oncol.  2008;26(21):3543.  
Schiller JH, H arrington D, Belani CP, et al. Comparison of Four Chemotherapy 
Regimens for Advanced Non -Small Cell Lung Cancer. N Engl J Med. 2002; 346:92 -98. 
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 123 of 176 
CONFIDENTIAL    
Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N,  Rodriguez -
Abreu D, Moro -Sibilot D, Thom as C, Barlesi F, Finley G, Kelsch C, Lee A,  Coleman S, 
Deng Y, Shen Y, Kowanetz M, Lopez -Chavez A, Sandler A, Reck M.  Atezolizumab for 
First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J  Med. 2018; 378: 
2288 -2301.  
Tecentriq ( atezolizumab ) inject ion, for intravenous use .  United States Prescribing 
Information.  South San Francisco, CA :  Genentech, Inc .  April 2021.  
Wang DD, Zhang S, Zhao H, Men AY, Parivar K. Fixed dosing versus body size -based  
dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol. 2009; 49(9):  
1012 -24. 
Thall, PF, Simon, RM, and Estey, RM. Bayesian sequential monitoring designs for  
single -arm clinical trials with multiple outcomes. Statistics in Medicine. 1995; 14(4):357 - 
79. 
Wang X, Feng Y, Bajaj G et al. Q uantitative characterization of the exposure -response  
relationship for cancer immunotherapy: A case study of nivolumab in patients with  
advanced melanoma. CPT Pharmacometr ics Syst Pharmaco l. 2017; 6(1): 40 -48. 
Wolchok JK, Chiarion -Sileni V, Gonzalez R, Rut kowski P, Grob JJ, Cowey CL, Lao CD,  
Wagstaff J, Schadendorf D, Ferrucci PF, Smylie M, DUmmer R, Hill A, Hogg D, Haanen  
J, Carlino MS, Bechter O, Mao M, Marquez -Rodas I, Guidoboni M, McArthur G, Lebbe  
C, Ascierto PA, Long GV, Cebon J, Sosman, J, Postow MA,  Callahan MK, Walker D,  
Rollin L, Bhore R, Hodi FS, Larkin J. Overall Survival with Combined Nivolumab and  
Ipilimumab in Advanced Melanoma. N Engl J Med. 2017; 377 (14): 1345 -1356.  
Zhao X, Suryawanshi S, Hruska M et al. Assessment of nivolumab benefit -risk profile of  
a 240-mg flat dose relative to a 3 -mg/kg dosing regimen in patients with advanced  
tumors. Ann Oncol . 2017; 28(8): 2002 -2008.  
Zsiros E, Lynam S, Attwood KM, et al. Efficacy and safety of pembrolizumab in 
combination with bevacizumab and oral met ronomic cyclophosphamide in the treatment 
of recurrent ovarian cancer: a phase 2 nonrandomized clinical trial. JAMA Oncol . 2021;7: 
78-85. 
 
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 124 of 176 
CONFIDENTIAL    
13. Appendices  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 125 of 176 
CONFIDENTIAL    
13.1 Appendix 1.  List of Abbreviations and Definitions of Terms  
 
Abbreviation or Term  Definition/Explanation  
ADA Anti-Drug Antibody  
ADCC  Antibody -dependent cellular cytotoxicity  
AML Acute Myeloid Leukemia  
AUC  area under the serum  concentration -time curve  
CFR U.S. Code of Federal Regulations  
CI Confidence Interval  
Cmax maximum observed serum concentration  
CRF case report form  
CTCAE  Common Terminology Criteria for Adverse Events  
DES Amgen data element standard  
DILI drug induced liver injury  
DLRM  dose level review meeting  
DLRT  dose level review team  
DLT Dose Limiting Toxicity  
ECG  electrocardiogram  
ECL Electrochemiluminiscent  
ECOG PS  Eastern Cooperative Oncology Group Performance Status  
EDC  electronic data capture  
Electronic Source Data 
(eSource)  source data captured initially into a permanent electronic record 
used for the reconstruction and evaluation of a trial.  
Enrollment  Date of enrollment confirmation letter from Amgen  
EOT End of Treatment  
Exposure -Response  
Analysis  mechanism -based modeling & simulation and statistical 
analyses based  on individua l pharmacokinetic ( PK) exposure 
(eg, population pharmacokinetic modeling) and response, which 
may include  pharmacodynamic (PD) effects, 
efficacy and safety endpoints.  
End of Follow -up defined as when the last subj ect completes the last 
protoco l-specified assessment in the study   
End of Study for Individual 
Subject  defined as the last day that protocol -specified procedures are 
conducted for an individual subject  

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 126 of 176 
CONFIDENTIAL    
Abbreviation or Term  Definition/Explanation  
End of Study (primary 
completion)  defined as the date when the last subject is assessed or 
receives an intervention for the final collection of data for the 
primary endpoint(s), for the purposes of conducting the primary 
analysis, whether the study concluded as planned in the protocol 
or was terminated early  
End of Study (end of trial)  defined as the date when the last subject across all sites is 
assessed or receives an intervention for evaluation in the study 
(ie, last subject last visit), following any additional parts in the 
study (eg,  long-term follow -up), as applicable  
End of Treatment  defined as the last assessment for the protocol -specified 
treatment phase of the study for an individual subject  
FIH First in Human  
FSH follicle stimulating hormone  
FFPE  Formalin fixed paraffin embedded  
GCP  Good Clinical Practice  
GLP Good Laboratory Practices  
HIPAA  Health Insurance Portability and Accountability Act  
HRT Hormone replacement therapy  
HUVEC  Human Endothelial Cells  
IBG Independent Biostatistics Group  
ICF informed consent form  
ICH International Conference on Harmonisation  
ICJME  International Committee of Medical Journal Editors  
IEC Independent Ethics Committee  
IP investigational product  
IPIM Investigational Product Instruction Manual  
IPRO  Immunophenotyping receptor occupancy  
IRB Institutional Review Board  
IUD intrauterine device  
IUS intrauterine hormonal -releasing system  
IV Intravenous  
LLOQ  Lower limit of quantification  
(m)TPI  (modified) Toxicity Probability Interval  
ORR  Overall Response Rate  
PBL Peripheral blood leukocytes  
PFS Progression free survival  
PPP Platelet poor plasma  
SAT safety assessment team  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 127 of 176 
CONFIDENTIAL    
Abbreviation or Term  Definition/Explanation  
Source Data  information from an original record or certified copy of the 
original record containing patient information for use in clinical 
research.   The information may include, but is not limited to, 
clinical findings, observations, or other activities in a clinical trial 
necessary for the reconstruction and evaluation of the trial.  
Source data are contained in source documents (original records 
or certified copies).  (ICH Guideline [E6]).  Examples of source 
data include Subject identification, Randomization identification, 
and Stratification Value.  
Study Day 1  defined as the first day that protocol -specified investigational 
product  administered to the subject  
TBL total bilirubin  
tmax time to achieve C max 
SUSAR  suspected unex pected serious adverse reaction  
TMF trial master file  
ULN upper limit of normal  
 
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 128 of 176 
CONFIDENTIAL    
13.2 Appendix 2.  Clinical Laboratory Tests  
The tests detailed in Table 13 -1 will be performed by the local laboratory  (unless 
specified otherwise ).  
Protocol -specific requirements for inclusion or exclusion of subjects are detailed in 
Sections  7.1 and 7.2 of the protocol.  
Additional tests may be performed at any time during the study as determined necessary 
by the investigator or required by local regulations.  
Table 13-1.  Analyte Listing  
Local Laboratory: 
Chemistry  Local  
Laboratory: 
Coagulation  Local  
Laboratory: 
Urinalysis  Local  
Laboratory: 
Hematology  Other Labs  
Sodium  
Potassium  
Chloride  
Bicarbonate or 
CO 2 
Total protein  
Albumin  
Calcium  
Calcium 
Corrected  
Glucose  
BUN or 
Urea /Total Urea  
Creatinine  
Estimated CrCl  
GFR, MDRD 
calculation  
Total bilirubin  
ALP 
AST (SGOT)  
ALT (SGPT)  
TSH 
Free T4  
 APTT  
PT/INR 
 Specific gravity  
pH 
Blood  
Protein  
Glucose  
Bilirubin  
WBC  
RBC  
Epithelial cells  
Bacteria  
Casts  
Crystals  RBC  
Hemoglobin  
Hematocrit  
MCV  
Platelets  
WBC  
Differential  
• Total Neutrophils  
• Eosinophils  
• Basophils  
• Lymphocytes  
• Monocytes  
 
 Central 
Laboratory : 
Antibodies  
PK sampling  
Whole blood for 
cytometry 
Serum2 
PD-L1 
dMMR  
MSI  
 
 
Local Laboratory : 
Serum or Urine 
Pregnancy  
Hep B surface 
antigen  
Hep B core 
antibody  
Hep C antibody  
HIV 
ACTH  
ANA 
ANCA  
(cytoplasmic and 
perinuclear)  
PD-L1 
dMMR  
MSI  
 
2 Not applicable to  China  
ACTH = Adrenocorticotropic hormone; ANA = Antinuclear Antibodies; ANCA = Antineutrophil cytoplasmic 
antibodies; ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate 
aminotransferase; BUN = blood urea nitrogen; dMMR  = Mismatch Repair Deficiency;  
 HDL = high density lipoprotein; Hep = hepatitis; HIV = human immunodeficiency virus;  
INR = international normalized ratio;  MCH = mean corpuscular hemoglobin; MCHC  = mean corpuscular 
hemoglobin concentration; MCV = mean corpuscular volume; MSI = Microsatellite Instability;  
PD-L1 = Programmed Death Ligand 1; PK = pharmacokinetics; PT = prothrombin time; APTT = partial 
thromboplastin time;  RBC = red blood cell count;  RDW = Red cell distribution width; SGOT = serum 
glutamic -oxaloacetic transaminase; SGPT - serum glutamic -pyruvic transaminase; WBC = white blood cell 
count  

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 129 of 176 
CONFIDENTIAL    
13.3 Appendix 3.  Study Governance Considerations  
Committee(s)  
Dose Level Review Team  
Dose level r eview team (DLRT) meetings will be held to review data, monitor safety, and 
make recommendations on dose determination.  See Section 8.4.1  for detailed 
information on the DLRM and DLRT.   
Regulatory and Ethical Considerations  
This study will be conducted in accordance with the protocol and with:  
 Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organization s of Medical 
Sciences International Ethical Guidelines  
 Applicable International Conference on Harmonisation ( ICH) Good Clinical 
Practice (GCP ) Guidelines  
 Applicable  ICH laws and regulations  
The protocol, protocol amendments, informed consent form, Investig ator’s Brochure, and 
other relevant documents (eg, subject recruitment advertisements) must be submitted to 
an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) by the 
investigator and reviewed and approved by the IRB/IEC .  A copy of the written approval 
of the protocol and informed consent form must be received by Amgen before 
recruitment of subjects into the study and shipment of Amgen investigational product.  
Amgen may amend the protocol at any time.  The investigator must submit and, w here 
necessary, obtain approval from the IRB/IEC  for all subsequent protocol amendments 
and changes to the informed consent document.  The investigator must send a copy of 
the approval letter from the IRB/IEC  and amended protocol Investigator’s Signature 
page to Amgen prior to implementation of the protocol amendment at their site.  
The investigator will be responsible for the following:  
 Providing written summaries of the status of the study to the IRB/IEC annually or 
more frequently in accordance with the r equirements, policies, and procedures 
established by the IRB/IEC  
 Obtaining annual IRB/IEC approval/renewal throughout the duration of the study.  
Copies of the investigator’s reports and the IRB/IEC continuance of approval 
must be sent to Amgen  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 130 of 176 
CONFIDENTIAL    
 Notifying t he IRB/IEC of serious adverse events occurring at the site, deviations 
from the protocol or other adverse event reports received from Amgen, in 
accordance with local procedures  
 Overall conduct of the study at the site and adherence to requirements of Title  21 
of the U.S. Code of Federal Regulations (CFR), ICH guidelines, the IRB/IEC, and 
all other applicable local regulations  
Recruitment Procedures  
Site staff may identify potential subjects from their existing patient population and/or may 
seek referral pat ients through existing professional networks or other community 
sources. All patient -facing materials must be reviewed/approved by the sponsor  
(Amgen Inc.) and the local IRB/IEC prior to use.  
Informed Consent Process  
An initial sample informed consent form is provided for the investigator to prepare the 
informed consent document to be used at his or her site.  Updates to the sample 
informed consent form are to be communicated formally in writing from the Amgen Trial 
Manager to the investigator.  The wri tten informed consent form is to be prepared in the 
language(s) of the potential patient population.  
The investigator or his/her delegated representative will explain to the subject, or his/her 
legally authorized representative, the aims, methods, anticipa ted benefits, and potential 
hazards of the study before any protocol -specific screening procedures or any 
investigational product(s) is/are administered and  answer all questions regarding the 
study.   
Subjects must be informed that their participation is voluntary.  Subjects or their legally 
authorized representative (defined as an individual or other body authorized under 
applicable law to consent, on behalf of a prospective subject, to the subject’s 
participation in the clinical study ) will then be required to sign a statement of informed 
consent that meets the requirements of 21 CFR 50, local regulations, ICH guidelines, 
Health Insurance Portability and Accountability Act requirements, where applicabl e, and 
the IRB/IEC  or study site.  
The medical record must include a statement that written informed consent was obtained 
before the subject was enrolled in the study and the date the written consent was 
obtained.  The authorized person obtaining the infor med consent must also sign the 
informed consent form.  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 131 of 176 
CONFIDENTIAL    
The investigator is also responsible for asking the subject if the subject has a primary 
care physician and if the subject agrees to have his/her primary care physician informed 
of the subject’s partici pation in the clinical study unless it is a local requirement.  The 
investigator shall then inform the primary care physician.  If the subject agrees to such 
notification, the investigator is to inform the subject’s primary care physician of the 
subject’s participation in the clinical study.  If the subject does not have a primary care 
physician and the investigator will be acting in that capacity, the investigator is to 
document such in the subject’s medical record.  
The acquisition of informed consent and the subject’s agreement or refusal of his/her 
notification of the primary care physician is to be documented in the subject’s medical 
records, and the informed consent form is to be signed and personally dated by the 
subject [or a legally acceptable repres entative] and by the person who conducted the 
informed consent discussion.  Subject withdrawal of consent or discontinuation from 
study treatment and/or procedures must also be documented in the subject’s medical 
records; refer to Section 9. 
Subjects must be re -consented to the most current version of the informed consent 
form(s) during their participation in the study , if applicable .  
The original signed informed consent form is to be retained in accordance with 
institutional policy, and a copy of the informed consent form(s) must be provided to the 
subject or the subject’s legall y authorized representative.  
If a potential subject is illiterate or visually impaired and does not have a legally 
acceptable representative, the investigator must provide an impartial witness to read the 
informed consent form to the subject and must allo w for questions.  Thereafter, both the 
subject and the witness must sign the informed consent form to attest that informed 
consent was freely given and understood.  (Refer to ICH GCP guideline, Section  4.8.9.)  
A subject who is rescreened is not required to  sign another informed consent form if  the 
rescreening occurs within 28  days from the previous informed consent form signature 
date. 
The informed consent form (ICF) will contain a separate section that addresses the use 
of remaining mandatory samples for o ptional future  research.  The investigator or 
authorized designee will explain to each subject the objectives of the future  research.  
Subjects will be told that they are free to refuse to participate and may withdraw their 
specimens at any time and for an y reason during the storage period.  A separate 
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 132 of 176 
CONFIDENTIAL    
signature will be required to document a subject’s agreement to allow any remaining 
specimens to be used for future  research.  Subjects who decline to participate will not 
provide this separate signature.  
Data Protection/Subject Confidentiality  
The investigator must ensure that the subject’s confidentiality is maintained for 
documents submitted to Amgen.  
Subject will be assigned a unique identifier by the sponsor.  Any subject records or 
datasets that are tran sferred to the sponsor will contain the identifier only; subject names 
or any information which would make the subject identifiable will not be transferred.  
On the Case Report Form ( CRF) demographics page, in addition to the unique subject 
identification number, include the age at time of enrollment.  
For s erious adverse events reported to Amgen, subjects are to be identified by their 
unique subject identification number, initials (for faxed reports, in accordance with local 
laws and regulations), and age (in accordance with local laws and regulations).  
Documents that are not submitted to Amgen (eg, signed informed consent forms) are to 
be kept in confidence by the investigator, except as described below.  
In compliance with governmental regulations/ICH GCP Guidelines, it is required that the 
investigator and institution permit authorized representatives of the company, of the 
regulatory agency(s), and the IRB/IEC  direct access to review the subject’s original 
medical records for verification of study -related  procedures and data.  Direct access 
includes examining, analyzing, verifying, and reproducing any records and reports that 
are important to the evaluation of the study.   
The investigator is obligated to inform and obtain the consent of the subject to per mit 
such individuals to have access to his/her study -related records, including personal 
information.  
Publication Policy  
To coordinate dissemination of data from this study, Amgen may facilitate the formation 
of a publication committee consisting of severa l investigators and appropriate Amgen 
staff, the governance and responsibilities of which are set forth in a Publication Charter.  
The committee is expected to solicit input and assistance from other investigators and to 
collaborate with authors and Amgen staff, as appropriate, as defined in the Publication 
Charter.  Membership on the committee (both for investigators and Amgen staff) does 
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 133 of 176 
CONFIDENTIAL    
not guarantee authorship.  The criteria described below are to be met for every 
publication.  
Authorship of any publicat ions resulting from this study will be determined on the basis 
of the Uniform Requirement for Manuscripts Submitted to Biomedical Journals 
International Committee of Medical Journal Editors Recommendations for the Conduct of 
Reporting, Editing, and Publica tions of Scholarly Work in Medical Journals, which states:   
Authorship credit is to be based on:  (1) substantial contributions to conception and 
design, acquisition of data, or analysis and interpretation of data; (2) drafting the article 
or revising it c ritically for important intellectual content; (3) final approval of the version to 
be published; and (4) agreement to be accountable for all aspects of the work in 
ensuring that questions related to the accuracy or integrity of any part of the work are 
appropriately investigated and resolved.  Authors need to meet conditions 1, 2, 3, and 4.  
When a large, multicenter group has conducted the work, the group is to identify the 
individuals who accept direct responsibility for the manuscript.  These individuals must 
fully meet the criteria for authorship defined above.  Acquisition of funding, collection of 
data, or general supervision of the research group, alone, does not justify authorship.   All 
persons designated as authors must qualify for authorship, and all  those who qualify are 
to be listed.   Each author must have participated sufficiently in the work to take public 
responsibility for appropriate portions of the content.  All publications (eg, manuscripts, 
abstracts, oral/slide presentations, book chapters) based on this study must be 
submitted to Amgen for review.  The Clinical Trial Agreement among the institution, 
investigator, and Amgen will detail the procedures for, and timing of, Amgen’s review of 
publications.  
Investigator Signatory Obligations  
Each c linical study report is to be signed by the investigator or, in the case of multicenter 
studies, the coordinating investigator.  
The coordinating investigator, identified by Amgen, will be any or all of the following:  
 A recognized  expert in the therapeutic area  
 An Investigator who provided significant contributions to either the design  or 
interpretation of the study  
 An Investigator contributing a h igh number of eligible subjects  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 134 of 176 
CONFIDENTIAL    
Data Quality Assurance  
All subject data relating to t he study will be recorded on printed or electronic CRF unless 
transmitted to the sponsor or designee electronically (eg, laboratory data, centrally or 
adjudicated data).  The investigator is responsible for verifying that data entries are 
accurate and corr ect by physically or electronically signing the CRF.  
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.  
The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.   
The sponsor or designee is responsible for the data management of this study including 
quality checking of the data.  
Clinical  monitors will perform ongoing source data ver ification to confirm that data 
entered into the CRF by authorized site personnel are accurate, complete, and verifiable 
from source documents; that the safety and rights of subjects are being protected; and 
that the study is being conducted in accordance w ith the currently approved protocol and 
any other study agreements, ICH GCP, and all applicable regulatory requirements per 
the sponsor’s monitoring plan.  
The investigator agrees to cooperate with the clinical monitor to ensure that any 
problems detected in the course of these monitoring visits, including delays in 
completing CRFs, are resolved.  
The Amgen representative(s) and regulatory authority inspectors are responsible for 
contacting and visiting the investigator for the purpose of inspecting the faci lities and, 
upon request, inspecting the various records of the clinical study (eg, CRFs and other 
pertinent data) provided that subject confidentiality is respected.  
In accordance with ICH GCP and the sponsor’s audit plans, this study may be selected 
for audit by representatives from Amgen’s Global Research and Development 
Compliance and Audit function (or designees).  Inspection of site facilities (eg, 
pharmacy, protocol -required therapy storage areas, laboratories) and review of 
study -related records wil l occur to evaluate the study conduct and compliance with the 
protocol, ICH GCP, and applicable regulatory requirements.  
Retention of study documents will be governed by the Clinical Trial Agreement.  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 135 of 176 
CONFIDENTIAL    
Case report forms (CRF)  must be completed in English.  TRADENAMES® (if used) for 
concomitant medications may be entered in the local language.  Consult the 
country -specific language requirements.  
All written information and other material to be used by subjects and investigative  staff 
must use vocabulary and language that are clearly understood.  
Source Documents  
The investigator is to maintain a list of appropriately qualified persons to whom he/she 
has delegated study duties.  All persons authorized to make entries and/or correc tions 
on CRFs will be included on the Amgen Delegation of Authority Form.  
Source documents provide evidence for the existence of the subject and substantiate 
the integrity of the data collected.  Source documents are filed at the investigator’s site.  
Sourc e documents are original documents, data, and records from which the subject’s 
CRF data are obtained.  These include but are not limited to hospital records, clinical 
and office charts, laboratory and pharmacy records, diaries, microfiches, radiographs, 
and correspondence.  Source documents may also include data captured in the CRF 
entries if the CRF is the site of the original recording (ie, there is no other written or 
electronic record of data, such as paper questionnaires for a clinical outcome 
assessme nt). 
Data reported on the CRF or entered in the electronic CRF that are transcribed from 
source documents must be consistent with the source documents or the discrepancies 
must be explained.  The investigator may need to request previous medical records or  
transfer records, depending on the study.  Also, current medical records must be 
available.  
The Investigator and study staff are responsible for maintaining a comprehensive and 
centralized filing system of all study -related (essential) documentation, suit able for 
inspection at any time by representatives from Amgen and/or applicable regulatory 
authorities.  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 136 of 176 
CONFIDENTIAL    
Elements to include:  
 Subject files containing completed CRFs, informed consent forms, and subject 
identification list  
 Study files containing the protoco l with all amendments, Investigator’s Brochure, 
copies of prestudy documentation, and all correspondence to and from the 
[IRB/IEC] and Amgen  
 Investigational product -related corresponden ce including [Proof of Receipts, 
Investigational Product Accountability  Record(s), Return of Investigational 
Product for Destruction Form(s), Final Investigational Product Reconcil iation 
Statement, as applicable  
 Non-investigational product(s), and/or medical device(s) or combination 
product(s) documentation, as applicable]  
Retention of study documents will be governed by the Clinical Trial Agreement.  
Study and Site Closure  
Amgen or its designee may stop the study or study site participation in the study for 
medical, safety, regulatory, administrative, or other reasons consis tent with applicable 
laws, regulations, and GCP.  
Both Amgen and the Investigator reserve the right to terminate the Investigator’s 
participation in the study according to the Clinical Trial Agreement.  The investigator is to 
notify the IRB/IEC in writing of the study’s completion or early termination and send a 
copy of the notification to Amgen.  
Subjects may be eligible for continued treatment with Amgen investigational product(s) 
by an extension protocol or as provided for by the local country’s regulator y mechanism.  
However, Amgen reserves the unilateral right, at its sole discretion, to determine 
whether to supply Amgen investigational product(s) and by what mechanism, after 
termination of the study and before the product(s) is/are available commerciall y. 
Compensation  
Any arrangements for compensation to subjects for injury or illness that arises in the 
study are described in the Compensation for Injury section of the Informed Consent that 
is available as a separate document.  
 
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 137 of 176 
CONFIDENTIAL    
13.4 Appendix 4.  Toxicity Management Guidelines  
Table 13-2.  Dose Modification and Toxicity Management Guidelines for Immune -Related Advers e Reactions Associated With 
AMG  404* 
Immune -Related  
Adverse 
Reactions  Severity (CTCAE Grade Version 
5.0 or Specific Conditions)  AMG 404 Dose 
Modification  Management with Corticosteroids 
and/or Other Therapies  Monitor & Follow -up 
Pneumonitis  Grade 2 (symptomatic, involves 
more than one lobe of the lung of 
25-50 of lung parenchyma, 
medical intervention indicated, 
limiting instrumental ADL)  Withhold  
Administer corticosteroids at an 
initial dose of 1 to 2 mg/kg/d  
prednisone (or equivalent) followed 
by taper. Consider additional 
immunosuppressive agent (eg, 
infliximab, mycophenolate, 
cyclophosphamide) if refractory to 
corticosteroids.  Monitor subjects for signs and 
symptoms of pneumonitis.  
Evaluate subjects with s uspected 
pneumonitis with radiographic 
imaging. Add prophylactic 
antibiotics for opportunistic 
infections.  Grade 3 (severe symptoms, 
hospitalization required, involves 
all lung lobes or  50 of lung 
parenchyma, limiting self -care 
ADL, oxygen indicated)  Permanently 
discontinue  
Grade 4 (life -threatening 
respiratory compromise, urgent 
intervention indicated [intubation])  
Page 1 of  8 
Footnotes defined on last page of this table  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 138 of 176 
CONFIDENTIAL    
Table 13 -2.  Dose Modification and Toxicity Management Guidelines for Immune -Related Adverse Reactions Associated With 
AMG  404* 
Immune -Related  
Adverse 
Reactions  Severity (CTCAE Grade Version 
5.0 or Specific Conditions)  AMG 404 Dose 
Modification  Management with Corticosteroids 
and/or Other Therapies  Monitor & Follow -up 
Colitis/Diarrhea  Grade 2 (increase of 4 -6 stools 
per day over baseline; moderate 
increase in ostomy output 
compared with baseline)  
Withhold  Administer corticosteroids at an 
initial dose of 1 to 2 mg/kg/d 
prednisone (or equivalent) followed 
by taper. Consider infliximab if 
symptoms refractory to 
corticosteroids within 2 -3 days.  Monitor subjects for signs and 
symptoms of enterocolitis (eg, 
diarrhea, abdominal pain, blood 
or mucus in stool with or without 
fever) and of bowel perforation 
(eg, peritoneal signs and ileus). 
For subjects with grade  2 
diarrhea suspecting colitis, 
consider GI consultation and 
endoscopy to rule out colitis.  Grade 3 (increase of 7 or more 
stools per day over baseline, 
incontinence; hospitalization 
indicated, severe increase in 
ostomy output compared with 
baseline, limiting self -care ADL)  
Grade 4 (life -threatening 
consequences; urgent 
intervention indicated)  Permanently 
discontinue  
Page 2 of  8 
Footnotes defined on last page of this table  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 139 of 176 
CONFIDENTIAL    
Table 13 -2.  Dose Modification and Toxicity Management Guidelines for Immune -Related Adverse Reactions Associated With 
AMG  404* 
Immune -Related  
Adverse 
Reactions  Severity (CTCAE Grade Version 
5.0 or Specific Conditions)  AMG 404 Dose 
Modification  Management with Corticosteroids 
and/or Other Therapies  Monitor  & Follow -up 
Hepatitis **1 Grade 1 ( AST or ALT  3 x ULN) 
without elevated total bilirubin  Continue  Consider holding for concerning lab 
value trend.  
Monitor with liver function 
tests more frequently until 
returned to baseline or 
stable.  Additional 
management per institutional 
and professional society 
guidelines.  Grade 2 (AST or ALT 3 -5 x ULN) 
without elevated total bilirubin   Withhold  Consider corticosteroids at an initial 
dose of 0.5 to 1 mg/kg/d prednisone 
(or equivalent) followed by  taper.  
Grade 3 (AST or ALT 5-20 x ULN) 
without elevated total bilirubin  
[Without a clear alternative etiology. 
If a clear alternative etiology, then 
withhold, do not discontinue 
AMG  404.]   
Permanently 
discontinue  Administer corticosteroids at an 
initial dose of 1 to 2 mg/kg/d 
prednisone (or equivalent) followed 
by taper. Consider mycophenolate 
mofetil if refractory to corticosteroids 
or no improvement after 3 days.  
Grade 4 (AST or ALT  20 x ULN) 
without elevated total bilirubin  
[Without a clear alternative etiology. 
If a clear alternative etiology, then 
withhold, do not discontinue 
AMG  404.]   Administer corticosteroids at an 
initial dose of 2 mg/kg/d prednisone 
(or equivalent) followed by taper. 
Consider mycophenolate mofetil if 
refractory  to corticosteroids or no 
improvement after 3 days.  
Grade  1 (AST or ALT  3 x ULN)  
with total bilirubin  1.5 x ULN  
[Without a clear alternative etiology. 
If a clear alternative etiology, then 
withhold, do not discontinue 
Consider holding for concerning lab 
value trend.  AMG 404.]  Administer corticosteroids at an 
initial dose of 2 mg/kg/d prednisone 
(or equivalent) followed by taper. 
Consider mycophenolate mofetil if 
refractory to corticosteroids or no 
improvement after 3 days.  
Page 3 of 8 
Footnotes defined on last page of this table  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 140 of 176 
CONFIDENTIAL    
Table 13 -2.  Dose Modification and Toxicity Management Guidelines for Immune -Related Adverse Reactions Associated With 
AMG  404* 
Immune -Related  
Adverse 
Reactions  Severity (CTCAE Grade Version 
5.0 or Specific Conditions)  AMG 404 Dose 
Modification  Management with Corticosteroids 
and/or Other Therapies  Monitor  & Follow -up 
Hypophysitis  Grade 3 or 4 (severe symptoms, 
medically significant or  
life-threatening  consequences, 
unable to perform ADL)  Withhold  Administer corticosteroids at an 
initial dose of 1 mg/kg/d prednisone 
(or equivalent)  followed by taper . In 
addition , initiate hormonal 
replacement therapy  as clinically 
indicated.  Monitor for signs and symptoms 
of hypophysitis. Consider 
endocrine consultation.  
Adrenal 
Insufficiency  Grade 3 or 4 (severe symptoms, 
medically significant or  
life-threatening  conse quences, 
unable to perform ADL)  Withhold  Initiate IV stress -dose 
corticosteroids on presentation 
(hydrocortisone 100 mg or 
dexamethasone 4 mg [if the  
diagnosis is not clear and ACTH 
stimulation testing will be needed]). 
Taper stress -dose corticoster oids 
down to maintenance doses 
(prednisone 5 to 10 mg daily) over 
1-2 weeks  after discharge.  Monitor for signs and symptoms 
of adrenal insufficiency.   
Consider endocrine consultation.  
Hypothyroidism  Grade 3 or 4 (severe symptoms, 
medically significant o r  
life-threatening  consequences, 
unable to perform ADL)  Withhold  Initiate thyroid hormone 
supplementation.  Monitor subjects for signs and 
symptoms of hypothyroidism. 
Consider endocrine consultation.  
Hyperthyroidism  Grade 3 or 4 (severe symptoms, 
medically significant or  
life-threatening  consequences, 
unable to perform ADL)   Withhold  Initiate -Blocker (eg, atenolol, 
propranolol) for symptomatic relief. 
For severe symptoms or concern for 
thyroid storm, initiate predn isone  
1-2 mg/kg/d (or equivalent) tapered 
over 1 -2 weeks. Consider use of 
SSKI or thionamide (methimazole or 
PTU).  Monitor subjects for signs and 
symptoms of hyperthyroidism. 
Consider endocrine consultation.  
Page 4 of  8 
Footnotes defined on last page of this table  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 141 of 176 
CONFIDENTIAL    
Table 13 -2.  Dose Modification and Toxicity Management Guidelines for Immune -Related Adverse Reactions Associated With 
AMG  404* 
Immune -Related  
Adverse 
Reactions  Severity (CTCAE Grade Version 
5.0 or Specific Conditions)  AMG 404 Dose 
Modification  Management with Corticosteroids 
and/or Other Therapies  Monitor & Follow -up 
Diabetes Mellitus  Grade 3 hyperglycemia (  250 to 
500 mg/dL [ 13.9 to 
27.8 mmol/L])  Withhold  Initiate insulin therapy.  Monitor subjects for 
hyperglycemia or other signs and 
symptoms of diabetes. Consider 
endocrine consultation.  Grade 4 hyperglycemia  
( 500 mg/dL [  27.8 mmol/L])  
Nephritis and 
Renal 
Dysfunction  Grade 2 (serum creatinine 1.5 - 
3.0 x baseline; 1.5 - 3.0 x ULN)  Withhold  Administer corticosteroids at an 
initial dose of 0.5 to 1 mg/kg/d 
prednisone (or equivalent) followed 
by taper. If worsening or no 
improvement occurs, increase dose 
of corticosteroids to 1 to 2 mg/kg/d 
prednisone (or equivalent).  Monitor changes in renal 
function. Evaluate for other 
causes of renal dy sfunction (eg,  
recent IV contrast, medications, 
fluid status, etc)  Grade 3 (serum creatinine 3.0 x 
baseline; 3.0 - 6.0 x ULN)  Permanently 
discontinue  Administer corticosteroids at an 
initial dose of 1 to 2 mg/kg/d 
prednisone (or equivalent) followed 
by taper.  Grade 4 (serum creatinine  6 x 
ULN; dialysis indicated ) 
Page 5 of  8 
Footnotes defined on last page of this table  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 142 of 176 
CONFIDENTIAL    
Table 13 -2.  Dose Modification and Toxicity Management Guidelines for Immune -Related Adverse Reactions Associated With 
AMG  404* 
Immune -Related  
Adverse 
Reactions  Severity (CTCAE Grade Version 
5.0 or Specific Conditions)  AMG 404 Dose 
Modification  Management with Corticosteroids 
and/or Other Therapies  Monitor & Follow -up 
Skin Grade 3 rash or suspected 
Stevens -Johnson syndrome 
(SJS) or toxic epidermal 
necrolysis (TEN)  Withhold  Administer corticosteroids at an 
initial dose of 1 to 2 mg/kg/d 
prednisone (or equivalent) followed 
by taper. Treat with topical 
emollients, oral antihistamines, and 
high-potency topical corticosteroids 
as indic ated.  Monitor subjects for suspected 
severe skin reacti ons and 
exclude other causes (eg,  
infection, an effect of another 
drug, a skin condition linked to 
another systemic disease, etc). 
For signs or symptoms of SJS or 
TEN, withhold study drug and 
refer the  patient for specialized 
care for assessment and 
treatment.  Grade 4 rash or confirmed SJS  
or TEN  Permanently 
discontinue  
Encephalitis  Grade 2 (moderate symptoms, 
some interference with ADL)  Withhold  Administer corticosteroids at an 
initial dose of 1 to 2 mg/kg/d 
prednisone (or equivalent) followed 
by taper.  Consider empirical antiviral 
(IV acyclovir) and antibacterial 
therapy until CSF results obtained 
and negative for aseptic meningitis.  Monitor subjects for neurologic 
symptoms and exclude other 
etiologies (eg,  infectious). 
Evaluation of patients with 
neurologic symptoms may 
include, but not be limited to, 
consultation with a neurologist, 
brain MRI, and lumbar puncture.  Grade 3 or 4 (severe symptoms, 
limiting self -care and aids 
warranted)  Permanently 
discontinue  
Page 6 of  8 
Footnotes defined on last page of this table  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 143 of 176 
CONFIDENTIAL    
Table 13 -2.  Dose Modification and Toxicity Management Guidelines for Immune -Related Adverse Reactions Associated With 
AMG  404* 
Immune -Related  
Adverse 
Reactions  Severity (CTCAE Grade Version 
5.0 or Specific Conditions)  AMG 404 Dose 
Modification  Management with Corticosteroids 
and/or Other Therapies  Monitor  & Follow -up 
Myocarditis  Grade 1 (abnormal cardiac 
 testing, including 
abnormal ECG)  Withhold  
Administer corticosteroids at an 
initial dose of 1 to 2 mg/kg/d 
prednisone (or equivalent) followed 
by taper.  Monitor patients with 
cardiovascular symptoms. 
Ensure adequate evaluation to 
confirm etiology and/or exclude 
other causes.  Grade 2 (abnormal screening 
tests with mild symptoms)  
Grade 3 (moderately abnormal 
testing or symptoms with mild 
activity)  Permanently 
discontinue  Grade 4 (moderate to severe 
decompensation, IV medication  
or intervention required, 
life-threatening conditions)  
All Other 
Immune -Related  
Adverse 
Reactions  Grade 3 adverse reaction 
involving a major organ  Withhold  Based on type and severity of 
adverse reaction, administer 
corticosteroids.  Refer to ASCO 
Clinical Practice Guidelines for 
additional recommendations.  Ensure adequate evaluation to 
confirm etiology and/or exclude 
other causes.  Life-threatening or Grade 4 
adverse reaction involving a 
major organ  Permanently 
discontinue  
Page 7 of  8 
Footnotes defined on last page of this table  

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 144 of 176 
CONFIDENTIAL    
Table 13 -2.  Dose Modification and Toxicity Management Guidelines for Immune -Related Adverse Reactions Associated  With 
AMG  404* 
Immune -Related  
Adverse 
Reactions  Severity (CTCAE Grade Version 
5.0 or Specific Conditions)  AMG 404 Dose 
Modification  Management with Corticosteroids 
and/or Other Therapies  Monitor & Follow -up 
Recurrent or 
Persistent 
Immune -Related  
Adverse 
Reactions  Recurrence of same Grade 3 or 
Grade 4 adverse reaction  
Permanently 
discontinue  Based on type and severity of 
adverse reaction, administer 
corticosteroids.  Additional 
immunosuppre ssive treatment may 
be required.  Ensure adequate evaluation to 
confirm etiology and/or exclude 
other causes.  Requirement for  10 mg/day 
prednisone (or equivalent) for 
more than 12 weeks  
Persistent grade 2 or 3 adverse 
reactions lasting 12 weeks or 
longer after last dose (ie, does 
not resolve to grade 0 or 1 within 
12 weeks)  
General considerations:  
 Corticosteroid taper should be initiated upon improvement of signs/symptoms and/or laboratory values to Grade 1 or less. Cont inue 
corticosteroid taper over the course of at least 4 to 6 weeks.  
 If AMG 404 has been withheld, treatment with AMG 404 may be re sumed after adverse event (or associated signs/symptoms/laboratory 
parameters) has been reduced to Grade 1 or less and corticosteroid has been tapered to prednisone  10 mg (or equivalent).  
 For severe and life-threatening immune -related  adverse reactions,  IV corticosteroids should be initiated first followed by oral corticosteroids. 
Other immunosuppressive treatment should be initiated if the event cannot be controlled by corticosteroids.  
Page 8 of 8  
* Recommendations adapted from the American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines for the Management  of Immune -Related Adverse 
Events in Patients Treated with Immune Checkpoint Inhibitor Therapy (JCO 2018)  
**Immune mediated hepatit is guidance adapted from the National Comprehensive Cancer Network (NCCN) Version 1.2020, Management of Immune Checkpoint 
Inhibitor -Related Toxicities  
1 In addition to Table 13 -2, which includes guidance on mitigation/management of suspected immune -mediated hepatitis, the protocol contains Table 12 -4 in 
Appendix  8, which offers general mitigation guidance for potential Drug -Induced Liver Injury (DILI). When applicable, first refer to Table 13 -2 for managing AST and/or 
ALT and/or total bilirubin elevations, when other liver parameters remain within normal limits (ie INR, ALP). Table 13 -2, withholding and discontinuation guidance is 
more conservative than Table 12 -4 guidance . 
 
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 145 of 176 
CONFIDENTIAL    

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 146 of 176 
CONFIDENTIAL    
Table 13-5.  Management  of Infusion -Related Reactions W ith AMG 404  
Severity ( CTCAE 
Grade Version 5.0 ) AMG 404 Dose 
Modifi cation  Management  Premedication at 
Subsequent 
Dosing  
Grade 1  (mild transient 
reaction;  infusion 
interruption not  
indicated; intervention 
not indicated ) Interrupt or 
slow the rate of 
the infusion  to 
50  or less of 
the standard 
rate.  Increase monitoring of 
vital signs as medically 
indicated until the 
subject is deemed 
medically stable.  
 If the infusion is 
interrupted, then after 
all symptoms have 
resolved, consider 
rechallenge with a 
reduced infusion rate 
(50  or less of 
standard rate ) and 
additional 
premedication (such as 
corticosteroids and 
antihistamines).  
 Treat per institutional 
guidelines.  None  
Grade 2  (therapy or 
infusion  interruption 
indicated but  responds 
promptly to symptomatic 
treatment (eg , 
antihistamines, NSAIDS,   
narcotics, IV fluids);  
prophylactic medications 
indicated for  24 hours) Interrupt or 
slow the rate of 
the infusion  to 
50  or less of 
the standard 
rate.  
For subjects 
who develop 
grade 2 
infusion -related 
reaction despite 
adequate 
premedication, 
permanent ly 
discontinue 
AMG 404.   Increase monitoring of 
vital signs as medically 
indicated until the 
subject is deemed 
medically stable.  
 If the infusion is 
interrupted, then after 
all symptoms have 
resolved, consider 
rechallenge with a 
reduced infusion rate 
(50  or less of 
standard rate) and 
additional 
premedication (such as 
corticosteroids and 
antihistamines).  
 Treat per institutional 
guidelines. Additional 
appropriate medical 
therapy may include but 
is not limited to IV 
fluids, antihistamines, 
NSAIDs, 
acetaminop hen, and 
narcotics.  Subject may b e 
premedicated 
1.5 hours  
( 30 minutes) prior 
to infusion of  
AMG 404 with:  
 Diphenhydramine 
50 mg orally (or 
equivalent dose of 
antihistamine).  
 Acetaminophen 
500-1000 mg 
orally (or 
equivalent dose of 
antipyretic).  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 147 of 176 
CONFIDENTIAL    
Grade 3 (prolonged [ eg, 
not rapidly  responsive to 
symptomatic  medication 
and/or brief interruption 
of infusion] ; recurrence 
of symptoms following 
initial improvement; 
hospitalization indicated 
for clinical sequelae ) 
 
OR 
 
Grade 4 (life-threatening 
consequen ces; urgent 
intervention indicated)  Permanently 
discontinue 
study drug.   Increase monitoring of 
vital signs as medically 
indicated until the 
subject is deemed 
medically stable.  
 Hospitalization may be 
indicated.  
 Treat per institutional 
guidelines. Additional 
appropriate medical 
therapy may include but 
is not limited to IV 
fluids, antihistamines, 
NSAIDs, 
acetaminophen, 
narcotics, oxygen, 
vasopressors, 
corticosteroids, and 
epinephrine. In cases of 
anaphylaxis, 
epinephrine should be 
used immediately.  No subsequent 
dosing  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 148 of 176 
CONFIDENTIAL    
13.5 Appendix 5.  Safety Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up and Reporting  
Definition of Adverse Event  
Adverse Event Definition  
 An adverse event is any untoward medical occurrence in a clinical study subject 
irrespective of a causal relationship with the study treatment.   
 Note:  An adverse event can therefore be any unfavorable and unintended sign (including 
an abnormal laboratory  finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of a treatment, combination product, medical device or procedure . 
 Note:  Treatment emergent adverse event will be defined in the SAP . 
 
Events Meeting the Adverse Event Definition  
 Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other 
safety assessments (eg, electrocardiogram, radiological scans, vital signs measurements), 
including those that worsen from baseline, that are consider ed clinically significant in the 
medical and scientific judgment of the investigator (ie, not related to progression of 
underlying disease).  
 Exacerbation of a chronic or intermittent pre -existing condition including either an increase 
in frequency and/or i ntensity of the condition.  
 New conditions detected or diagnosed after study treatment administration even though it 
may have been present before the start of the study.  
 Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
 Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
treatment or a concomitant medication.  Overdose per se will not be reported as an 
adverse event/serious adverse event unless it is an intentional overdose taken with 
possible suici dal/self -harming intent.  Such overdoses are to be reported regardless of 
sequelae.  
 For situations when an adverse event or serious adverse event is due to the underlying 
disease under study (ie , advanced solid tumor) report all known signs and symptoms.  
Death due to disease progression in the absence of signs and symptoms should be 
reported as the primary tumor type (eg, non-small cell lung cancer, malignant melanoma, 
etc).  Note:  The term “disease progression” should not be used to describe the adverse 
event.  
 “Lack of efficacy” or “failure of expected pharmacological action” per se will not be reported 
as an adverse event or serious adverse event.  Such instances will be captured in the 
efficacy assessments.  However, the signs, symptoms, and/or clinical  sequelae resulting 
from lack of efficacy will be reported as adverse event or serious adverse event if they fulfill 
the definition of an adverse event or serious adverse event.  
 
Events NOT Meeting the Adverse Event Definition  
 Medical or surgical procedure (eg, endoscopy, appendectomy):  the condition that leads to 
the procedure is the adverse event.  
 Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).  
 Anticipated day -to-day fluctuati ons of pre -existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 149 of 176 
CONFIDENTIAL    
Definition of Serious Adverse Event  
A Serious Adverse Event is defined as any untoward medical occurrence that, meets 
at least 1 of the following serious criteria : 
Results in death (fatal)  
Immediately life -threatening  
The term “life -threatening” in the definition of “serious” refers to an event in which the 
subject was at risk of death at the time of the event.  It does not refer to an event, which 
hypothetically might have caused death, if it were more severe.  
Requires in -patient hospitalization or prolongation of existing hospitalization  
In general, hospitalization signifies that the subject has been detained (usually involving at 
least an overnight stay) at the hospital or emergency ward for observation and/or treatment 
that would not have been appropriate in the physician’s office or outpatient setting.  
Complications that occur during hospitalization are an adverse e vent.  If a complication 
prolongs hospitalization or fulfills any other serious criteria, the event is serious.  When in 
doubt as to whether “hospitalization” occurred or was necessary, the adverse event is to be 
considered serious.  Hospitalization for el ective treatment of a pre -existing condition that 
did not worsen from baseline is not considered an adverse event.  
Results in persistent or significant disability/incapacity  
The term disability means a substantial disruption of a person’s ability to condu ct normal 
life functions.  This definition is not intended to include experiences of relatively minor 
medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle) which may interfere  with or prevent 
everyday life functions but do not constitute a substantial disruption.  
Is a congenital anomaly/birth defect  
Other medically important serious event  
Medical or scientific judgment is to be exercised in deciding whether serious adverse ev ent 
reporting is appropriate in other situations such as important medical events that may not 
be immediately life -threatening or result in death or hospitalization but may jeopardize the 
subject or may require medical or surgical intervention to prevent 1  of the other outcomes 
listed in the above definition.  These events are typically to be considered serious . 
Examples of such events include invasive or malignant cancers, intensive treatment in an 
emergency room or at home for allergic bronchospasm, blood  dyscrasias or convulsions 
that do not result in hospitalization, or development of drug dependency or drug abuse.  
 
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 150 of 176 
CONFIDENTIAL    
Recording Adverse Events and Serious Adverse Events  
Adverse E vent and Serious Adverse Event Recording  
 When an adverse event  or serious adverse event occurs, it is the responsibility of the 
investigator to review all documentation (eg, hospital progress notes, laboratory, and 
diagnostics reports) related to the event.  
 The investigator will then record all relevant adverse event/serious adv erse event 
information in the Event case report form (CRF).  
 The investigator must assign the following adverse event attributes:  
o Adverse event diagnosis or syndrome(s), if known (if not known, signs or symptoms);  
o Dates of onset and resolution (if resolved) ; 
o Did the event start prior to first dose of investigational product, other protocol -required 
therapies ; 
o Assessment of seriousness;  
o Severity (or toxicity defined below);  
o Assessment of relatedness to investigational product (s), non -investigational product(s) , 
other protocol -required therapies , and/or study -mandated activity and/or procedures ;  
o Action taken ; and 
o Outcome of event . 
 If the severity of an adverse event changes from the date of onset to the date of resolution, 
record a single event for each level of severity on the Event CRF   
 It is not acceptable for the investigator to send photocopies of the subject’s medical 
records to sponsor  in lieu of completion of the Event CRF page.  
 If specifically requested, the investigator may need to provide additional follow -up 
information, such as discharge summaries, medical records, or extracts from the medical 
records.  In this case, all subject identifiers, with the exception of the subject number, will 
be blinded on the copies of the medical records bef ore submission to Amgen . 
 The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information.  In such cases, the diagnosis (not the 
individual signs/symptoms) will be documented as the adverse ev ent/serious adverse 
event.  
Evaluating Adverse Events and Serious Adverse Events  
Assessment of Severity  
The investigator will make an assessment of severity for each adverse event and serious 
adverse event reported during the study.  The assessment of severity will be based on:   
The Common Terminology Criteria for Adverse Events , version 5.0 which is available at the 
following  location:   http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm . 
 
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 151 of 176 
CONFIDENTIAL    
Assessment of Causality  
 The investigator is obligated to assess the relationship between investigational product  
non-investigational product(s), other protocol -required therapies , and/or study -
mandated activity and/or  procedure  and each occurrence of each adverse event/serious 
adverse event.  
 Relatedness means that there are facts or reasons to support a relationship between 
investigational product and the event.  
 The inves tigator will use clinical judgment to determine the relationship.  
 Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study treatment administration 
will be co nsidered and investigated.  
 The investigator will also consult the Investigator’s Brochure in his/her assessment.  
 For each adverse event/serious adverse event, the investigator must document in the 
medical notes that he/she has reviewed the adverse event/se rious adverse event and has 
provided an assessment of causality.  
 There may be situations in which a serious adverse event has occurred and the 
investigator has minimal information to include in the initial report.  However, it is very 
important that the in vestigator always make an assessment of causality for every event 
before the initial transmission of the serious adverse event data.  
 The investigator may change his/her opinion of causality in light of follow -up information 
and send a serious adverse event  follow -up report with the updated causality assessment.  
 The causality assessment is 1 of the criteria used when determining regulatory reporting 
requirements.  
 
Follow -up of Adverse Event and Serious Adverse Event  
 The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by Amgen  to 
elucidate the nature and/or causality of the adverse event or serious adverse event as fu lly 
as possible.  This may include additional laboratory tests or investigations, 
histopathological examinations, or consultation with other health care professionals.  
 If a subject is permanently withdrawn from protocol -required therapies because of a 
serious adverse event, this information must be submitted to Amgen.  
 If a subject dies during participation in the study or during a recognized follow -up period as 
defined in Section 10.2.3.1.1 , the investigator will provide Amgen with a copy of any 
post-mortem findings including histopathology.  
 New or updated information will be recorded in the originally completed Event CRF.  
 The investigator will submit any updated serious adverse event data to Amgen  within 
24 hours of receipt of the information.  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 152 of 176 
CONFIDENTIAL    
Reporting of Serious Adverse Event  
Serious Adverse Event Reporting via Electronic Data Collection Tool  
 The primary mechanism for reporting serious adverse event will be the electronic data 
capture (EDC) system.  
 If the EDC system is unavailable for more than 24 hours, then the site will report the 
information to Amgen using paper -based Serious Adverse Event  Contingency Report Form 
(also referred to as the electronic Serious Adverse Event (eSAE) Contingency Report 
Form)  (see Figure 13 -1) within 24 hours of the investigator’s knowledge of the event.  
 The site will enter the serious adverse event data into the electronic system as soon as it 
becomes available.  
 After the study i s completed at a given site, the EDC system will be taken off -line to prevent 
the entry of new data or changes to existing data.  
 If a site receives a report of a new serious adverse event from a study subject or receives 
updated data on a previously report ed serious adverse event after the EDC has been taken 
off-line, then the site can report this information on a paper -based  Serious Adverse Event  
Contingency Report Form . 
 Once the study has ended, serious adverse event(s) should be reported to Amgen 
(regardless of causality) if the investigator becomes aware of a serious adverse event.  The 
investigator should use the paper -based Serious Adverse Event Contingency Report Form 
to report the event.  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 153 of 176 
CONFIDENTIAL    
Figure 13-1.  Sample Electronic Serious Adverse Event Contingency  Report  Form  
(Paper -Based Form)  
 
 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 154 of 176 
CONFIDENTIAL    
 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 155 of 176 
CONFIDENTIAL    
 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 156 of 176 
CONFIDENTIAL    
 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 157 of 176 
CONFIDENTIAL    
 
 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 158 of 176 
CONFIDENTIAL    
13.6 Appendix 6.  Contraceptive Guidance and Collection of Pregnancy 
and Lactation Information  
Study -specific contraception requirements for male and female of childbearing potential 
are outlined in Section 7.2. 
Male and female study subjects of childbearing potential must receive pregnancy 
prevention counseling and be advised of the risk to the fetus if they become pregnant or 
father a child during treatment and for 6 months (female  study subjects ) and 8  months 
(male  study subjects ) after the last dose of AMG  404. 
Definition  of Females of Childbearing Potential  
A female  is considered fertile following menarche and until becoming post -menopausal 
unless permanently sterile.  Permanent sterilization methods include hysterectomy, 
bilateral salpingectomy, and bilateral oophorectomy.  
Females  in the following categories are not  considered  female of  childbearing potential : 
 Premenopausal female with 1 of the following:  
o Documented hysterectomy ; 
o Documented bilateral salpingectomy ; or 
o Documented bilateral oophorectomy . 
Note:  Site personnel documentation from the following sources is  acceptable:  1) 
review of subject’s medical records; 2) subject’s medical examination; or 3) 
subject’s medical history interview . 
 Premenarchal  female  
 Postmenopausal female  
o A postmenopausal state is defined as no menses for 12 months without 
an alternative  medical cause.  A high follicle stimulating hormone (FSH) 
level in the postmenopausal range may be used to confirm a 
postmenopausal state in women not using hormonal contraception or 
hormonal replacement therapy (HRT).  However, in the absence of 
12 month s of amenorrhea, a single FSH measurement is insufficient.  
o Females on HRT and whose menopausal status is in doubt will be 
required to use 1 of the non -hormonal highly effective contraception 
methods if they wish to continue their HRT during the study.  Oth erwise, 
they must discontinue HRT to allow confirmation of postmenopausal 
status before study enrollment  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 159 of 176 
CONFIDENTIAL    
Contracept ion Methods for Female Subjects  
Highly Effective Contraceptive Methods  
Note:  Failure rate of <1% per year when used consistently and correct ly. 
 Combined (estrogen and progestogen  containing ) hormonal contraception 
associated with inhibition of ovulation (oral, intravaginal, or transdermal)  
 Progestogen -only hormonal contraception associated with inhibition of ovulation 
(oral, injectable, implan table)  
 Intrauterine device  
 Intrauterine hormo nal-releasing system  
 Bilateral tubal ligation/occlusion  
 Vasectomized partner (p rovided that partner is the sole sexual partner of the 
female subject of childbearing potential and that the vasectomized partner has 
received medical assessment of the surgical success)  
 Sexual abstinence (d efined as refraining from heterosexual intercourse during 
the entire period of risk associated with the study treatments ; the reliability of 
sexual abstinence must be evaluated in  relation to the duration of the trial and 
the preferred and  usual lifestyle of the subject ) 
Contraception Methods for Male Subjects   
 Sexual abstinence (d efined as refraining from heterosexual intercourse during 
the entire period of risk associated w ith protocol -required therapies ; the reliability 
of sexual abstinence must be evaluated in relation to the duration of the trial and 
the preferred and usual lifestyle of the subject )  
 Use a condom during treatment and for an additional 8 months  after the last dose  
of protocol -required therapies  
The female partner should consider using  an acceptable method of effective 
contraception such as:   hormonal, IU D, IUS, female barrier method (diaphragm, cap, 
sponge [a female condom is not an option because there is a ri sk of tearing when both 
partners use a condom]).  
Note:  If the male’s sole female partner is of non -childbearing potential or has had a 
bilateral tubal ligation/occlusion, he is not required to use additional forms of 
contraception during the study.  
Unacce ptable Methods of Birth Control for  Male and Female Subjects  
Birth control methods that are considered unacceptab le in clinical trials include:  
 Periodic abstinence (calendar, symptothermal, post -ovulation methods)  
 Withdrawal (coitus interruptus)  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 160 of 176 
CONFIDENTIAL    
 Spermicide s only  
 Lactational amenorrhea  method  
Collection of Pregnancy Information  
Female Subjects Who Become Pregnant  
 Investigator will collect pregnancy information on any female subject who 
becomes preg nant while taking protocol -required therapies through 6 month s 
after last dose of AMG 404 ,
 Information will be recorded on the Pregnancy N otification Form (see 
Figure  13-3).  The form must be submitted to Amgen Global Patient Safety within 
24 hours of learning of a subject’s pregnancy.  (Note:   Sites are not required to 
provide any information on the Pregnancy Notification Form that violates the 
country or regions local privacy laws) . 
 After obtaining the female subject’s signed authorization for release of pregnancy 
and infant health information, the investigator will collect pregnancy and infant 
health informat ion and complete the pregnancy questionnaire for any female 
subject who becomes pregnant while taking protocol -required therapies through 
6 months  after last dose of AMG 404,   
This information will be forwarded to Amgen Global Patient Safety.  Generally, 
infant follow -up will be conducted up to 12  months after the birth of the child (if 
applicable).  
 Any termination of pregnancy will be reported to Amgen Global Patient Safety, 
regardless of fetal status (presence or absence of anomalies) or indication for 
procedure.  
 While pregnancy itself is not considered to be an adverse event or serious 
adverse event, any pregnancy complication or report of a congenital anomaly or 
developmental delay, fetal death, or suspected adv erse reactions in the neonate 
will be reported as an adverse event or serious adverse event.  Note that an 
elective termination with no information on a fetal congenital malformation or 
maternal complication is generally not considered a n adverse event , but still must 
be reported to Amgen as a pregnancy exposure case . 
 If the outcome of the pregnancy meets a criterion for immediate classification as 
a serious adverse event (eg, female subject experiences a spontaneous 
abortion, stillbirth, or neonatal death or there is a fetal or neonatal congenital 
anomaly) the investigator will report the event as a serious adverse event.  
 Any serious adverse event occurring as a result of a post -study pregnancy which 
is considered reasonably related to the study treatment b y the investigator, will 
be reported to Amgen Global Patient Safety as described in  Section  13.5.  While 
the investigator is not obligated to actively seek this information in former study 
subjects, he or she may learn of a serious adverse event through spontaneous 
reporting.  
 Any female subject who becomes pregnant while participating will discontinue 
study treatment (see Section 9.1 for de tails).   

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 161 of 176 
CONFIDENTIAL    
Male Subjects With Partners Who Become Pregnant  
 In the ev ent a male subject fathers a child during treatment,  
 and/ or 
8 months  after last dose of AMG 404 the information will be recorded on the 
Pregnancy Notification Form .  The form (see Figure 13 -3) must be submitted to 
Amgen Global Patient Safet y within 24 hours of the site’s awareness of the 
pregnancy.  (Note:  Sites are not required to provide any information on the 
Pregnancy Notification Form  that violates the country or regions local privacy 
laws).  
 The investigator will attempt to obtain a signed authorization for release of 
pregnancy and infant health informa tion directly from the pregnant female partner 
to obtain additional pregnancy information.  
 After obtaining the female partner’s signed authorization for release of pregnancy 
and infant health information, the investigator will collect pregnancy outcome and  
infant health information on the pregnant partner and her baby and complete the 
pregnancy questionnaires.  This information will be forwarded to Amgen Global 
Patient Safety.  
 Generally, infant follow -up will be conducted up to 12 months after the birth of the 
child (if applicable).  
 Any termination of the pregnancy will be reported to Amgen Global Patient Safety 
regardless of fetal status (presence or absence of anomalies) or indication for 
procedure.  
Collection of Lactation Information  
 Investigator will co llect lactation information on any female subject who 
breastfeeds w hile taking protocol -required therapies through 6 months  after the 
last dose of AMG 404 ,  
 Information will be recorded on the Lactation Notification  Form (see below) and 
submitted to Amgen Global Patient Safety within 24 hours of the investigator’s 
knowledge of event.  
 Study treatment will be discontinued if female subject breastfeeds during the 
study as described in exclusion criterion 221. 
 With the f emale subjects signed authorization for release of mother and infant 
health information, the investigator will collect mother and infant health 
information and complete the lactation questionnaire on any female subject who 
breastfeeds while taking protocol -required therapies through 6 months  after 
discontinuing protocol -required therapies.  
 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 162 of 176 
CONFIDENTIAL    
Figure 13-3.  Pregnancy and Lactation Notification Form s 
 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 163 of 176 
CONFIDENTIAL    
 
 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 164 of 176 
CONFIDENTIAL    
13.7 Appendix 7.  Sample Storage and Destruction  
Any blood , , PK, and   sample collected according to the Schedule of 
Activi ties ( Section  3.2) can be  analyzed for any of the tests outlined in the protocol and 
for any tests necessary to minimize risks to study subjects.  This includes testing to 
ensure analytical methods produce reliable and valid data throughout the course of the 
study.  This can also include, but is not limited to, investigation of unexpected results, 
incur red sample reanalysis, and analyses for method transfer and comparability.  
All samples and associated results will be coded prior to being shipped from the site for 
analysis or storage.  Samples will be tracked using a unique identifier that is assigned t o 
the samples for the study.  Results are stored in a secure database to ensure 
confidentiality.  
If informed consent is provided by the subject, Amgen can do additional testing on 
remaining samples (ie, residual and back -up) to investigate and better understand  
advanced solid tumors ,  the dose response and/or prediction of response to AMG  404,  
characterize antibody response , and characterize aspects of the molecule (eg, 
mechanism of action/target, metabolites).  Results from this analysis are to be 
documented and maintained but  are not necessarily reported as part of this study.  
Samples can be retained for up to 20 years.   
Since the evaluations are not expected to benefit the subject directly or to alter the 
treatment course, the results of  
 are not placed in the subject’s medical record and are not to be 
made available to the subject, members of the family, the personal physician, or other 
third parties, except as specified in the informed consent.  
The subject retains the right to request that the sample material be destroyed by 
contacting the investigator.  Following the request from the subject, the investigator is to 
provide the sponsor with the required study and subject number so that any remaining 
blood , serum  samples and any other components from the cells can be 
located and destroyed.  Samples will be destroyed once all protocol -defined procedures 
are completed.  However, information collected from samples prior to  the request for 
destruction, will be retained by Amgen.  
The sponsor is the exclusive owner of any data, discoveries, or derivative materials from 
the sample materials and is responsible for the destruction of the sample(s) at the 
request of the subject th rough the investigator, at the end of the storage period, or as 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 165 of 176 
CONFIDENTIAL    
appropriate (eg, the scientific rationale for experimentation with a certain sample type no 
longer justifies keeping the sample).  If a commercial product is developed from this 
research proje ct, the sponsor owns the commercial product.  The subject has no 
commercial rights to such product and has no commercial rights to the data, information, 
discoveries, or derivative materials gained or produced from the sample.  See  
Section 13.3 for subject confidentiality.  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 166 of 176 
CONFIDENTIAL    
13.8 Appendix 8.  Hepatotoxicity Stopping Rul es:  Suggested Actions and 
Follow -up Assessments and Study T reatment Rechallenge 
Guidelines  
Subjects with abnormal hepatic laboratory values (ie, alkaline phosphatase [ALP], 
aspartate aminotransferase [AST], alanine aminotransferase [ALT], total bilirubi n [TBL]) 
and/or international normalized ratio (INR) and/or signs/symptoms of hepatitis (as 
described below) may meet the criteria for withholding or permanent discontinuation of 
Amgen investigational product or other protocol -required therapies, as specif ied in the 
Guidan ce for Industry Drug -Induced Liver Injury:  Premarketing Clinical Evaluation, 
July 2009 . 
Criteria for Withholding and/or Permanent Discontinuation of Amgen Investigational 
Product and Other Protocol -required Therapies Due to Potential Hepatotoxicity  
The following stopping and/or withholding rules apply to subjects for whom another 
cause of their changes in liver biomarkers (TBL, INR and transaminases) has not been 
identified.  
Important alternative causes for elevated AST/ALT and/or T BL values include, but are 
not limited to:  
 Hepatobiliary tract disease  
 Viral hepatitis (eg, hepatitis A/B/C/D/E, Epstein -Barr Virus, cytomegalovirus, herpes 
simplex virus, varicella, toxoplasmosis, and parvovirus)  
 Right sided heart failure, hypotension or any cause of hypoxia to the liver causing 
ischemia  
 Exposure to hepatotoxic agents/drugs or hepatotoxins, including herbal and dietary 
supplements, plants and mushrooms  
 Heritable disorders causing impaired glucuronidation (eg, Gilbert’s syndrome, 
Crigler -Najjar syndrome) and drugs that inhibit bilirubin glucuronidation (eg, indinavir, 
atazanavir)  
 Alpha -one antitrypsin deficiency  
 Alcoholic hepatitis  
 Autoimmune hepatitis  
 Wilson’s disease and hemochromatosis  
 Nonalcoholic fatty liver disease including steatohepa titis 
 Non-hepatic causes (eg, rhabdomyolosis, hemolysis)  
 If investigational product(s) is/are withheld, the subject is to be followed for possible 
drug-induced liver injury (DILI) according to recommendations in the last section of 
this appendix.  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 167 of 176 
CONFIDENTIAL    
Rechalle nge may be considered if an alternative cause for impaired liver tests ALT, AST, 
ALP) and/or elevated TBL, is discovered and the laboratory abnormalities resolve to 
normal or baseline (see next section in this appendix).  
Table 13-6.  Conditions for Withholding and/or Permanent Discontinuation of 
Amgen Investigational Product and Other Protocol -required Therapies Due to 
Potential Hepatotoxicity  
Analyte  Temporary Withholding  Permanent Discontinuation  
TBL  3x ULN  
at any time   2x ULN  
  OR 
INR --  1.5x (for subjects not on 
anticoagulation therapy)  
 OR AND  
AST/ALT   8x ULN at any time  
 5x ULN but  8x ULN for  1 week  
 5x ULN but  8x ULN and unable to 
adhere to enhanced monitoring schedule  
 3x ULN with clinical signs or symptoms 
that are consistent with hepatitis (such as 
right upper quadrant pain/tenderness, 
fever, nausea, vomiting, and jaundice)  In the presence of no important 
alternative causes for elevated 
AST/ALT and/or TBL values  
 3x ULN (when baseline was  ULN)  
 OR  
ALP  8x ULN at any time  -- 
ALP  alkaline phosphatase; ALT  alanine aminotransferase; AST  aspartate aminotransferase;  
INR  international normalized ratio; TBL  total bilirubin; ULN  upper limit of normal  
Criteria for Rechallenge of Amgen Investigational Product and Other 
Protocol -required Therapies After Potential Hepatotoxicity  
The decision to rechallenge the subject is to  be discussed and agreed upon 
unanimously by the subject, investigator, and Amgen.  
If signs or symptoms recur with rechallenge, then Amgen investigational product is to be 
permanently discontinued.  Subjects who clearly meet the criteria for permanent 
discontinuation (as described in Table 13 -6) are never to be rechallenged.  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 168 of 176 
CONFIDENTIAL    
Drug -induced Liver Injury Reporting and Additional Assessments  
Reporting  
To facilitate appropriate monitoring for signals of DILI, cases of concurrent AST or AL T 
and TBL and/or INR elevation, according to the criteria specified in the above, require 
the following:  
 The event is to be reported to Amgen as a serious adverse event within 24  hours of 
discovery or notification of the event (ie, before additional etiolo gic investigations 
have been concluded)  
 The appropriate Case Report Form (CRF) (eg, Event CRF) that captures information 
necessary to facilitate the evaluation of treatment -emergent liver abnormalities is to 
be completed and sent to Amgen  
Other events of hepatotoxicity and potential DILI are to be reported as serious adverse 
events if they meet the criteria for a serious adverse event defined in Section  13.5. 
Additional Clinical Assessments and Observation  
All subjects in whom investigational product(s) or protocol -required therapies is/are 
withheld (either permanently or conditionally) due to potential DILI as specified in  
Table 13 -6 or who experience AST or ALT elevations  3 x upper limit of normal (ULN) 
or 2-fold increases above baseline values for subjects with elevated values before drug 
are to undergo a period of “c lose observation” until abnormalities return to normal or to 
the subject’s baseline levels.   
Assessments that are to be performed during this period include:  
 Repeat AST, ALT, ALP, bilirubin (BIL) (total and direct), and INR within 24 hours  
 In cases of T BL  2x ULN or INR  1.5, retesting of liver tests, BIL (total and direct), 
and INR is to be performed every 24 hours until laboratory abnormalities improve  
Testing frequency of the above laboratory tests may decrease if the abnormalities 
stabilize or the investigational product(s) or protocol -required therapies has/have been 
discontinued AND the subject is asymptomatic.  
Initiate investigation of alternative causes for elevated AST or ALT and/or elevated TBL.  
The following are to be considered depending on  the clinical situation:  
 Complete blood count with differential to assess for eosinophilia  
 Serum total immunoglobulin (Ig)G, anti -nuclear antibody anti -smooth muscle 
antibody, and liver kidney microsomal antibody -1 to assess for autoimmune hepatitis  
 Serum acetaminophen (paracetamol) levels  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 169 of 176 
CONFIDENTIAL    
 A more detailed history of:  
o Prior and/or concurrent diseases or illness  
o Exposure to environmental and/or industrial chemical agents  
o Symptoms (if applicable) including right upper quadrant pain, 
hypers ensitivity -type rea ctions, fatigue, nausea, vomiting and fever  
o Prior and/or concurrent use of alcohol, recreational drugs and special diets  
o Concomitant use of medications (including non -prescription medicines and 
herbal and dietary supplements), plants, and mushrooms  
 Viral s erologies  
 Creatine phosphokinase, haptoglobin, lactate dehydrogenase and peripheral blood 
smear  
 Appropriate liver imaging if clinically indicated  
 Appropriate blood sampling for pharmacokinetic analysis if this has not already been 
collected  
 Hepatology cons ult (liver biopsy may be considered in consultation with a 
hepatologist)  
Follow the subject and the laboratory tests (ALT, AST, TBL, INR) until all laboratory 
abnormalities return to baseline or normal or considered stable by the investigator.  The 
“close observation period” is to continue for a minimum of 4  weeks after discontinuation 
of all investigational product(s) and protocol -required therapies.  
The potential DILI event and additional information such as medical history, concomitant 
medications and laboratory results must be captured in the corresponding CRFs.  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 170 of 176 
CONFIDENTIAL    
13.9 Appendix 9.  ECOG  Perfor mance Status  and NYHA Classification  
 Eastern Cooperative  Oncology Group Performance Scale  
ECOG Performance Status Scale  
Grade  Descriptions  
0 Fully active, able to carry on all pre -disease performance without restriction.  
1 Restricted in physically strenuous activity, but ambulatory and able to carry out 
work of a light or sedentary nature (eg , light housework, office work).  
2 Ambulatory and capable of all self -care, but unable to carry out any work 
activities.  Up and about more than 50% of waking hours.  
3 Capable of only limited self -care, confined to bed or chair more than 50% of 
waking hours.  
4 Completely disabled.  Cannot carry on any self -care.  Totally confined to bed or 
chair.  
5 Dead.  
Source:  Oken et al, 1982  
New York Heart Association Functional Classification  
Class I  No limitation of physical activity. Ordinary physical activity does not cause 
undue fatigue, palpitation or dyspnea.  
Class II  Slight limitation of physical activity. Comfortable at rest, but ordinary 
physical activity results in fatigue, palpitation or dyspnea.  
Class III  Marked limitation of physical activity. Comfortable at rest, but less than 
ordinary activity causes fatigue, palpitation or dyspnea.  
Class IV  Unable to carry out any physical activity without discomfort. Symptoms of 
cardiac insufficiency may be present even at rest. If any physical activity 
is undertaken, discomfort is increased.  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 171 of 176 
CONFIDENTIAL    
13.10  Appendix 10.  Modified Response Evaluation Criteria in Solid 
Tumo rs Version 1.1 (Modified RECIST 1.1)  
This study utilizes modified RECIST 1.1 criteria, which includes required confirmation of 
disease progression, and the following modification to RECIST 1.1:  
 Up to 5 target lesions per organ and 10 total are allowed (compared to 2 per 
organ and 5 total for standard RECIST 1.1) to increase lesion sampling and 
reduce assessment error.  
Definitions  
 Measurable lesions:  
o Measurable  Tumor  Lesions  – Non-nodal lesions with clear borders that 
can be accurately  measured  in at least 1 dimension  with longest  
diameter   10 mm in CT/MRI  scan  with slice thickness  no greater than  
5 mm.  When  slice thickness  is greater  than 5 mm, the minimum  size of 
measurable  lesion  should  be twice  the slice thickness.  
o Nodal  Lesions  - Lymph  nodes  are to be considered  pathologically  
enlarged  and measurable,  a lymph  node  must  be  15 mm in short  axis 
when  assessed  by CT/MRI  (scan  slice thickness  recommended  to be no 
greater than  5 mm).   At baseline  and in follow -up, only the short  axis will 
be measured  and followed.  
 Nodal  size is normally  reported as  two dimensions  in 
the axial plane.   The smaller  of these  measures  is 
the short  axis (perpendicular  to the longest  axis).  
o Irradiated  Lesions  - Tumor  lesions  situated in  a previously  irradiated area,  
or in an area subjected  to other  loco-regional therapy,  are not 
measurable  unless  there  has been demonstrated  progression in the 
lesion  prior to enrollment.  
 Non-measurable Lesions  
o All other  lesions,  including  small  lesions  (longest  diameter  10 mm or 
pathological lymph  nodes  with  10 mm but  to  15 mm short  axis with 
CT scan slice thickness  no greater  than 5 mm) are considered 
non-measurable and characterized as non -target lesions.  
o Other examples of non -measurable lesions include:  
▪ Lesions with prior local treatment:  tumor lesions situated in a 
previously irradiated area, o r an area subject to other 
loco-regional therapy, should not be considered measurable 
unless there has been demonstrated progression in the lesion.  
▪ Biopsied lesio ns 
▪ Categori cally, clusters of small lesions, bone lesions, 
inflammatory breast disease, and leptomeningeal disease are 
non-measurable.  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 172 of 176 
CONFIDENTIAL    
Methods  of Measurement  
 Measurement  of Lesions  - The longest  diameter  of selected  lesions  should  
be measured in the plane  in which  the images  were  acquired  (axial  plane).  
All measurements  should  be taken  and recorded  in metric  notation.   All 
baseline  evaluations  should be performed as  closely  as possible to the 
beginning  of treatment  and not  more  than 4 weeks  before study  Day 1. 
 Methods  of Assessment  - The same  method of assessment  and the same  
technique  should be used  to characterize each identified and  reported lesion  
throughout  the trial. 
 CT/ MRI – Contrast -enhanced  CT or  MRI should be used  to assess  all 
lesions.   Optimal  visualization and  measurement  of metastasis  in solid 
tumors  requires  consistent  administration  (dose  and rate) of IV contrast  as 
well as timing  of scanning.   CT and MRI should  be performed  with  5 mm 
thick contiguous slices.  
Baseline documentation  of “Target”  and “Non -target”  lesions  
 Target  Lesions  - All measurable  lesions  up to a maximum  of five (5) lesions  
per organ  and ten (10) lesions  in total,  representative  of all involved  organs  
should  be identified as  target  lesions  and recorded and  measured at  
baseline.  
o Target  lesions  should be  selected  on the basis of their size (lesions  with 
the longest  diameter)  and suitability  for accurate  repeated  
measurements.  
o Pathologic  lymph  nodes  (with short  axis  15 mm) may be identified as 
target  lesions.   All other  pathological nodes  (those with short  axis 
 10 mm but  15 mm) should be considered non -target  lesions.  
 A sum of the diameters  (longest  for non-nodal  lesions,  short  axis for 
nodal  lesions)  for all target  lesions  will be calculated and  reported  as the 
baseline  sum of diameters.  The baseline sum of diameters  will be used  
as reference by which  to characterize objective  tumor  response.  
 Non-Target  Lesions  - All other  lesions  (or sites of disease)  including  
pathological  lymph  nodes  should be identified as non -target  lesions  and 
should also  be recorded  at baseline.   Measurements  of these  lesions  
are not required , and these  lesions  should be followed  as “present”,  
“absent”,  or “unequivocal progression”  throughout  the study.   In 
addition,  it is possible to record  multiple  non-target  lesions  involving  the 
same organ  as a single  item on the case  report  form (eg,  “multiple 
enlarged  pelvic  lymph  nodes”  or “multiple liver metastases”).  
Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 173 of 176 
CONFIDENTIAL    
Response Criteria  
Evaluation of Target  Lesions  
* Complete  Response  (CR):  Disappearance  of all target  lesions.   Any pathological  
lymph  nodes  (whether  target  or non-target)  must  have  
reduction  in short  axis to  10 mm. 
* Partial  Response  (PR):  At least  a 30 decrease  in the sum of the diameters  of 
target  lesions,  taking  as reference  the baseline  sum of 
diameters.  
* Progressive  Disease  (PD):  At least a relative 20  increase and an absolute increase 
of 5 mm in the sum of the diameters of target lesions, 
taking as reference the smallest sum on study, or the 
appearance of one or more new lesions.  
* Stable Disease (SD)  Neither  sufficient  shrinkage  to qualify  for PR nor sufficient  
increase  to qualify  for PD, taking as reference the smallest 
sum of diameters since the treatment started.  
Evaluation of Non -target  Lesions  
 
1 To achieve  “unequivocal  progression”  on the basis  of the  non-target disease, there must be  an overall  level 
of substantial  worsening in  non-target disease  such  that, even  in presence  of SD or PR in  target  disease,  
the overall  tumor  burden  has increased  sufficiently  to merit  discontinuation  of therapy.  A modest “increase”  
in the size of one  or more  non-target  lesions  is usually  not sufficient to  qualify for  unequivocal  progression  
status.  
Evaluation of  Overall Response  
The best overall response is the best response recorded from the start of the study 
treatment until the end of treatment or disease progression/recurrence (taking as 
reference for PD the smallest measurements recorded since the treatment started).   
In general, the subject's best response assignment will depend on the findings of both 
target and non -target disease and will also take in to consideration the appearance of 
new lesions.  

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 174 of 176 
CONFIDENTIAL    
Time  Point response:   Subjects with Target (/- Non-target) Disease  
Target Lesions  Non-target Lesions  New Lesions  Overall Response  
CR CR No CR 
CR Non-CR/non -PD No PR 
CR Not evaluated  No PR 
PR Non-PD or not all 
evaluated  No PR 
SD Non-PD or not all 
evaluated  No SD 
Not all evaluated  Non-PD No NE 
PD Any Yes or No  PD 
Any PD Yes or No  PD 
NE  Not evaluable  
Time  Point Response:   Subjects  with Non-Target  Disease  Only  
 

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 175 of 176 
CONFIDENTIAL    
Overall Response:  Confirmation of  Complete Response ( CR) and Partial 
Response (PR)  required  
 
Special  Notes on  Response  Assessment  
 Nodal lesions  – Lymph  nodes  identified  as target  lesions  should  always  have  the 
actual short  axis measurement recorded,  even  if the nodes  regress  to below 
10 mm on study.  In order to qualify  for CR, each  node  must  achieve  a short  axis 
 10 mm, NOT total disappearance.  Nodal target lesion short axis measurements 
are added together with target lesion’ longest diameter measurements to create 
the sum of target  lesion diameters for a particular assessment ( time point ). 
 Target  lesions  that become  “too small  to measure”  – While  on study,  all lesions  
(nodal  and non-nodal) recorded at  baseline  should  have  their measurements  
recorded  at each  subsequent  evaluation.  If a lesion becomes less than 5  mm, the 
accuracy of the measurement becomes reduced.  Therefore, lesions less than 
5 mm are considered as being “too small to measure”, and are not measured.  With 
this designation, they are assigned a default measurement of  5 mm.  No lesion 
measurement less than 5 mm should be recorded, unless a lesion totally 
disappears and “0” can be recorded for the measurement.  

Product:  AMG 404   
Protocol Number:  20180143  
Date:  20 May 2022  Page 176 of 176 
CONFIDENTIAL    
 New lesions  – The term “new lesion” always refers to the presence of a new 
finding that is definitely tumor.  N ew findings that only may be tumor, but may be 
benign (infection, inflammation, etc.) are not selected as new lesions, until that 
time when the review is certain they represent tumor.   
 If a new lesion is equivocal, for example because of its small size, c ontinued 
therapy and follow -up evaluation will clarify if it represents truly new disease.  
If repeat scans  confirm  there  is definitely  a new lesion,  then progression  
should  be declared  using  the date of the initial  scan.  
 A lesion  identified on a follow -up study  in an anatomical location  that was not 
scanned  at baseline is  considered  a new lesion and  will indicate  disease  
progression, regardless of any response th at may be seen in target or 
non-target lesions present from baseline.  
 Subjects with a global  deterioration  of health  status  requiring  discontinuation  of 
treatment  without  objective  evidence  of disease  progression  at that time should  be 
classified  as having  “symptomatic  deterioration.”   Every  effort  should be  made  to 
document the objective  progression  with an additional imaging assessment even  
after discontinuation  of treatment.  
 In some  circumstances  it may be difficult to  distinguish  residual disease  from 
scar or normal  tissue.  When  the evaluation  of complete  response (CR) depends  
on this determination,  it is recommended  that the residual lesion  be further 
investigated by fluorodeoxyglucose -positron emission tomography ( FDG-PET) or 
PET/computed tomography ( PET/ CT), or possibly fine  needle  aspirate/biopsy, to 
confirm  the CR status.  
Confirmation  Measurement / Duration of Response  
 Response  Confirmation  - In non-randomized  trials where  response is  the 
primary  endpoint,  confirmation  of PR and CR is required  to ensure  
responses  identified  are not the result  of measurement error.  
 Duration  of overall  response  – The duration of overall response  is 
measured  from the time measurement  criteria are first met for CR/PR 
(whichever  is first recorded)  until the first date the recurrent  or progressive  
disease  is objectively  documented.  
 Duration  of Stable Disease - SD is measured  from the start of the 
treatment  until the criteria  for disease progression  are met, taking as 
reference  the smallest  measurements  recorded  since  the treatment  started.  
 
Product:  AMG 404  
Protocol Number:  20180143  
Date:  20 May 2 022 Page 1 of 54 
Amgen Proprietary - Confidential  
FORM -492529 ,   Effective Date: 02 Mar 2020 ,  Version: 6.0 Amendment 6 
Protocol Title:  A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and 
Pharmacodynamics of AMG 404, a Programmed Death -1 (PD -1) Antibody,  
 in Patients With Advanced Solid Tumors  
 
Amgen Protocol Number AMG  404 20180143  
EudraCT Number:  2018 -004268 -80 
NCT Number:  NCT3853109  
 
Amendment Date:  20 May 2022  
 
Rationale:  
The protocol, dated May 20th, 2022,  was amended  to discontinue clinical trial activities for 
study  20180143, to allow for extended treatment for an additional 24  months for subjects who 
continue to receive clinical benefit from treatment with AMG  404, to update safety language, 
and to clari fy/correct other items in the protocol.  Please note, the study is not being stopped for 
safety reasons or lack of efficacy.  
Changes include:  
 Updated Section 3.2 Schedule of Activities to include extended treatment for Cohorts 
1-9. 
 Updated Section 2 Protocol Synopsis and Section 3.1 S tudy Schema to clarify that 
Cohort 5 was a China/Taiwan/Hong Kong -specific expansion cohort   
 Updated  Section 4.5.3 Risks  with current  safety information.   
 Deleted Section 7.2 Exclusion Criteria,  exclusion criterion  #242 to remove a duplicate d 
criterion.  

Product:  AMG 404  
Protocol Number:  20180143  
Date:  20 May 2 022 Page 2 of 54 
Amgen Proprietary - Confidential  
FORM -492529 ,   Effective Date: 02 Mar 2020 ,  Version: 6.0  Added Section 10.1.3 Extended Treatment Period for subjects who continue to receive 
clinical benefit f rom treatment with AMG  404 beyond 24 months of treatment.  
 Updated Section 10.2.2 Efficacy Assessments to incorporate extended treatment and 
cohort closures.  
 Updated Section 10.2.3.1.1.3 Serious Adverse Events After the Protocol -required 
Reporting Period to  clarify SAE collection post study.  
 Updated safety template language.  
 Administration, typographical, and formatting changes were made throughout the 
protocol.  
 

Product:   AMG 404   
Protocol Number:   20180143   
Date:  16 July 2021  Page 1 of 97 
Amgen Proprietary - Confidential  
FORM -492529 ,   Effective Date: 02 Mar 2020 ,  Version: 6.0 Amendment 5  
Protocol Titile:  A Phase 1 Study to Evaluate Safety, Tolerability, 
Pharmacokinetics and Pharmacodynamics of AMG 404, a Programmed Death -1 
(PD-1) Antibody,  in 
Patients With Advanced Solid Tumors  
Amgen Protocol Number (AMG 404) 20180143  
EudraCT Number:  2018 -004268 -80 
 
Amendment Date:  16 July 2021 
 
Rationale:  
The following changes were made to the protocol, dated July 16th, 202 1,  
 
 
 to expand cohort 5 to include additional NMPA certified sites for 
expanded access to subjects, to provide SARS -COV2 guidance to investigators and site 
staff, to update the  AMG  404 stopping rules,  and to clarify/correct other items in the 
protocol.  

Product:   AMG 404   
Protocol Number:   20180143   
Date:  16 July 2021  Page 2 of 97 
Amgen Proprietary - Confidential  
FORM -492529 ,   Effective Date: 02 Mar 2020 ,  Version: 6.0 

Product:   AMG 404   
Protocol Number:   20180143   
Date:  16 July 2021  Page 3 of 97 
Amgen Proprietary - Confidential  
FORM -492529 ,   Effective Date: 02 Mar 2020 ,  Version: 6.0 

Product:   AMG 404   
Protocol Number:   20180143   
Date:  16 July 2021  Page 4 of 97 
Amgen Proprietary - Confidential  
FORM -492529 ,   Effective Date: 02 Mar 2020 ,  Version: 6.0 

Product:   AMG 404   
Protocol Number:   20180143   
Date:  16 July 2021  Page 5 of 97 
Amgen Proprietary - Confidential  
FORM -492529 ,   Effective Date: 02 Mar 2020 ,  Version: 6.0 Cohort 5 changes include:  
 Updated overall design (section 6.1) to include NMPA certified sites . 
 Updated inclusion criterion #111 (section 7.1) to include NMPA certified sites . 
SARS -COV2  changes include:  
 Added dose modification guidelines (section 8.4.5) for SARS -COV2 infection . 
 Added SARS -COV2 Vaccination guidance (section 8.8.2.1) for all Cohorts . 
Other changes include:  
 Updated  and added  stopping rules for AMG 404 monotherapy (section 11.4.1) .  
 Updated references (section 12) . 
 Updated template safety language . 
 Administration, typographical and formatting changes were made throughout the 
protocol.  
Description of changes:  
Section:  Global  
Change:  The Amgen global version date was changed from 24 Nove mber  2020 to 
16 July 2021. 
Section:  Global  
Replace:  
A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and 
Pharmacodynamics of AMG 404,a Programmed Death -1 (PD -1) Antibody, in Patients 
With Advanced Solid Tumors  
With:  
A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and 
Pharmacodynamics of AMG 404, a Programmed Death -1 (PD -1) Antibody,  
 in Patients With Advanced Solid 
Tumors  
Section:  Global  
Replace: Table 2 -1 
With: Section 3.2  
Section:  Title Page,  Key Sponsor Contact  
Replace:  
Name:  , MD  
, DSc, MSc  

Product: AMG  404 
Protocol Number: 20180143   
 Page 1 of 30 
Amgen Proprietary - Confidential  Amendment 4 
Protocol Title:  A Phase  1 Study to Evaluate Safety, Tolerability, Pharmacokinetics 
and Pharmacodynamics of AMG  404, a Programmed Death -1 (PD -1) Antibody, in 
Patients with Advanced Solid Tumors  
 
Amgen Protocol Number (AMG 404) 20180143  
 
Amendment Date:  24 November  2020  
 
Rationale:  
The following changes were made to the protocol, dated November  24th, 2020, to 
integrate revised contraceptive and safety follow -up requirements  based on current 
half-life data , and to clarify/correct other items in the protocol .  
Revised requirements based on current half -life data included :  
 Updated exclusion criterion #221, 222, and 223 to clarify the time period for 
female and male restrictions regarding pregnancy and contraception.  
 Updated section 7.4.3.4, section 9.2.3.1.6, and appendix 6 to clarify the time 
period for female and male restrictions regarding pregnancy and contraception.  
Other changes include:  
 Updated overall design to clarify  subjects with complete response treatment 
duration beyond 12 months.  
 Updated subject eligibility criteria to clarify  prior systemic treatments excluded.  
 Updated study schema formatting.  
 Updated schedule of activities to reflect protocol updates . 
 Updated risks in section 3.3.3 to include hypothyroidism.  
 Updated exclusion criterion #201 to clarify benign asymptomatic tumor exception.  
 Updated exclusion criterion #202 to clarify the exception of other malignancies 
which do not require systemic therapy.  

Product: AMG  404 
Protocol Number: 20180143   
 Page 2 of 30 
Amgen Proprietary - Confidential   Updated exclusion criterion #208 to clarify corticosteroid exception.  
 Updated exclusion criterion #217 to clarify anti arrhythmia medication.  
 Updated language for AMG 404 i nterruptions or discontinuations due to safety 
reasons.  
 Added dose modification due to surgery during study treatment clarification in 
section 7.4.5.  
 Updated section 9.1.3, section 9.2.3.1.1.1, and section 9.2.3.1.1.2 to align with 
current safety language and requirements.  
 Updated section 9.1.5 end of study to clarify end of study for a particular study 
subject.  
 Updated section 9.2.2 efficacy assessments to clarify complete response 
evaluations.   
 Updated Table  12-3 to clarify instructions for AMG 404 dose modification and 
management of toxicities.  
 Updated section 9.2.8.5, section 9.2.8.5.1, section 10.4.2.4 to clarify 
pharmacokinetic  collections.  
 Administration, typographical and formatting changes were made throughout the 
protocol  
 

Product:  AMG 404  
Protocol Number:  20180143  
Date:  31 January 2020  Page 1 of 37 
CONFID ENTIAL  
  Amendment  3 
Protocol Title:  Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics 
and Pharmacodynamics of AMG 404, a Programmed Death -1 (PD -1) Antibody, in 
Patients W ith Advanced Solid Tumors  
 
Amgen Protocol Number 20180143  
IND Number 140964  
EudraCT number 2018 -004268 -80 
 
Amendment Date:  31 January 2020  
Rationale:  
The purpose of this amendment  includes : 
 To add Cohorts 7 -9 to evaluate efficacy of AMG 404 ;  
 To add additional subjects are being added to Cohort 4 to gain additional safety 
informati on at the higher dose ; 
 To revise the purpose,  eligibility,  statistics and tumor evaluation sections to align 
with the additional cohorts ; 
 To add information on the Recommended Phase 2 Dose selection ;  
 To incorporate China Country Specific Supplement version 1 information ; and   
 To revise the hepatitis toxicity management ( Appendix 4) to align with the 
hepatotoxicity stopping rules ( Appen dix 8 ). 
In addition, g rammatical and typographical errors were corrected throughout  the protocol 
document.  
The consent  and addendum consent forms were  revised to reflect protocol updates .  
The version  number and  date on all documents was updated  

Product:  AMG 404  
Protocol Number:  20180143  
Date:  15 July 2019  Page 1 of 25 
CONFIDENTIAL  
  Amendment  2 
Protocol Title:  Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics 
and Pharmacodynamics of AMG 404, a Programmed Death -1 (PD -1) Antibody, in 
Patients with Advanced Solid Tumors  
 
Amgen Protocol Number 20180143  
IND Number 140964  
EudraCT number 2018 -004268 -80 
 
Amendment Date:  15 July 2019  
Rationale:  
This purpose of this amendment  is to:  
 Add Cohort 5, a  China specific cohort at the RP2D  and added Inclusion Criteria 
111 to define subject population for Cohort 5  
 Add Cohort 6, additiona l subjects at the RP2D  
 Revised Inclusion Criteria 109, decreasing eGFR for subjects enrolled to Cohorts 
3 and 6 based on initial FDA feedback  
 Dose -limiting toxicity ( DLT) section updated based on Japanese Health Authority 
feedback  
 Removal of Disease Relate d Events (DRE)  to align with Amgen’s internal 
guidelines  
 Minor revisions/clarifications throughout  
The consent  and addendum con sent forms were  revised to reflect protocol updates .  
The version  number and  date on all documents was updated  

Product:  AMG 404  
Protocol Number:  20180143  
Date:  02 JAN 2019                                                                                              Page 1 of 9 
Confidential 
  Amendment  1 
Protocol Title:  Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics 
and Pharmacodynamics of AMG 404, a Programmed Death -1 (PD -1) Antibody, in 
Patients with Advanced Solid Tumors  
 
Amgen Protocol Number 20180143  
IND Number 140964  
EudraCT number 2018 -004268 -80 
 
Amendment Date:  02 JAN 2019  
 
Rationale:  
This amendment reflects revisions in response to FDA feedback. The consent form was 
revised to reflect protocol updates and an addendum consent was added in response to 
FDA feedback.  
 
The version date  on all documents was updated and minor typos were corrected.  
 
Protocol Revisions:  
 
Section: Global  
Replace:  
The version is updated to Amendment 1 and the date is updated to 02 JAN 2019 . 
 
Section: 1.0 Protocol Synopsis  and Section 4.1  
Replace : Delete strikethrough text, add bolded text  
 
Overall Design  
This is a first -in-human (FIH), multicenter, non -randomized, open -label, phase 1 study to 
evaluate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of 
AMG 404 in subjects wit h advanced solid tumors.  The study may be conducted in 
Australia, United States, France, Poland, United Kingdom, Belgium, South Korea, 
Taiwan, Japan, and Canada. Other countries or regions may participate.  The study will 
comprise of 3 4 cohorts  to evalua te the safety, tolerability, PK and PD of AMG 404  with 
the following doses: Cohort 1 – 240 mg Cohort 2 -  480 mg, Cohort 23 – Expansion at 
the dose of 480 mg, and Cohort  34 – Exploratory Dose of 1050 mg. AMG 404 will be 
administered intravenously (IV) over approximately 30 minutes, every 4 weeks in 
subjects with advanced solid tumors .  Cohort s 23 and 34 can be opened once Cohort  12 
has been completed and determined to be tolerable. The DLT evaluation period will be 
28 days .  The Dose Level Review Meeting (DL RM) may recommend escalation to the 
next planned dose, escalation to an intermediate dose (a dose lower than the next 
planned dose), continuation or delay in dosing, repetition or expansion of a cohort, de -
escalation to a lower dose, or termination of the study .  Administration  of AMG 404 (in all 
cohorts ) may continue until evidence of disease progression, intolerance to study 
medication, withdrawal of consent, or in the absence of the above up to 12 months if 
subject achieves a complete response, and up to  24 months if partial response or stable 